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Abstract 
Malaria continues to be an enormous health-threat in the developing world and the 
emergence of drug resistance has further compounded the problem. The parasite-specific 
enzyme, 1-deoxY-D-xylulose-S-phosphate reductoisomerase (DXR), has recently been validated 
as a promising antimalarial drug target. The present study comprises a combination of 
synthetic, physical organic, computer modelling and bioassay techniques directed towards the 
development of novel DXR inhibitors. A range of 2-heteroarylamino-2-oxoethyl- and 2-
heteroarylamino-2-oxopropyl phosphonate esters and their corresponding phosphonic acid 
salts have been synthesised as analogues of the highly active DXR inhibitor, fosmidomycin. 
Treatment of the heteroarylamino precursors with chloroacetyl chloride or chloropropionyl 
chloride afforded chloroamide intermediates, Arbuzov react ions of which led to the 
corresponding diethyl phosphonate esters. Hydrolysis of the esters has been effected using 
bromotrimethylsilane. Twenty-four new compounds have been prepared and fully 
characterised using elemental (HRMS or combustion) and spectroscopic (1- and 2-D NMR and 
IR) analysis. A 31p NMR kinetic study has been carried out on the two-step silylation reaction 
involved in the hydrolysis of the phosphonate esters and has provided activation parameters 
for the reaction. The kinetic analysis was refined using a computationa l method to give an 
improved fit with the experimental data. 
Saturation transfer difference (STD) NMR analysis, computer-simulated docking and enzyme 
inhibition assays have been used to eva luate the enzyme-binding and -inhibition potential of 
the synthesised ligands. Minimal to moderate inhibitory activity has been observed and 
several structure-activity relationships have been identified. In silica exploration of the DXR 
active site has revealed an additional binding pocket and information on the topology of the 
active site has led to the de novo design of a new series of potential ligands. 
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1. INTRODUCTION 
1.1. Malaria 
1.1.1. The world-wide burden of malaria 
Man has battled with malaria for thousands of years and its associated, recurring fevers are 
alluded to in some of the earliest historical records.' Spreading from a few isolated regions as 
populations grew and new territories were colonised, malaria became a world-wide disease by 
the early 1800's' little was known about the vector or causative agent of malaria until the 
1880's when Charles Laveran identified the plasmodium parasite in the blood of infected 
patients! In 1897, Ronald Ross demonstrated that malaria is transmitted by mosquitoes, a 
discovery for which he won a Nobel Prize in 1902.' However, the full life cycle of the parasite, 
including its various tissue stages, was not discovered until 1948 when it was first described by 
Garnham and Shortt! 
Malaria can be caused by any of the four plasmodium species Plasmodium Jalciparum (P. 
falciparum), Plasmodium ovale (P. ovole), Plasmodium vivax (P. vivax), or Plasmodium 
malariae (P. malariae). ' P. Ja/Ciparum is the most common of the plasmodium species and, in 
2004, was one of the highest causes of death world-wide from a single infectious agent. ' 
Recent statistics indicate that there are 3.3 billion people in the world at risk from malaria, 247 
million reported cases of the disease annually and the disease is estimated to cause almost a 
million deaths each year. Of these deaths, 91% occur in Africa - 85% in children under the age 
of five ',4 As illustrated in Figure 1, there are 109 countries in which malaria is endemic, 45 of 
which are in Africa.' In the 1970's, Africa accounted for only half of the world's malaria 
burden, whereas currently, about 90% of the world's cases occur in sub-Saharan Africa' In 
sharp contrast to these statistics, according to Casman and Dowlatabadi, only 10% of 
international funding assigned to fighting malaria is spent in this region.' 
There is a significant correlation between malaria endemic regions and lack of development, 
the disease being generally most severe amongst people living in poor socio-economic 
circumstances. This results in a vicious cycle in which the prevalence of malaria interferes with 
the survival and education of children and the productivity ofthe working population as well 
as straining the resources of governments' 
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Figure 1. Estimated world-wide incidence of malaria per 1000 population, 2006.'(Reproduced with 
permission from the World Health Organisation.) 
In addition to many localised efforts, the World Health Organisation (WHO) has made efforts 
to control and eradicate malaria world-wide with a combination of preventative measures 
including:- long-lasting insecticidal nets; indoor spraying of insecticides; artemisinin-based 
combination therapy; and intermittent preventive treatment in pregnancy. ' Apart from a small 
number of countries which have significantly decreased their malaria burden, the majority 
operate far below the targets set for the different prevention and control measures. These 
targets are based on the Millennium Development Goals which include the aim that "by 
2015, ... malaria is no longer a major cause of mortality and no longer a barrier to social and 
economic development and growth anywhere in the world ."· Since its inception in 1998, the 
"Roll Back Malaria" campaign has taken on this task, aiming to reduce malaria mortality by 
50% by 2010 and 75% by 2015 4 Litsios, however, concludes that the approaches used thus far 
to control malaria need to be re-assessed, as the public health systems currently in place are 
incapable of effecting the required response; he calls for an "educated response", "com munity 
collaboration" and "the attention of the entire scientific community."s 
Many factors such as poverty, population growth and movement, social unrest, government 
instability and climate change, need to be taken into account when considering malaria and its 
potential spread or eliminationS Some of the most successful malaria control programmes 
have been based on dichlorodiphenyltrichloroethane (DDT) spraying and there is much debate 
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as to whether the insecticide's ill-famed environmental effects outweigh its effectiveness in 
controlling malaria.' Many regions of the world, particularly Central and South America, Asia 
and countries of the former Soviet Union achieved significant reductions in malaria in the 
1980's but have since slackened their malaria control programmes and experienced a re-
emergence of the disease, in some cases with the additional problem of drug-resistant 
strains' Parasite resistance to the current antimalarial drugs is particularly severe in the 
Indochinese peninsula .' Although there is little information on the interactions between 
malaria and the Human Immunodeficiency Virus (HIV). some data suggests that HIV-infected 
people are more likely to suffer from severe malaria. Z 
Attempts to combat malaria have been hampered to some extent by a lack of economic 
incentive for pharmaceutical companies to research and develop new antimalarial drugs. As 
Milhous and Kyle express so succinctly, "From a commercial perspective, it makes little sense 
to turn out costly pharmaceuticals for people who cannot afford shoes." 7 In response to this, 
the World Bank and the International Federation of Pharmaceutical Manufacturers 
Associations have established the Medicines for Malaria Venture which aims to discover, 
develop and register affordable new drugs." As resistance to current drugs increases, scientists 
and health authorities are increasingly realising that a continued effort applied to the 
discovery of new classes of antimalarial drugs is vital in order to have new drugs at hand when 
resistance to the current drugs develops· Although some success, and even eradication, in 
some areas has been achieved with the current tools, it is important that these successes do 
not lead to complacency. New tools for control and new drugs for the treatment of malaria are 
necessary if such achievements are to be sustained and extended.' 
1.1.2. The life cycle of the malaria parasite 
Despite its small size, the complex biology and life cycle of the malaria parasite, as shown in 
Figure 2, make it a particularly difficult organism to target in drug development. In addition, 
the parasite lives within the host cells, out of reach of the immune system, and changes the 
expression of its genes continually to exploit the different environments it experiences in 
different host cells ' The mechanisms of invasion of host cells, gene expression and signalling 
pathways are poorly understood but potentially provide many targets for the development of 
drugs and va ccines.10 
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Figure 2. Life cycle of the malaria parasite showing stages in the human and the mosquito .'IReproduced 
with permission.) 
When an infected female anopheles mosquito bites a human, it releases sporozoites from its 
sa livary glands into the blood of the human host. The sporozoites invade liver ce lls 
(hepatocytes) where they grow and divide for 6 - 15 days (the pre-erythrocytic stage) . At the 
end of this stage, thousands of merozoites are released into the bloodstream where they 
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attach to and invade red blood cellsll This is the part of the life cycle on which most attention 
has been focused for the development of potential vaccines against malaria." 
In the red blood cells, the plasmodium undergoes the asexual erythrocytic stages of its life 
cycle, the stage targeted by most antimalarial drugs' The parasite forms a thin biconcave disc 
in a sac known as the parasitophorous vacuole. Here it feeds on haemoglobin and sequesters 
nutrients from the plasma. The product of haemoglobin digestion crystallises out as a dark 
pigment called haemozoin. The merozoites excrete proteins which modify the red blood cell 
membrane so that it sticks to the lining of the blood vessels, thus minimising the transport and 
destruction of infected red blood cells by the liver and spleen. The merozoites grow into 
trophozoites which are the most active in feeding and red blood cell modification.' The 
trophozoites mature into schizonts and the nucleus of each schizont divides, resulting in about 
16 nuclei which form into merozoite buds. The red blood cell then bursts, releasing the small, 
egg-shaped, merozoites. The free merozoites then adhere to and invade new red blood cells, 
forming a new parasitophorous vacuole' This 48 - 72 hour cycle is responsible for the 
recurring fevers and chills which are the most well known clinical symptoms of malaria 'O•ll 
Some merozoites eventually differentiate into sexual forms (gametocytes), an important step 
in the life cycle which provides an intriguing target for arresting parasite development."lf the 
gametocytes are taken up by another female mosquito in a blood meal, they mature into male 
and female gametes and fertilisation occurs, forming a zygote which matures into an ookinete. 
This ookinete is motile and burrows into the mid-gut wall of the mosquito to form an 
oocyst."·" The ookinetes divide mitotically, filling the oocycsts with sporozoites. When the 
oocyst bursts, the sporozoites migrate to the salivary glands from which they may be injected 
into a new human hostll The cycle in the mosquito takes approximately 7 - 18 days and 
involves six different forms of the plasmodium, a factor which complicates the potential 
control of the parasite in the mosquito vector" 
1.1.3. Current antimalarial drugs: targets and resistance 
Attempts to make a malaria vaccine date back as far as 1912 but have thus far been 
unsuccessful, due mostly to the complex nature and life cycle of the parasite.' Each stage of 
the life cycle produces a different immune response, generally weak and poorly understood. 
There have, however, been some promising new developments, involving deoxyribonucleic 
acid (DNA) vaccines and synthetic and recombinant antigen production, which are in clinical 
trials."·lS.' Milhous and Kyle, however, have advised that "we should not dilute the search for 
new drugs with overly optimistic expectations for a vaccine.'" 
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The current antimalarial drugs mostly target the asexual erythrocytic stages of the parasite life 
cycle and are classified into four main families, viz., the antifolates, the 
hydroxynapthoquinones, the quinolines and artemisinin derivatives.' The structures of a 
selection ofthe current antimalarials are shown in Figure 3. 
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Figure 3. Structures of some current antimalaria! drugs showing examples from each of the four main 
classes,l 
The antifolates (sulfadoxine 1, pyrimethamine 2, cycloguan il, trimethoprim, chlorproguanil 
and the sulfonamides) target the plasmodial enzymes dihydrofolate reductase (DHFR) and 
dihydropteroate synthase (DHPS) which form part of the folate biosynthetic pathway.7". The 
sulfa drugs, such as sulfadoxine 1, inhibit DHPS and are p-aminobenzoic acid analogues which 
act as antagonists," They are also widely used as antibacterial agents." Pyrimethamine 2 and 
sulfadoxine 1 (Fansidar) act synergistically and are particularly effective in combination as they 
target both DHFR and DHPS in the folate biosynthetic pathway, decreasing purine and 
pyrimidine synthesis and thereby inhibiting the synthesis of DNA. Generally, resistance to 
DHFR and DHPS inhibitors in malaria parasites is due to point mutations in the target enzymes. 
Some parasites, however, achieve partial resistance simply by expressing more of the relevant 
enzyme and thus increasing the ratio of enzyme to inhibitor," When designing new drugs in 
this class of antimalarials, consideration needs to be given to their potential effectiveness 
against current drug-resistant strains and the possible inclusion of features to counter the 
parasite's ability to adapt." 
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Atovaquone 3 belongs to the class of hydroxynapthoquinones which inhibit mitochondrial 
respiration by disrupting electron transport in the parasite.' Atovaquone is often combined 
with proguanil in the drug Malarone' Resistance to atovaquone, used alone, arises quite 
rapidly and has been attributed to mutations in the cytochrome b gene." 
The most well-known member of the quinoline class of antimalarials is quinine 4, the oldest 
antimalarial drug in Western medicine, and still widely used as a last recourse for severe 
malaria" Quinine, a 4-aminoquinoline derivative, is a natural-product drug, extracted from 
the bark of cinchona trees native to South America . The active ingredient, quinine, was 
isolated in 1820 and is thought to act by interfering with the formation of haemozoin, the 
malarial pigment, from haeme. Resistance to quinine has arisen in several scattered regions 
around the world but the mechanism of the resistance is not fully known, although mutations 
in the piert gene are thought to be involved."·l9 Resistance to quinine is not wide-spread in 
sub-Saharan Africa and this compound still finds use as a fast-acting and effective antimalarial 
drug' Chloroquine 5, a 4-aminoquinoline derivative, has been a widely-used and very valuable 
antima larial because it is:- active against all four plasmodial species which infect humans; safe 
for pregnant women and children; and inexpens ive .20 Chloroquine is thought to act by 
interfering with the function of the parasite food vacuole, possibly preventing the 
detoxification of haeme (in a similar manner to quinine), inhibiting haemoglobin protease 
activity or raising the pH of the vacuole.'· The wide-spread use of chloroquine as an 
antimalarial drug has been very successful in reducing the malaria burden in some areas but 
the emergence of resistance has curtailed its effectiveness world-wide.'· Resistance to 
chloroquine was first noticed in the 1960's and has been partly attributed to population 
migration, poor health services and improper use of antimalarial drugs.' The mechanism of 
resistance to chloroquine has not been fully determined but it has been found that the 
accumulation of chloroquine in the food vacuoles of resistant parasites is far less than in 
susceptible parasites.' Chloroquine resistance-reversers, which would be co-administered with 
chloroquine to restore its effectiveness, are being investigated.' Studies on the design of new 
aminoquinolines have given rise to compounds which show some promising action against 
chloroquine-resistant parasites'" 
Artemisinin 6 is the active principle in the ext ract of the sweet wormwood tree, Artemisia 
annua, and has been used as a herbal medicine in China for over 2000 years." The mechanism 
of action has been suggested to involve iron-dependent free-radical generation.' The endo-
peroxide bridge in the structure of artemisinin has been found to be crucial for its activity and 
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is thought to interact with the iron in haeme resulting in the format ion of the free radicals l ' 
Artemisinin is usually used in combination with other drugs as recrudescence is common due 
to the drug's short half-life when it is used alone, especially for short periods. 2" Since there is a 
potential problem with neurotoxicity caused by artemisinin, derivatives, such as synthetic 
trioxanes and tetraoxanes, are being explored.' Although resistance to artemisinin is not wide-
spread, there have been reports of reduced efficacy of the drug in some areas.21 An additional 
drawback of this drug is that the cost per treatment is prohibitively high for most people in 
sub-Saharan Africa"l8 
In addition to the above four classes, some antibiotics such as tetracyclines and macrolide 
antibiotics are effective antimalarials and these compounds are thought to act by inhibiting 
protein synthesis in the mitochondrion or the plastid." Knowledge of the mechanisms of 
resistance to the current drugs can aid in the design of new drugs in addition to seeking to 
target parasite-specific pathways in rational drug design,' particularly as the emergence of 
resistance has been recorded for all the current antimalarial drugs." Several routes to new 
drug discovery are being pursued in attempts to counter the emergence of resistance. These 
include:- natural product screening; investigating traditional medicine leads; structure-based 
drug design and molecular modelling; and molecular biology techniques to identify potentia l 
targets. ' 
1.2. New targets for antimalarial drugs based on the non-
mevalonate pathway 
1.2.1. The non-mevalonate pathway for isoprenoid biosynthesis 
Isoprenoids are found in all living organisms and carry out a wide variety of functions, 23 Some 
isoprenoids are essential metabolites, such as sterols involved in membrane stabilisation, 
quinones in the electron transport chain and carotenoids involved in photosynthesis; others 
are used in the synthesis of secondary metabolites." The mevalonate pathway for the 
synthesis of isoprenoids is well known and has been extensively studied for over 50 years,25 
This pathway involves condensation of three molecules of acetyl coenzyme A to form 3-
hydroxy-3-methylglutaryl coenzyme A, which is then converted, via mevalonate, to 
isopentenyl pyrophosphate (IPP)." IPP and its isomer, dimethylallyl pyrophosphate (DMAPP), 
form the universal building blocks for isoprenoids," In 1993 it was discovered that an 
alternative pathway for the synthesis of isoprenoids exists and this was termed the non-
mevalonate or DOXP/MEP pathway, shown in Figure 4,25 Rohmer and co-workers established 
that pyruvate 7 and glyceraldehyde-3-phosphate 8 are the precursors which combine to form 
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l-deoxy-o-xylulose-S-phosphate (DOXP) 9, a reaction catalysed by DOXP synthase.25". An 
intramolecular rearrangement and reduction is then effected by DOXP reductoisomerase 
(DXR) to convert DOXP to 2-C-methyl-O-erythritol-4-phosphate (MEP) 1028 - a t ransformation 
found to require nicotinamide adenine dinucleotide phosphate (NADPH) and a cofactor:-
Mn"; Mg" ; or Co", The intermediate aldose phosphate is produced between the 
isomerisation and reduction steps," In the t hird step, MEP is linked to cytidi ne triphosphate 
(CTP) to form compound 11, and phosphorylation of the 2-hydroxy group of M EP in an 
adenosine triphosphate (ATP)-dependent reaction yields compound 12.'· This is followed by 
cyclisation to 2-C-methyl-o-erythritol-2,4-cyclodiphosphate 13 and intramolecular elimination 
of the diphosphate, The final conversion to IPP 14 is achieved by two reduction and two 
dehydration steps,'· 
The DOXP/MEP pathway contains promising potential target enzymes for drug development 
because it is used in several pathogenic species of bacteria and protozoa but not in humans." 
In addition to being present in species of both Gram-positive and Gram-negative bacteria, the 
DOXP/MEP pathway is also found in many eukaryotes such as algae and higher plants."'" In 
higher plants, the mevalonate pathway is utilised in the cytoplasm for the synthesis of sterols 
whilst the non-mevalonate pathway is utilised in the chloroplasts for the synthes is of 
photosynthesis-related isoprenoids," Attention has been focused on the development of 
inhibitors for DOXP/MEP pathway en zymes in pathogen ic species such as Helicobacter pylori 
(H. pylori), Mycobacterium tuberculosis (M. tuberculosis), Escherichia coli (E. coli) and, most 
importantly in the present context, P. Jalciparum, 29 
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1.2.2. Mechanism of the 1-deoxY-D-xylulose-5-phosphate reductoisomerase (DXR) 
catalysed conversion of 1-deoxy-D-xylulose-5-phosphate (DOXP) to 2-C-methyl-D-
erythritol-4-phosphate (MEP) 
The DXR-catalysed conversion of DOXP to MEP has been shown to proceed via the 
intermediate 2-C-methylerythrose-4-phosphate 15 but there has been no conclusive evidence 
forthe detailed mechan ism by which the reaction occurs. " In the first proposed mechanism, a 
retro-aldol/aldol rearrangement, the 4-hydroxyl group of DOXP 9 is oxidised and the C(3)-C(4) 
bond cleaved in a retro-aldol process to give the enol/enol ate of hydroxyacetone and 
glycoaldehyde phosphate, as shown in Figure 5a;",31 an aldol reaction between these two 
intermediates then gives 2-C-methylerythrose-4-phosphate 15.",31 The second proposed 
mechanism parallels the ketal acid reductoisomerase pathway and involves an a-ketol 
rearrangement, as shown in Figure 5b32 In this mechanism, the 3-hydroxyl group of DOXP is 
deprotonated and oxidised to a carbonyl group, followed by migration of C-4 to C-2 to give the 
common aldehyde intermediate 15.",31 Argyrou and Blanchard mention a third possibility 
involving a 1,2-hydride shift followed by a 1,2-methyl shift, as shown in Figure 5c, but this 
mechanism was not supported by the results of NMR experiments using "C-Iabelled 
material. 30 
The 2-C-methylerythrose-4-phosphate intermediate 15 formed by one (or more) ofthe above 
mechanisms is then reduced by NADPH, converting the aldehyde moiety to a primary 
alcohol30 The stereochemistry of the product 10 is determined by preferential migration of 
the C-4 moiety to the re-face at C-2; this is then followed by re-face attack of NADPH on the 
intermediate, as shown in Figure 6. The pro-S-hydrogen at C-1 of MEP is derived from the C-3 
hydrogen of DOXP, whilst the pro-R-hydrogen at C-l originates from the 4-S-hydrogen of 
NADPH in the subsequent reduction step."'" 
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Figure 5. Three possible mechanisms for the conversion of DOXP 9 to 2-C-methylerythrose-4-phosphate 
10:- a) retro-aldol/aldol rearrangement; b) a-ketal rearrangement; c) 1,2-hydride shift.30•31 
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Figure 6, Stereochemical aspects of the DXR reaction via the a-ketal pathway (Fig. Sb). Attack of C-4 on 
C-2 from the back (re-face attack on the DOXP C-2 carbonyl) followed by attack of NADPH pro-S 
hydrogen (marked with *) from the front (re-face attack on the C-1 carbonyl of the intermediate 15).34,35 
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Hoeffler et 01. (2002) attempted to verify the existence of the a-ketol rearrangement 
mechanism of the isomerisation step by synthesising DOXP analogues lacking the 3- or 4-
hydroxyl group (16 and 17, respectively; Figure 7). The first step of this mechanism involves 
deprotonation of the 3-hydroxyl group, and would result in the formation of the MEP 
analogue 18 if the 3-hydroxy compound 16 were used as the substrate. If the 4-hydroxy 
isomer 17 were used as the substrate, the a-ketol rearrangement mechanism would not be 
possible. When these ana logues were tested as substrates for DXR, however, it was found that 
both compounds 16 and 17 failed to act as substrates for DXR, as NADPH was not oxidised, but 
did reversibly inhibit the enzyme" Although these experiments were unable to prove the a-
keto I rearrangement, they did establish the importance of both the 3- and 4-hydroxy groups in 
the enzyme substrate . A further experiment was undertaken using C-l"C-labelled DOXP, but 
formation of " C-Iabelled hydroxyacetone, which would be produced by the retro-aldol/aldol 
mechanism, could not be confirmed. 37 Moreover, the two putative intermediates, 
hydroxyacetone and glycoaldehyde phosphate, were not recognised by DXR and the 
experiments proved inconclusive. 37 
OH R 
0, .J--. ./'-.. ...-P, 
'I '-/ ' 0 b- OH 
CH, 
o 
II 
O~...-P, 
I I 0 b- OH 
CH, OH 
H,C OH 0 
- \ .,- II 
HO~ ...-P, 
o 1_ OH 
o 
16 17 18 
Figure 7. Structures of DOXP analogues 16 and 17 and the MEP analogue 18." 
1.2.3. Discovery of fosmidomycin and its potential os a DXR inhibitor 
The natural product fosmidomycin 19, shown in Figure 8, was isolated from Streptomyces 
lovenduloe in the 1970's and found to have antibiotic and herbicidal properties'··29., .... Once 
the DOXP/MEP pathway was known, Kuzuyama et 01. investigated the effect of fosmidomycin 
on bacteria with and without this pathway and established that fosmidomycin is an inhibitor of 
the DOXP/MEP pathway'O Shortly afterwards, it was found that fosmidomycin inhibits DXR in 
a dose-dependent manner, as does its acetyl derivative FR900098 20.'··41 The antimalarial 
properties of these two compounds were reported by Jomaa et 01. who found that these 
compounds showed low toxicity and were able to clear mice of the rodent malaria paraSite 
Plasmodium vinckei.41 In humans, fosmidomycin was shown to be effective as a treatment for 
uncomplicated P. /alciparum malaria but a high rate of recrudescence was observed with short 
treatment courses.29.'. Additional disadvantages encountered in the use of fosmidomycin are 
its very short half-life in the blood and its low lipophilicity which leads to poor absorption in 
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the gut and difficulty in crossing phospholipid membranes.'" As a result, combination 
therapies with other antimalarials have been investigated and the combination of 
fosmidomycin with clindamycin has shown a synergistic effect" The high levels of DXR 
inhibition by fosmidomycin and FR900098, however, make these compounds particularly 
promising lead compounds which may be modified to produce effective antimalarial drugs. 38 
fosrnid°lTrfcin 
19 
FRJ00098 
20 
Figure 8. Structures of the lead compounds fosmidomycin 19 and FR900098 20 . 
1.3. Properties and structural features of I-deoxY-D-xylulose-5-
phosphate reductoisomerase (DXR) 
1.3.1. Kinetic properties of DXR 
The enzyme DXR is found in the apicoplast of malaria plasmodia." The apicoplast is a non-
photosynthetic, plastid-like organelle, found at the anterior end of the cell. It is thought to be 
involved in penetrating host tissues although its metabolic function has stil l not been fully 
determined"",4',,, Secondary endosymbiosis of an alga is thought to have been the origin of 
this organelle's presence in the phylum Apicomplexa41•4l The apicoplast is an organelle not 
presen t in human cells and therefore the DXR enzyme presents a promising drug target, 
especially as it is essential for the survival of the parasite. 
The characterisation of DXR has been well summarised by Proteau in terms of its cofactor 
requirements, mechanism and kinetic parameters" Some of the first investigations into the 
nature of EcDXA: were carried out by Takahashi et 01. in 1998." These studies revealed that 
NADPH is used as the coenzyme rather than nicotinamide adenine dinucleotide (NADH) and 
the optimum pH was proposed to lie between 7.5 and 8.0." Kuzuyama et 01., however, found 
the optimum pH to be between pH 7.0 and 8.5 (greater than 75% of maximum activity) and 
maximum activity was obtained between 40 and 60°C, although the enzyme was not heat 
stable above 50 0c." Studies on the metal cation revealed that one of the cations Mn'·, Co" or 
Mg'· is required; no activity was detected in the presence of Ca'·, Ni'·, Zn'·, Cu '·, Fe'· or 
ethylenediaminetetraacetic acid (EOTA)." The enzyme has a half-life of approximately 3 days 
at 4 °c but retains almost all of its activity for a year when stored at -20°C in 50% glycerol'o 
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When stored at 4 °c in 100 mM Tris-HCI buffer (pH 7.5), the enzyme was found to have 
retained 90% of its activity after one month'S 
The Michaelis Constant, KM, of an enzyme is defined as the substrate concentration at which 
the velocity of the reaction is half of its maximum value" A small KM value means that the 
enzyme achieves maximum catalytic efficiency at low substrate concentrations and hence KM 
can also be used as a measure of the affinity of an enzyme for its substrate" The catalytic 
constant or turnover number of an enzyme, k"" is the ratio of the maximal ve locity to the 
total enzyme concentration and indicates the number of reaction processes each active site 
catalyses per unit time.46 The catalytic efficiency of an enzyme is measured by the quantity 
k"tiKM, the apparent second-order rate constant of the enzymatic reaction" Argyrou and 
Blanchard point out that, due to the presence of inactive enzyme which contributes to the 
protein concentration, experimental k", and k"tiKM values must be regarded as lower Iimits 'O 
The kinetic parameters for DXR from several organisms have been investigated by a number of 
authors. Argyrou and Blanchard carried out experiments to determine the k,,,, KM and ko,tiKM 
values of M.tuberculosis DXR (MtDXR) for each of the metal cofactors (Mn", Mg" and Co" ) 
for both the forward and reverse reactions. The reciprocal plots showed lines intersecting left 
of the y-axis and above the x-axis, suggesting a sequential mechanism. '0 Studies of the pH 
dependence of the kinetic parameters indicated the presence of two deprotonated groups 
(with pK, values of ca. 7.4) which are predicted to bind to the metal cation. 'o Mac Sweeney et 
01." determined the KM values of fcDXR for the three metal cofactors (Mn", Mg" and Co'+) at 
pH values of 7.8 and 6.0 and found them to be similar to those of MtDXR for Mn'+ and Co'+; 
the KM for Mg'+ was higher than that for the other two metals but lower than that determined 
for MtDXR or Synechocysitis DXR. For both MtDXR and fcDXR, the KM increased as the pH 
decreased and th is was attributed to protonation at low pH of the carboxylate-containing 
residues binding to the metal ion, resulting in a decreased metal affinity." Kuzuyama et 01. 
also determined the kinetic parameters of fcDXR for each of the metal cofactors and 
concluded that the enzyme activity depends significantly on the in vivo concentration of each 
cation.45 
1.3.2. Crystal structures of DXR 
There are several crystal structures of DXR available in the Protein Data Bank (PDB; E.C. 
1.1.1.267), from f.coil, Z.mobilis and M.tuberculosis but none as yet for DXR from P. 
!alciparum. 48 The crystal structure of f. coli DXR (fcDXR) obtained by Mac Sweeney et 01. 47 
verified previous proposals"·49 that DXR exists as a V-shaped, 86 kDa homodimer, comprising 
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three domains36,47 The large N-terminal domain (residues 1-150) contains the NADPH cofactor 
binding site and is comprised of a seven-stranded parallel ~-sheet and seven a-helices, as 
shown in Figure 9'7,so The structure of this domain, however, needs to be accepted with 
caution as Hoeffler et 01. point out that studies undertaken on histamine-tagged proteins must 
take into account the potential interference of the His-tag with cofactor binding.37 A 
connective region made up of residues 150-285 includes most of the active site as well as a 
flexible 'lid' (residues 206-216), which closes over the substrate or inhibitor and excludes 
solvent from the active site .'6,47 The C-terminal domain (residues 312-398) is thought to playa 
structural role in supporting the active site and is made up of a four-helix bundle, 36,47 In the 
model of p, !alciparum DXR (P/DXR) published by Goble et 01" the corresponding domains 
were found to be residues 1-160 for the N-terminal domain, residues 161-340 for the 
connective domain and residues 341-417 for the C-terminal domain,51 The overall structure, as 
well as the orientations of the catalytic residues in P/DXR, was found to be similar to that of 
EcDXR.51 
N-terminal domain 
C-terminal domain 
Flexible loop NADPH 
Fosmidomycin Metal-binding site 
1+------ Connective region 
Figure 9, Diagram of EcDXR showing secondary structure, a-Helices are shown in red, ~-sheets in yellow 
and turns in blue. Bound fosmidomycin 19 and NADPH are shown in ball-and-stick format, coloured by 
atom type, The diagram was created from PDB structure lQOL,47 
The structure of the apo-enzyme (10NN) revealed several different loop conformations, 
showing the flexibility of this region when no ligand or cofactor is bound 36,52 In 2002, Yajima et 
01, produced the first crystal structure with NADPH bound and this structure (INS) showed a 
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more ordered loop region" This structure contains a sulphate ion positioned in the region in 
which the phosphonate group of the substrate or inhibitor would bind." The binding of the 
inhibitor was investigated by Steinbacher et 01. who published an EcDXR crystal structure 
containing fosmidomycin and Mn" in the active site and identified the metal-coordinating 
residues and ligand-binding interactions." Although the electron density observed for the loop 
region was more ordered in this structure than that of the apo-enzyme, it was still partly 
disordered and the NADPH-binding site was blocked by the C-terminal region of a 
neighbouring molecule." Two structures obtained for the enzyme from Z. Mobilis (ZmDXR); 
(lROK and 1ROL) were very similar in overall structure and active-site architecture to that of 
EcDXR except for some differences in the interactions with the adenine ring of NADPH.50•52 
Yajima et 01. published EcDXR structures (1T1S and 1T1R) with bisphosphonate inhibitors 
which bound differently to fosmidomycin, with the bisphosphonate mOiety displacing the 
metal ion." The tight-binding structure of EcDXR with fosmidomycin and NADPH (lQOL) and 
the DOXP-NADPH-DXR ternary structure (lQOQ) released by Mac Sweeney et 01. revealed the 
interactions of the active-site residues with the inhibitor and the substrate and also showed a 
fully ordered loop region interacting with the ligand in a closed conformation. 47,50 
Unfortunately, the crystals were obtained at pH 5,0 at which value the metal binding is very 
weak and DXR is not catalytically active" Silber et 01, have suggested that the interactions 
identified from this structure are likely to be different to those taking place in vivo because of 
different protonation states of the active-site residues, 34,52 Several structures of MtDXR with 
different combinations of cofactors and inhibitors published by Henriksson et 01, show the 
active-site residues and reveal certain differences between MtDXR and EcDXR, especially 
relating to the metal coordination, " Instead of regarding crystallography as a static picture, 
these authors aimed to use the binding of different substrates and cofactors to reveal some of 
the dynamic properties of the enzyme" 
The quaternary complex of EcDXR with fosmidomycin, NADPH and Mg" (2EGH) obtained by 
Yajima et 01, in 2007 revealed that the electron density data for the loop region could be 
resolved and that interactions of the loop with the inhibitor could be observed. 53 Comparison 
of the quaternary complex with that of a structure lacking NADPH revealed small differences, 
which suggested that DXR is structurally flexible and that both cofactors are needed for 
correct positioning of the substrate in the active site, 53 However, the only metal ion to be 
successfully incorporated into the crystal structure was Mg" , despite the authors' attempts to 
obtain crystals with Mn" and Co" as cofactors " 
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In the absence of a reported crystal structure of PjDXR, a 3-D model of PjDXR was built by 
Singh et aI" using comparative protein modelling techniques, based on the crystal structures 
of EcDXR (lQOL) and ZmDXR (lROL) "o Comparison of this PjDXR model with EcDXR indicated 
that the overall structures and interactions with fosmidomycin are largely similar"o 
Verification of the model using docking studies, including the metal cofactor, showed good 
correlation between the docking sco res and the ICso values and indicated substrate-like 
binding of inhibitors and common binding modes, so Unfortunately, since this model was not 
publically available, another homology model of PjDXR has been developed by Goble et aI" 
which incorporates the results of further docking studies and more recent inhibition studies on 
PjDXR,51,S4 Comparison of this PjDXR model with the EcDXR crystal structure lQOL revealed 
largely sim ilar structures, corresponding regions in the Ramachandron plots and similar 
catalytic residues, 51 Although the NADPH-binding residues appear to be largely the same in 
both EcDXR and PjDXR, some differences in the loop region were noted and it was predicted 
that the loop is likely to change conformation significantly on binding of the inhibitor, 51 
1.3.3. Role and binding of the divalent metal cation 
It is well established that DXR requires the presence of a divalent metal cation for its catalytic 
activity, and the position of the metal in the active site is reasonably well defined,24 In the 
MtDXR crysta l structure," a Mn" ion is present with an octahedral geometry involving 
coordination to three water molecules and the act ive-site residues AsplSl, GlulS3 and 
Glu222;" the corresponding residues in EcDXR are AsplSO (D15O), GlulS2 (Em) , Glu231 
(E",),,,,47 
a b c 
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O~r~CHJ 
E 1S? I ,., .0 
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Figure 10. Binding of Mn" to active-site residues (in £,co"1 and ligands:- a) DOXP 9; b) 2-C-
methylerythrose-4-phosphate 15; c) MEP 10; and d) fosmidomycin 19.'6,47,53 
As shown in Figure 10, coordination of fosmidomycin 19 (d) to the metal cation (via axial and 
equatorial interactions) is considered to be the same as that exhibited by the substrate, DOXP 
9 (a) , ",47 Steinbacher et aI" however, suggest that coordination of the intermediate 15 (b) and 
the product 10 (c) is diequatorial, stating that coordination of these compounds trans to 
AsplS0 and Glu231 would lead to incorrect stereochemistry in the product. " ,47 Henriksson, on 
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the other hand, has proposed that the divalent metal cation (M") serves as an anchor for the 
0-2 and 0 -3 atoms of the substrate, DOXP 9, and that these remain coordinated during the 
rearrangement and become the 0 -1 and 0 -2 hydroxyl groups of MEP 10." Mac Sweeney, 
however, reported that the role of the M" in the isomerisation step is not known but that it is 
necessary for the subsequent reduction."'" Comparison of MtDXR structures in the presence 
and absence of the cofactors has indicated that the Mn" coordination is not greatly affected 
by the binding of NADPH." The (N-formyl-N-hydroxy)amino group offosmidomycin 19 and the 
metal-bind ing residues are thought to undergo slight conformational changes in order to 
coordinate to the metal," but this has yet to be confirmed for EcDXR as the only available 
structure containing both fosmidomycin and NADPH (lQOL) fails to show binding of 
fosmidomycin to the metal." The reason given for the absence of the metal is that the crystal 
was obtained at pH 5.0, at which value the metal-binding affinity of DXR is thought to be 
reduced." At t his pH, the conformations of the acidic residues expected to coordinate Mg" 
also do not adopt the required octahedral geometry as they are not protonated and are 
therefo re expected to interact differently.47." Magnesium (as Mg") is thought to be the 
cofactor present in vivo as its intracellu lar concentration is similar to the k", value of the 
enzyme.lO.55 However, DXR can use Mn", Co" or Mg" and the specificity of MtDXR for the 
metal was found to follow the order:- Co" > Mn" > Mg''.'o Hoeffler et 01. found that a lower 
concentration of Mn" than Mg" gave maximum activity, and suggested that DXR has a higher 
affinity for Mnl< than for Mg" although the intermediate, methylerythrose phosphate 15 was 
found to bind more efficiently to Mg" than Mn'·.37 According to Bock et 01., the ionic radius of 
Mn" (0.75 A) is larger than that of Mg" (0.65 A) and therefore Mn", as the softer acid, prefers 
to bind to a site containing both nitrogen and oxygen donors, whereas Mg" , a harder acid, 
prefers oxygen donors alone - as in compound 15.56 For thei r docking studies using AutoDock, 
Silber et 01. and other researchers have replaced Mn" in the binding site by Mg'·. The 
justification given is tliat either metal can be utilised by active DXR, as the coord ination 
chemistry of the two meta ls is very similar, but that Mg" is better parameterised for use with 
the docking programme."·57 The mechanism, however, is thought to be the same whichever 
metal is involved." 
Analysis of the crystal structure of EcDXR (lQOL) reveals a distorted octahedral coordination 
sphere around Mg" involving Glu152, Glu231, Asp150, Lys125 and the 2-ca rbonyl and 3-
hydroxyl oxygens of DOXP." Perruchon et 01. have argued that, in order to inhibit the enzyme, 
the divalent cation must be complexed and that the hydroxa mate group suits the metal-
coordination sphere bestS '.57 This proposal has been supported by Giessmann et 01. who 
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found that replacing the hydroxamate group in the inhibitor, fosmidomycin 19, with other 
metal-coordinating groups led to a decrease in the inhibitory properties.54 The pK, of the 
fosmidomycin hydroxamate group is thought to be influenced by the coord inated metal ion 
resulting in deprotonation of the N-hydroxyl group and a planar arrangement of the 
hydroxamate group.52.54 The hydroxamate moiety is also well oriented for coordination to the 
metal as the distances from the metal centre t o each of the oxygen atoms are fairly similar 
(M"·O(H)N: 2.1 A; C=O"'M: 2.4 A). 52 
Argyrou and Blanchard have proposed that the divalent metal ion is involved in facilitating 
ionisation of the substrate hydroxyl group and stabilising the intermediate by electrostatic 
interactions with the coordinating hydroxyl groups;'D when the loop region closes over the 
active Site, the change in the dielectric conditions is thought to increase the strength of these 
interactions .52 The pK, values of the three carboxylate moieties of the coordinating active-site 
residues are higher than might otherwise be expected due, it is thought, to their proximity to 
each other. As a result, unless a sui table metal cation is present, these moieties are 
predominantly protonated at neutral pH.'D 
1.3.4. Ligand-binding residues of DXR 
The active-site residues of DXR have been identified from the available crystal st ructures 
containing fosmidomycin 19 or DOXP 9 as bound ligands. The enzyme is relat ively flexible, and 
it is thought to rearrange considerably during substrate and NADPH binding to form a catalytic 
pocket over which a loop closes to isolate the active site. 47•54 The resulting active site has been 
described as having three regions, namely, a phosphonate-binding pocket, a narrow region 
accommodating the carbon backbone of the ligand and a metal-coordination site which also 
binds the hydroxamate moiety of fosmidomycin 19.47 
In all of the published DXR crystal structures, fosmidomycin 19 binds in the active site with the 
hydroxamate group oriented towards the metal cation and the phosphonate group occupying 
a positively charged phosphonate-binding pocket. 33.47.52 There is little evidence of ' reverse' 
binding in wh ich the phosphonate group coordinates to the metal. 58 Cheng and Oldfield have 
suggested that phosphonate-metal chelation wou ld involve a strained four-membered ring 
whereas hydroxamate-metal chelation would afford a more relaxed five-membered ring, 
assuming two coordination sites are occupied in each case, as illustrated in Figure 115 8 
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Figure 11. Suggested coordination of the divalent metal M" with a) the phosphonate group to afford a 
4-membered chelate; and b) the hydroxamate group to afford a 5-membered chelate" 
The phosphonate-binding region involves the residues Ser186, Ser222, Asn227 and Lys228 
(residue numbering from lQOL as shown in Figure 12), which act as hydrogen-bond donors to 
the negatively charged phosphonate oxygen atoms.54•57 This phosphonate-receptor charge 
interaction was shown to be important following experiments in which ligands which were 
uncharged, but had suitable hydrogen-bonding groups, displayed no inhibitory activity against 
DXR.57 The hydrophobic backbone of fosmidomycin is shielded from the solvent by the active-
site 'lid' (residues 206-216) and is positioned approximately parallel to the Il-indole ring of 
Trp212 which lies ca. 4 A away (Figure 12).47 Two of the six coordination sites of the metal are 
occupied by the fosmidomycin hydroxamate group which is thought to adopt a planar 
arrangement and to be deprotonated.52 The residues Glu231, Glu152 and the backbone 
nitrogen of Ser151 are also thought to interact with the hydroxamate mOiety.47 
Figure 12. Illustration of the active site of EcDXR (PDS code 1QOL) showing significant binding residues. 
Bound fosmidomycin 19 is shown in ball-and-stick format, NADPH as sticks and protein residues in 
wireframe with the amino acids labelled. All structures are coloured according to element. (Generated 
using the Discovery Studio Visualizer 2.0.) 
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The substrate DOXP 9 interacts with DXR in a similar fashion to fosmidomycin 19 with the 
phosphate group forming hydrogen bonds to 5er186, Asn227 and Lys228, as shown in Figure 
13'7 There is a difference, however, in that His209 hydrogen bonds to the alkyl oxygen of the 
DOXP phosphate moiety whilst the phospho nate moiety of fosmidomycin shows no such 
interaction with this residue '7 The histidine residues His153, His209 and His257 have all been 
found to be essential for DXR activity and are thought to playa role either in catalysis or in the 
positioning of the substrate."·47 As is the case with fosmidomycin 19, the DOXP backbone lies 
roughly parallel to the ~-indole ring of Trp21247 and the 2-carbonyl oxygen is hydrogen-
bonded to Glu152 and the amide nitrogen of 5er151. The 3-hydroxyl group of DOXP 9 is 
involved in hydrogen-bonding interactions with Lys125 and Glu231, while the 4-hydroxyl 
group is hydrogen-bonded to Glu152, Asn227 and Lys228.47 Glu222 (in MtDXR) is thought to 
deprotonate the 3-hydroxyl group of OOXP 933 and, from comparisons of the wild-type enzyme 
with mutant varieties, Glu231 is considered to playa crucial role in the DOXP-MEP reaction." 
Figure 13. Illustration of the active site of EcDXR (PDB code 1QOQ) showing Signi ficant binding residues. 
Bound DOXP 9 is shown in ball-and-stick format, NADPH as sticks and protein residues in wireframe with 
the amino acids labelled. All structures are coloured according to element. (Generated using the 
Discovery Studio Visualizer2.0.) 
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The NADPH-binding region consists of a conserved group of residues at the N-term inus of the 
protein." Experiments in which Gly14 was substituted with aspartic acid suggest that Gly14 
may play an important role in maintaining the secondary and tertiary structure of the protein 
as well as being part of the NADPH-binding region'S Henriksson identified the residues in 
MtDXR which interact with NADPH and found that NADPH is positioned close to both the 
inhibitor fosmidomycin 19 and Mn",33 This observation was considered to restrict the length 
of potential fosmidomycin analogues although Henriksson has argued that longer compounds 
could project into a nearby hydrated cavity lined by Thr175, Ser245 and His248 (in MtDXR). " 
He proposed that binding of the substrate or inhibitor increases the binding of NADPH. The 
binding of NADPH, however, was found to have minimal effect on Mn" coordination." NADPH 
is considered to bind prior to the inhibitor or substrate and to stabilise the hydrogen bonds 
formed when the 'lid' closes.47 The close proximity of NADPH to the substrate is necessary for 
the second part of the reaction in which the pro-S-hydrogen of C-4 on the nicotinamide ring of 
NADPH is transferred to C-2 of 2-C-methylerythrose-4-phosphate.47 Henriksson has suggested 
that the NADPH-binding site, in addition to the active si te, could be investigated as a potential 
binding region in the design of new inhibitors. 33 
Closure of the flexible loop (Ser186-Arg216 in EcDXR) is effected by a hydrogen bond between 
Ser186 and His209 and is thought to lead to the tight-binding conformation of the ligand," 
which is th en shielded from the solvent by the 'lid'. The two residues Ser186 and His209 are 
brought together as the lid closes, with Gly185 acting as a 'hinge,.47 Met214 is also part of the 
hinge and Ortmann et 01. have proposed that the backbone N-H of this residue cou ld 
hydrogen-bond with a suitably placed ligand or inhibitorS' Silber et 01. have shown the loop 
region to have significantly different conformations in the apo-enzyme, the fosmidomycin-
Mn" complex and the NADPH complex, and suggest that only relatively small ligands will allow 
the loop to close properly. " 
1.4. Structure-activity relationships of fosmidomycin and DOXP 
analogues 
Many analogues of DOXP 9, fosmidomycin 19 and FR900098 20 have been synthesised and 
have been investigated in terms of their inhibitory properties. Although very few of these have 
proven more effective than fosmidomycin in inhibiting EcDXR, the structure-activity data they 
provide can be used to direct the design of further analogues. For closely related compounds, 
there appears to be a good correlation between the ICso values of the ligands in both EcDXR 
and PjDXR, showing that EcDXR is a useful model for the less stable PjDXR. 60 
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The phosphate group of DOXP 9 is involved in interactions with the active-site residues in a 
similar manner to that of the phosphonate group of fosmidomycin and several studies have 
been carried out to establish the importance of this group." In one such study, it was found 
that neither deoxyxylulose nor erythrose-4-phosphate act as substrates for DXR. 34 Due to the 
susceptibility of the phosphate O-P bond to cleavage by phosphatases, the phospho nate group 
which contains the more stable C-P bond is commonly used in the design of potential 
inhibitors; this substitution appears to have little detrimental effect on the inhibition 
properties.61 The phospho nate derivative of DOXP, compound 21 (Figure 14), serves as an 
alternative substrate for DXR but has lower activity than DOXp.34 Giessmann et 01., however, 
have pointed out that the additional oxygen atom of a phosphate group would have the ability 
to form additional hydrogen bonds with nearby residues. 54. 61 
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Figure 14. Structures of selected DOXP and fosmidomycin analogues 21-30 showing variation of the 
phosphonate moiety, backbone region and hydroxamate moiety. 
The necessity of having a negative charge on the phospho nate group was studied by 
investigating the binding potential of structural analogues which are intrinsically neutral but 
are still able to form hydrogen bonds with the active-site residues. 57 Both sulfone and 
sulphonamide moieties, such as compound 22, were tested on DXR but proved to have no 
activity as inhibitors, illustrating the importance of both the negative charge on the 
24 
phosphonate moiety and of hydrogen-bonding potentia!.57 Compounds with on ly a single 
negative charge showed greatly reduced activity relative to fosmidomycin, further supporting 
this finding.57 
One explanation for the limited efficacy of fosmidomycin is that its overall hydrophilicity 
results in poor absorption, and, consequently, Reichenburg et 0/. investigated diaryl ester pro-
drugs of fosmidomycin based on the rationale that the ester linkages would be cleaved in vivo 
by non-specific plasma esterases. Diphenyl phosphonate ana logues, such as compound 23, 
proved, in fact, to be more active than FR900098 20 when administered orally. However, 
substitution on the phenyl rings tended to decrease activity, possibly due to a reduction in the 
rate of ester cleavage caused by steric hindrance" An interesting observation was made by 
Courtois et 0/. who found that, in some cases, hydrolysis of the diethyl phosphonates to the 
acids led to a reduction in inhibitory activity in plant cells." 
Considering the dimensions of the binding site, it appears that there is little scope for the 
design of inhibitors much larger than fosmidomycin 19 which would be able to occupy the 
same binding site. The active-site cleft is, in fact, relatively small and Mac Sweeney et 0/. have 
suggested that any inhibitors longer than fosmidomycin are likely to displace NADPH or bind 
to the open conformation of DXR'7 Several studies, however, have suggested the presence of 
adjacent pockets which may have the potential to bind bulky and hydrophobic groups. In one 
such study by Giessmann et 0/., the relatively high inhibitory activity of an O-phenyl-
substituted fosmidomycin analogue was considered to support the existence of a hydrophobic 
binding region some distance from the active site.54 In fact, the study of fosmidomycin 
analogues with large hydrophobic groups attached to the phosphonate moiety has indicated 
the existence of an additional lipophilic binding region beyond the phosphonate-binding site. 
Interactions of these hydrophobic groups with the protein have been found to partially 
. compensate for the resultant loss of one negative charge on the phosphonate moiety. 57 
Contrary to expectations, the activities of the mono-methyl, -ethyl and -propyl phosphonate 
esters of FR900098, such as compound 24, have been observed to increase w ith increasing 
length of the alkyl chain, supporting the presence of a hydrophobic pocket adjacent to the 
binding site. 57 The acyl residue which distinguishes FR9000098 20 from fosmidomycin 19 is 
thought to be the limit to which the hydroxamate moiety can be extended.54 Elongation of the 
acyl cha in beyond the hydroxamate moiety has, in fact, led to a decrease in activity, although 
the addition of a carbonyl group, as in compound 25, appeared to mitigate this, possibly by 
acting as a hydrogen-bond acceptor from the backbone NH of Met214 (f.co/i). 59 Substitution 
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at the a-position of the backbone region suggested the presence of a hydrophobic pocket 
close to the phosphonate-binding region.'o This was supported by the promising activity of a-
substituted fosmidomycin analogues, of which the 3,4-dichlorophenyl substituent, compound 
26, was the most effective'o A hydrated cavity bound by the residues Thr175, 5er245 and 
His248 (in MtDXR) has also been identified as a possible binding pocket for fosmidomycin 
analogues containing a phenyl group attached to ( _4." These studies show that the design of 
novel DXR inhibitors need not be limited to compounds which only occupy the fosmidomycin 
binding site. Incorporation of a hydrophobic alkyl or aryl group capable of occupying an 
adjacent pocket cou ld enhance a ligand's membrane permeability, receptor-binding and 
inhibiting potential. "·S9·'o 
Few variations in the three-carbon spacer of fosmidomycin have been explored, possibly 
because the binding of the phosphonate and hydroxamate groups anchor the molecule in the 
DXR binding cavity, leaving little scope for variation at these points. Experiments involving a 
shorter carbon spacer have shown that the three-ca rbon distance between the phosphonate 
and hydroxamate moieties is crucial. 64 Rotationally restricted fosmidomycin analogues 
incorporating a three-membered ring, such as compound 27 (Figure 14), have been 
synthesised and shown to inhibit DXR.6S The stereochemistry at the two chiral centres proved 
to be significant as the enantiomerically pure trans-inhibitor was much more effective than 
the corresponding racemic mixture.6S Based on this work and the success of a-aryl substituted 
analogues, Devreux et al. synthesised analogues containing both an a-aryl substituent and an 
a,ll-unsaturated moiety, such as compound 28, but these all showed minimal activity, 
suggesting that the combination of these two groups limited the rotational freedom 
excessively." 
Although the coordination of the hydroxamate moiety of fosmidomycin to the metal ion has 
been shown to be important, several other metal-coordinating groups have been explored. 54 
Hydroxyurea and carboxylic acid analogues of fosmidomycin, such as compound 29, have been 
synthesised by Kurz et al.; unfortunately, no binding or inhibition assay data appear to have 
been published on these compounds."·68 A reversal ofthe order ofthe hydroxamate moiety of 
fosmidomycin to form hydroxamic acids, such as compound 30, resulted in inhibitors showing 
almost the same activity as fosm idomycin. 69 These compounds were also found to inhibit the 
growth of E. coli strains, including a strain resistant to fosmidomycin." 
The study of analogues of DOXP 9, the intermediate 2-C-methyl-D-erythrose-4-phosphate 15 
and MEP 10 has highlighted crucial structural features in these molecules. The 3-hydroxyl 
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group does not appear to be essential for binding but is important for catalysis, as is the 4-
hydroxyl group.54.7. Hoeffler et 01. have shown that the methyl group of the intermediate 15 is 
vital for binding to the enzyme although elongation of this group to ethyl, as in compound 31 
(Figure 15), decreases activity, implying that the metal-coordination site is sterically 
constrained."·7. Replacement of the methyl ketone moiety of DOXP with an amide moiety, as 
in compound 32, and variations in the stereochemistry of the hydroxyl groups has resulted in 
compounds which failed to act as substrates for DXR but proved to be weak inhibitors.'· 
Successive replacement of the i-methyl hydrogens of DOXP with fluorine atoms was carried 
out by Fox and Poulter;71 the di- and tri-fluorinated analogues acted as moderate DXR 
inhibitors, whilst the mono-fluorinated analogue 33 proved to be a good substrate for the 
enzyme.71 
31 32 
Figure 15. Structures of selected DOXP analogues. 
1.5. Aims of the present investigation 
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Understanding the global importance of malaria and the potential of DXR as a promising drug 
target, the overall aim of this project has been to synthesise and evaluate a series of potential 
DXR inhibitors. More specifically, this has involved the following objectives. 
i) Synthesis of a series of diethyl 2-heteroarylamino-2-oxoethyl- and 2-heteroarylamino-2-
oxopropyl-phosphonate esters and their corresponding phosphonic acid sa lts. 
ii) Investigation of the use of the saturation transfer difference (STD) experiment as a 
nuclear magnetic resonance (NMR) screening tool to study the ability of the synthesised 
compounds to bind to DXR. 
iii) Testing of the synthesised compounds in a DXR-inhibition assay to determine their 
inhibitory activity and to explore structure-activity relationships. 
iv) Simulated docking studies of the inhibitors to investigate their ability to fit in the DXR 
active site and their potential interactions with the active-s ite residues. 
v) Exploration of the active sites of EcDXR and PjDXR to highlight any differences between 
them and to identify any nearby potential binding pockets or residues. 
vi) Design of a series of novel DXR inhibitors incorporating known structure-activity 
relationships and any information brought to light in the above investigations. 
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2. RESULTS AND DISCUSSION 
2.1. Synthesis of potential DXR inhibitors 
During the investigation of glutamine synthetase inhibitors as potential antituberculosis 
agents, compound 34 was found to exhibi t binding to EcDXR in STD NMR experiments and a 
low level of EcDXR inhibition in enzyme inhibition assaysn Severa l se ries of analogues of 
compound 34, with various substituents on the phenyl ring, were consequently prepared in a 
cognate study in our group, and some of these compounds showed binding in STD 
experiments." The phosphonated acetanilide 34 was therefore identified as a possible lead 
compound for the design of novel inhibitors of DXR and, in the present study, attention has 
been given to the synthesis of analogues in which the benzene ring is replaced by a 
heterocyclic system. 
Structure-activity studies of fosmidomycin and its analogues have highlighted the importance 
of a metal-coordinating moiety (especially nitrogen- or oxygen-containing functionalities) for 
binding to the hard divalent metal cation in the DXR active site. 74 The heterocyclic and amide 
moieties in compounds 35a-e (Figure 16) were expected to serve this function in addition to 
providing a degree of rigidity and hydrophobicity. In studies by Kuntz et of., reversa l of the 
hydroxamate moiety of fosmidomycin 19 did not appear to decrease the inhibitory activity 
and it was hoped that the amide moiety wou ld have similar interactions with the active-site 
residues." Ester pro-drugs of fosmidomycin analogues have been shown to exhibit increased 
lipophilicity and absorption:"""· and the phosphonate esters 35a-e were expected to provide 
similar advantages. 
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Figure 16. Initial set of phosphonate ester targets 35a-e. 
Since the phosphonate esters 35a-e could well be hydrolysed in vivo, it was decided that the 
disodium salts 36a-e of the corresponding acids (Scheme 1) shou ld also be prepared and 
subjected to enzyme-binding and -inhibition stud ies. Access to the phosphonate esters 35a-e 
and the disodium salts 36a -e is outlined in Scheme 1. 
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Scheme 1. Synthesis of phosphonate esters 35a-e and the disodium salts 36a-e of the corresponding 
phosphonic acids. 
Reagents and conditions:- (i) NaH, chloroacetyl chloride, THF, 6 h, r.t. ; (ii) triethyl phosphite, 9 h, reflux 
(110 ' C); (iii) TMSBr. DeM, overnight, r.t. and then O.4M-NaOH. 
The formation of the amide bond in the a-chloroamides 38a-e is achieved by reaction of 
chloroacetyl chloride with the respective primary am ines 37a-e in THF, sodium hydride serving 
to deprotonate, and thus enhance the nucleophilicity of, the amines. Nucleophilic acyl 
substitution with loss of chloride occurs preferentially at the less hindered and more 
electrophilic carbonyl carbon in chloroacetaldehyde, as shown in Figure 17. 
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Figure 17. Mechanism of the formation of the amide bond between a primary amine and chloroacetyl 
chloride. 
Thu s, acylation of the respective primary amines 37a-e wi th chloroacetyl ch loride afforded the 
known chloroacetamides 38b-e in yields in excess of 70% and in sufficient purity (after 
washi ng with hexa ne), as indica ted by 'H and "e NMR analysis, to be used without further 
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purification. The pattern of signals between O.S and 2.0 ppm in Figure 18 was observed in the 
NMR spectra of all the crude products, and was attributed to high-boiling alkanes present in 
the mineral oil used to store the NaH. Repeated washing of the products with hexane 
successfully removed the oil. Each of the products was characterised by the presence of the 
chloromethylene singlet at ca. 4.2 ppm in the 'H NMR spectrum as shown in Figure 18. The 2-
aminopyridine derivative 38a, however, required chromatographic purification prior to use to 
remove residual starting material and other impurities. Intramolecular cyclisation or 
polymerisation are possible competition reactions and could account for the lower yields 
obtained in repeated preparations of compound 38a (Table 1, p. 34). 
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Figure 18. 'H NMR spectrum of compound 38b (CDCI" 600 MHz); 'mineral oi l impurities. 
An alternative procedure was explored for the synthesis of compounds 38a and 38d. This 
method" involves direct addition of chloroacetyl chloride to the amine in dichloroethane 
followed by neutralisation with aqueous sodium hydroxide, and appeared to work well for the 
furfurylamine derivative 38d, giving a clean product after work-up with a yield of 91%. 
However, this approach failed to give the 2-aminopyridine derivative 38a; analysis of the crude 
reaction mixture showed the presence of 2-aminopyridine 37a but none of the expected 
product 38a. A microwave-assisted variation of this method also failed to yield the desired 
product 38a. 
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The next step involved introduction of the phosphonate ester moiety viG the Arbuzov reaction. 
Each of the chloroacetamides 38a-e was heated under reflux with neat triethyl phosphite for 9 
hours to yield the diethyl phosphonates 3Sa-e. In this reaction, the trivalent phosphorus 
attacks the chloromethylene carbon, displacing chloride to form an intermediate 
phosphonium salt, which cleaves to afford ethyl chloride and the pentavalent phosphonate 
ester as shown in Figure 19." 
~-[ BO~P~R] --... I 
ao 
Figure 19. Mechanism ofthe Arbuzov reaction. ?8 
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The diethyl phosphonates 3Sb-e were readily isolated in reasonable yields (48% to 100%; 
Table 1, p. 34), the excess triethyl phosphite being effectively removed by repeated washing 
with hexane and evaporation under high vacuum for several hours. 'H NMR analysis of the 
products clearly showed the disappearance, in each case, of the chloromethylene singlet at CG. 
4.2 ppm and the appearance of a methylene proton doublet at CG. 3 ppm as shown in Figure 
20. Coupling to the adjacent 31 p nucleus results in splitting of the methylene signal, with a 
characteristic coupling constant of CG. 21 Hz. As with the ch loroacetylation step, the 2-
aminopyridine derivative 3Sa was obtained, repeatedly, in lower yields (12%) and purity than 
the other phosphonate esters. Since attempts to purify compound 3Sa on silica gel proved 
unsuccessful, the subsequent hydrolysis step was carried out on the crude material and the 
product, 36a, was purified by reverse-phase chromatography on a C18 column followed by 
reverse-phase HPLC. As the aim was to obtain the compounds for bioassay, further 
optimisation of the synthetic method was not explored. 
All of the phosphonate esters 3Sa-e are new and were fully characterised by elemental 
(HRMS) and spectroscopic (IR and 1- and 2-D NMR) analysis. The characteristic coupling to the 
adjacent 31p nucleus seen in the ' H NMR spectrum (Figure 20) was also observed in the proton 
decoupled BC spectrum of compound 35b (Figure 21). Coupling to the adjacent 31 p nucleus 
results in splitting of the methylene carbon signal at CG. 36 ppm with a large coupl ing constant 
of 131 Hz and the splitting (1=4.5 Hz) can even be observed in the carbonyl carbon signal at 
162.5 ppm. The C-5' nucleus is highly deshielded by the adjacent oxygen atom and the signal 
was assigned by analysis of the multiplicity-edited HSQC NMR spectrum. The HMBC NMR 
spectrum for compound 35b (Figure 22) reveals the correlation between the CH, P protons and 
the carbonyl carbon as well as between the 4'- and 5'-methine protons and the C-3' carbon. 
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Figure 20. ' H NMR spectrum of compound 35b showing coupling of CH, to 31p (CDCI, . 600 MHz). 
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Figure 21. Proton decoupled "c NMR spectrum of compound 35b (CDCI,. 150 MHz). 
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Figure 22. HMBC NMR spectrum of compound 35b (CDeI" 600 M Hz). 
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Table 1. Percentage isolated yields of chloroacetamides 38a-e, phosphonate esters 3Sa-e and disodium 
phosphonate salts 36a-e. 
R-NH2 RNHCO.CH,GI RNHCO.CH, P(O)OEt, RNHCO.CH,P(O)O,Na, 
37a-e 38a-e 35a-e 36a-e 
a Cl 21 12 2.3 ~ NH2 
NH, 
b CN 100 48 100 0/ 
C f[~NH' 70 59 100 N 
d ~NH' 84 (91)" 62 100 
0 
e Yz~NH' 74 67 100 
0 
'Synthesis by direct addition of chloroacetyl chloride to furfurylamine.77 
Since hydrolysis of the phosphonate esters 35a-e is expected to occur in vivo,,,,62,,,,,., the 
disodium salts 36a-e of the corresponding phosphonic acids were also required for in vitro 
enzyme inhibition assays, Microwave-assisted hydrolysis of the esters 35b-d in acetonitrile," a 
method used successfully in our group on similar compounds," was attempted using 
bromotrimethylsilane (TMsBr) in acetonitrile but there was little or no evidence of the 
hydrolysis products despite several attempts. t Several methods for the conversion of 
phosphonate esters to the corresponding phosphonic acids have been reported. 
Phosphonation using dibenzyl phosphite followed by hydrogenolysis with hydrogen gas and 
palladium-on-carbon catalysis has proved successful in many instances,59 and the 
transformation has also been achieved by treatment of phosphonate esters with TMsBr at 
room temperature in dichloromethane followed by hydrolysis (Scheme 4, p. 53),54,82 The latter 
method" was attempted for the hydrolysis of the phosphonate ester 35e, followed by 
t Subsequently, however, it was discovered that the temperature control on the microwave rotor had 
been malfunctioning and this may have been the cause of the failure of the reaction. 
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treatment with aqueous sodium hydroxide and extraction into ethyl acetate, but NMR analysis 
of the organic phase showed that only starting material was present. The reported 
procedureS4 requires reaction of the phosphonate ester with TMSBr for 2 hours. It was 
therefore decided to monitor the reaction over an extended period of time using 31p NMR 
spectroscopy and it was found that stirring the reaction mixture overnight followed by 
titration with aqueous sodium hydroxide generally afforded the disodium salts of the 
respective phosphonic acids in quantitative yield (Table 1). The 2-aminopyridine system, 
however, again presented difficulties with the disodium sa lt 36a being obtained, after 
purification by reverse-phase HPLC, in only 2.3% yield. Having established the suitability of 31 p 
NMR spectroscopy to follow the reaction with TMSBr, it was decided to undertake a full 
kinetic study ofthe reaction, the details of which are discussed in Section 2.2. 
Comparison of the 'H NMR spectra of the phosphonate ester 35b and the disodium salt 36b 
(Figure 23) clearly shows the disappearance of the signals corresponding to the ethyl groups at 
co. 1.3 and 4.1 ppm. All hydrolysis products were purified by reverse-phase column 
chromatography and compou nds 36a and 36c were further purified by reverse-phase HPLC. 
The disodium sa lts 36b-e are all new compounds and were fully characterised by elemental 
(HRMS) and spectroscopic (IR and 1- and 2-D NMR) analysis. 
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Figure 23, ' H NMR spectra of phosphonate ester 35b (top; COCl" 600 MHz) and disodium salt 36b 
(bottom; 0,0, 600 MHz) showing disappearance of ethyl ester signals (highlighted in orange) on 
hydrolysis. 
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A dynamic NMR study was carried out to investigate the rotameric possibilities of the 
phosphonic acid salts. Delocalisation of the amide nitrogen lone-pair electrons, as shown in 
Figure 24 for compound 36c, confers a degree of rigidity on the amide bond and may result in 
the existence of two conformers interconversion of which occurs on the NMR timescale. A 
variable temperature NMR study may therefore be used to determine the presence of the two 
rotamers and, if such rotamers exist, the energy barrier to rotation. 
Figure 24. Two possible rotamers of compound 36c due to restricted rotation about the amide N-CO 
bond. 
Compound 36c was selected for the dynamic NMR study as apparent doubling of the signals 
was observed in the 'H NMR spectrum at 297 K (Figure 25). ' H NMR spectra of compound 36c 
were recorded as the temperature was increased in 5 K increments from 283 K to 333 K. If the 
doubling of the signals at 297 K were due to the presence of rotamers, it was expected that, as 
the temperature increased, the signals would move closer together and eventually coalesce as 
distinct populations of the two conformers become indistinguishable on the NMR timescale. 
Selected 'H NMR spectra of compound 36c at temperatures between 283 K and 333 K are 
shown in Figure 26 and it is clear that there is no variation in the chemical shift difference 
between the signals over this temperature range. The dynamic NMR study therefore excluded 
the possibility of rotamers at 297 K and it was concluded that steric factors result in the 
existence of only one rotamer w ithin the temperature range studied. HPLC purifi ca tion of 
compound 36c subsequently confirmed these results, showing that the low intensity signals 
observed in Figure 25 were due to residual starting material, compound 35c! 
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Figure 25. 'H NMR spectrum of compound 36c showing doubling of the CH, P, 4' -H and 5'-H signa ls (D,D, 
600 MHz). 
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Figure 26. ' H NMR spectra (D,D, 600 MHz) of compound 36c at selected temperatures. The pairs of 
signals (CH, P, 4'-H and 5'-H) analysed are highlighted. 
38 
Comparison of the structure of fosmidomycin 19 and several of the fosmidomycin analogues 
(such as compounds 2362 and 3069) reported in the literature suggested that an increase in 
inhibitory activity may be achieved by increasing the distance between the amide and 
phosphonate moieties in compounds 35a-e and 36a-e. The active-site cleft of DXR is relatively 
small and it is considered that analogues either much shorter or much longer than 
fosmidomycin are unlikely to be effective inhibitors.47•6' Analogues of compound 34 
incorporating an ethylene rather than a methylene spacer between the amide and 
phosphonate moieties, have been prepared in our group and have shown increased inhibition 
in EcDXR enzyme-inhibition assays,,,·n . ., and the heterocyclic analogues, 39a-e (Figure 27) and 
their corresponding disodium phosphonic acid salts 40a-e, were therefore prepared. 
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Figure 27. Structures of the second set of phosphonate esters 393-e. 
Access to the phosphonate esters 39a-e and the disodium salt s 40a-e of the corresponding 
phosphonic acids is outlined in Scheme 2. 
0 0 0 II II 
R-NH2 ~ R ........ NH~CI ii R/NH~P\-O~ ilj II /NH~P_ _ + • R \ _O .Na 
o 0, o No 0 
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Scheme 2. Synthesis of phosphonate esters 393-e and the corresponding phosphonic acid sal ts 40a-e. 
Reagents and conditians:- (i) NaH, chloropropionyl chloride, THF, overnight, r.t.; (ii) triethyl phosphite, 9 
h, reflux (110 0q ; (iii) TMSBr, OeM, overnight, r.t. and then OAM-NaOH. 
The 3-chloropropionyl derivatives 41a-e were synthesised by the reaction of chloropropionyl 
chloride with the respective primary amines 37a-e, following the methodology used for the 
methylene analogues 38a-e, and were were isolated in reasonable yields ranging from 36% to 
100% (Table 2). After washing with hexane to remove residual high-boiling alkanes, 
compounds 41b, 41c and 41d were used without further purification whilst compounds 41a 
and 41e required purification by column chromatography before they cou ld be used in the 
phosphonation step. The presence of a pair of methylene triplets at ca. 3.0 and 3.9 ppm in the 
39 
'H NMR spectra of each of the 3-chloropropionyl derivatives 41a-e confirmed the presence of 
the ethylene linking group. Low intensity signa ls at ca. 5.9, 6.4 and 6.6 ppm were common ly 
observed in the ' H NMR spectra of the crude products, suggesting that loss of HCI may have 
occurred resu lting in formation of the (l,~-unsaturated amides as minor products. 
Table 2. Percentage isolated yields of ~-chloroamides 41a-e, phcisphonate esters 39a-e and disodium 
phosphonic acid salts 40a-e. 
R·NHl RNHCO.CHlCHlCI RNHCO.CH,CH, P(O)OEt, RNHCO.CH,CH, P(O)O,Na, 
37a·e 41a·e 39a-e 40a·e 
a Cl 39 33 100 (crude) ~ NH2 
NH, 
b eN 100 74 27 0 / 
c i[J-NH, 62 69 13.9 N 
d ~NH' 63 80 81 
0 
e Yz~NH2 I S 84 40 61 
0 
Reverse-phase HPLC was used to separate the mixture of products formed during the 
synthesis of compound 41a and characterisation of the compounds in the fractions obtained 
(Figure 28) gave some insight into the reason for the low yields obtained in this case. The first 
fraction was the desired product 41a which showed that the reaction had been successful to 
some degree, although the yield following HPLC was only 39%. The second fraction contained 
a mixture of compound 41a and the imide 42, resulting from reaction of two chloropropionyl 
chloride molecules with the amine 37a, followed by loss of HCI from one of the 3-
chloropropionyl moieties to give the a, ~-unsaturated amide. The third fraction contained 
compound 43, also an imide but containing a second pyridine ring; its formation is attributed 
to conjugate addition of a second molecule of 2-aminopyridine 37a to the (l, ~-unsaturated 
imide 42. Loss of HCI from the product 41a resulted in the format ion of the (l,~-unsaturated 
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amide 44 which was isolated in only 2% yield from the fourth fraction. Formation of small 
amounts of the a,J3-unsaturated amides during the synthesis of the other compounds in this 
series 41b-d is no doubt due to the added stability afforded by the extended conjugation. 
Interestingly, there was no evidence of the format ion of the side-products corresponding to 
compounds 42 and 43 in the synthesis of the analogues 41b-e. 
41. 42 44 
Figure 28. Products formed during the synthesis of compound 413 . 
The 1- and 2-D NMR spectra used to characterise compound 43 are shown in Figures 29-34. 
Integration of the 'H NMR spectrum (Figure 29) indicated the presence of two pyridine and 
two ethylene moieties and the absence of signals between 5.5 and 6.5 ppm showed that no 
a,J3-unsaturated system was present. Comparison of the ' H_'H coupling constants and analysis 
of the COSY spectrum (Figure 30) confirmed the presence of two ethylene moieties by 
showing the coupling of 2-CH, with 3-CH, and 2"-CH, with 3"-CH, . The aromatic proton signals 
from the two pyridine rings were ass igned following identification of the 6'" -H signal at 8.32 
ppm, deshielded by the adjacent nitrogen atom, and the coupling between the 6'''- and 5"'-, 
the 6'- and 5'-, the 4'''- and 3'''- and the 4'- and 3'- protons. The BC DEPT 135 spectrum (Figure 
31) clearly showed the CH, signals of the two ethylene moieties and allowed identification of 
the quaternary carbon signals in the proton decoupled "C spectrum (Figure 32). Assignment of 
the CH and CH, carbon signals was assisted by analysis of the multiplicity-edited HSQC 
spectrum (Figure 33) in which the CH, signals (negative phasing) are shown in blue and the CH 
(and CH,) signals (positive phasing) are shown in red. Analysis of the HMBC spectrum, shown 
in Figure 34, confirmed the aSSignment of the aromatic proton and carbon signals and allowed 
assignment of the C(0)-1 and C(0)-1" signals due to their correlation with the 2- and 3-CH, 
and 2"- and 3"-CH, protons, respectively. Correlation between the C-2' carbon signal and the 
3'- and 6'-H proton signals and, likewise, the C-2'" carbon signal and the 3"'- and 6"'-H proton 
signals was used to assign these two quaternary carbon signals, as shown in Figure 34. 
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Figure 30. COSY NMR spectrum of compound 43 (0,0, 600 MHz). 
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Figure 31. Be DEPT 135 NMR spectrum of compound 43 (0 20, 150 MHz) . 
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Figure 32. Proton decoupled B e NMR spectrum of compound 43 (020, 150 MHz). 
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Figure 33. Multiplicity-edited HSQC NMR spectrum of compound 43 (0,0, 600 MHz). 
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Arbuzov phosphonation of the ~-chloroamides 41a-e proceeded smoothly, affording the 
phosphonate esters 39a-e in moderate to good yields (Table 2). Several washings with hexane 
were required to remove the excess triethyl phosphite but, in general, the phosphonation 
reaction proved to be a very clean reaction. Compounds 39a, 39b, 39d, and 3ge were all oils 
but the thiazole derivative 39c crystallised out on the addition of hexane yielding crystals of 
high purity. Splitting of the signals due to coupling to " P can be observed in both the ' H and 
l3C spectra, even as far down the chain as the amide carbonyl signal. 
Employing the variation of Giessman's method" described earlier, the phosphonate esters 
39a-e were hydrolysed to afford the disodium salts 40a-e of the corresponding phosphonic 
acids. Purification of the salts was attempted using HP20 resin chromatography but this 
approach proved unsuccessful due to the high aqueous solubility of the sodium salts which 
precluded adequate retention by the stationary phase. Reverse-phase HPLC, eluting with 
water, was therefore used to purify the final products for full characterisation and bioassay. 
The absence of the ethyl ester signals in the ' H NMR spectra of the disodium salts provided 
clear evidence of the success of the hydrolysis reaction. 
The 1- and 2-D NMR spectra obtained for compound 40c are shown in Figures 3S-40 and were 
used to characterise this compound. The 'H NMR spectrum (Figure 35) clearly shows the two 
aromatic and two methylene proton signals, with the complex splitting patterns of the 
methylene signals arising from their proximity to the " P nucleus. The downfield signal at 7.39 
ppm was assigned to the 4'- proton on the basis of the expected deshielding by the adjacent 
nitrogen atom, and hence, the signal at 7.11 ppm was assigned to the 5'- proton. Coupling 
between these two protons and the 2- and 3-methylene protons is evident in the COSY 
spectrum (Figure 36). The amide proton signal could not be observed due to exchange of this 
proton with the D,O solvent. The BC DEPT 135 spectrum (Figure 37) clearly shows the two 
methylene carbon nuclei while the absence of signals at 158.9 and 174.5 ppm in the DEPT 
spectrum permitted their assignment in the proton decoupled l3C spectrum to the quaternary 
carbon nuclei. The splitting (J=130.5 Hz) of the signal at 24.3 ppm in the proton decoupled l3C 
spectrum (Figure 38) permitted assignment of this signal to the 3-methylene carbon adjacent 
to the " P. Once this signal had been assigned, analysis of the HSQC spectrum (Figure 39) led to 
the assignment of the corresponding methylene proton signal at 1.73 ppm and, hence, the 
remaining signal at 2.65 ppm to the 2-methylene protons. Assignment of the l3C signal at 
136.8 ppm to the C-4' nucleus also reflects the deshielding by the adjacent nitrogen atom. The 
HMBC spectrum (Figure 40) shows correlation of C-2' to the 4'- and 5'-methine protons and 
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the carbonyl carbon to the 2- and 3-methylene protons, thus allowing assignment of the two 
remaining BC signals at 158.9 and 174.5 ppm to C-2' and the carbonyl carbon respectively . 
Doublets observed in the HMBC spectrum were attributed to one-bond couplings between 
carbon and proton nuclei and were identified by comparison with the H5QC spectrum. The 3l p 
spectrum of compound 40c shows a single signa l at 20.9 ppm, illustrating that complete 
hydrolysis of the phosphonate ester 39c had taken place. 
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Figure 35. ' H NMR spectrum of compound 40c after HPLC (D,O, 600 MH,). 
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Figure 36, COSY NMR spectrum of com pound 40c after HPLC (D,O, 600 MHz). 
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Figure 37, "e DEPT l35 NMR spectrum of compound 40c after HPLC (D,O, 150 MHz). 
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Figure 38. Proton decoupled "c NMR spectrum of compound 40c after HPLC (D,O, 150 MHz). 
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Figure 40. HMBC NMR spectrum of compound 40c after HPLC (0,0, 600 MHz). 
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For comparative purposes, the phosphonate ester 45 and the disodium phosphonate salt 46 
were prepared from 3-chloropropiophenone 47 as illustrated in Scheme 3. Separation of the 
phosphonate ester 45 from the excess triethyl phosphite proved particularly difficult as the 
product was miscible with the hexane used for washing. The 31p NMR spect rum indicated the 
presence of a mixture of phosphorus-containing products and column chromatography was 
used to purify the phosphonate ester 45, subsequent hydrolysis of which afforded the 
disod ium salt 46 which was included in the EcDXR enzyme assays (Section 2.3.2.). 
47 
o 
----.O-~ .. ~ Jl -'" A 
Ph/ "'-./ 'P-OEt 
\ 
45 OEt 
o 
ii "Ph~W _ + 
\~O +Na 
46 0 Na 
o 
II Ph~CI 
Scheme 3. Synthesis of the ~-keto phosphonate 45 and corresponding disodium sal t 46. 
Reagents and conditians:- (i) triethyl phosphite, 9 h, reflux (110 'C); (ii) TMSBr, DCM, overnight, r.t. and 
then O.4M-NaOH. 
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2.2. Kinetic study of the reaction of phosphonate esters with 
bromotrimethylsilane 
As indicated earlier, attempts to hydrolyse the phosphonate esters 35b, 35c and 35d using the 
method of Kumar8l were unsuccessfu l and the synthesis of the disodium salt 36e, using the 
method of Geissmann,54 appeared to require a longer reaction time than indicated in the 
literature. In order to elucidate the process, the kinetics of the consecutive trans-esterification 
reactions leading to the formation of the bis(silyl) ester 48 from the phospho nate ester 35e 
(Scheme 4) were investigated. The bis(silyl) ester 48 hydrolyses readily to the phosphonic acid 
salt 36e on treatment with aqueous NaOH . The use of bromotrimethylsilane (TMSBr) to form 
bis(silyl) esters was introduced by McKenna in 1977 and, while the reaction progress has been 
monitored previously by ' H and 31p NMR spectroscopy, no kinetic studies have been carried 
out." Although some studies have employed 31 p NMR to investigate the kinetics of binding to 
a sorbent"' and to measure the in vivo levels of phosphate metabolites," the technique has 
not been widely used to study the kinetics of reactions in organic synthesis. 
o 
NH...,/""'II . + 
o S......"......- II P- ONa 
T}-II 0 b -Na+ NaOH(aq) ~ N ~.~~~ 
36e 
o 
II 
o s ......"......- NHl j-OSiM"3 T}-~ 0 OSiM"3 
48 
Scheme 4. Two-step reaction between the phosphonate ester 35e and TMSBr. 
Characterisation of the bis(trimethylsilyl)phosphonates 48 and SO (Figure 41) was carried out 
in the reaction mixture due to the highly labile nature of these compounds. The NMR signals 
of these compounds were well resolved from those of the by-product ethyl bromide (EtBr), 
excess TMSBr and the 1,3,5-trimethoxybenzene (TMB) used as an internal standard. The NMR 
spectra used to characterise compound 48 are shown in Figures 42 and 43. 
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Figure 41. Structures of the bis(trimethylsilyl)phosphonates 48 and 50. 
The ' H NMR spectrum of the bis(trimethylsiIVI)phosphonate 48 (Figure 42) indicated the 
presence of the two trimethvlsilVloxV groups, with the highlV shielded protons resonating as a 
singlet at -0.03 ppm with a relative integra l of 18. The signal due to excess TMSBr was 
identified as the broad singlet at 0.43 ppm. The characteristic doublet at 3.45 ppm was 
assigned to the methvlene protons adjacent to the 31p nucleus and the two singlets due to the 
TMB standard were identified bV their 1:3 integral ratio and the deshielding of the methoxv 
protons. Assignment of the signals at 1.57 and 3.32 ppm to the EtBr bVproduct was made bV 
analvsis of the COSY spectrum. The signals in the proton decoupled BC spectrum (Figure 43) 
were assigned following analvsis of the multiplicitv-edited HSQC spectrum and HMBC 
spectrum. The 31 p NMR spectrum showed a single signal at -0.69 ppm. 
Figure 42. ' H NMR spectrum of compound 48 together with EtSr, TMSSr and TMS (CDCI" 600 MHz). 
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Figure 43. Proton decoupled BC NMR spectrum of compound 48 together with EtBr, TMSBr and TMB 
(CDCI" 150 MHz) , 
Conversion of the diethyl phosphonate 35e to the bis(trimethylsilyl)phosphonate 48 involves 
the replacement of two ethyl groups by two trimethylsilyl groups, and is presumed" to follow 
a mechanism (Scheme 5) similar to that of the Arbuzov reaction, 
o 
II S,., ~P-o/ , 
R'~ \ 
OR 
Scheme S. Proposed mechanism for the reaction of a phosphonate diester with TMSBr, 82 
R' : Et 
'H and 3lp NMR spectra were obtained for solutions of the substrate 35e in dry CDCI, at 90 s 
intervals during the course of the reaction, and the concentrations of the three phosphorus-
containing species (35e, 49 and 48) were determined from the relative integral data. The 3lp T, 
relaxation times for each of these species were measured to ensure that the recycle 
(acquisition + delay) time used (2.9 s) permitted complete relaxation of the phosphorus nuclei 
and, hence, that the integral data are proportional to their relative concentrations, Inverse-
gated proton decoupling was also used. Concentrations of TMSBr were determined from the 
corresponding 'H NMR spectra, using 1,3,5-trimethoxybenzene (TMB) as an internal standard. 
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The 31p T, relaxation times and 31 p chemical shift values (relative to that of the phosphoric acid 
standard) are shown in Table 3. It is apparent, from the 31p spectra illustrated in the stack-plot 
(Figure 44), that the Signals of the three phosphorus nuclei are well resolved and that the 
phosphorus nuclei are progressively shielded as the ethyl groups are replaced by trimethylsilyl 
groups. 
Table 3. 31 p Chemical shift values and T, relaxation times of phosphorus-containing species. 
35. 
. , . . , . . . , . 
" 
co 
" 
Compound Ii (ppm) T, (ms) 
35e 
49 
48 
. . I ' • 
" 
19.19 
9.37 
-0.69 
536 
542 
553 
o 
II o II 
o s-/NH1P-OSiM~ 
~~ 0 bEt 
o s-/NH1~-os iMe3 ~~ 0 OSiMe3 
48 
49 
• I .••. I .• . , . •• , .••. , . ... I . . . . . , 
, , 
-, -10 -lS -:" 0 -:il~ -lO 
Figure 44. Stack-plot illustrating 31p NMR signals for starting material 35e, intermediate 49, and product 
48 at 30 min intervals, at 285 K. 
A plot of the concentrations of the starting material 35e and the mono- and disilylated 
derivatives (49 and 48, respectively) against time (Figure 45) reveals curves, which are typical 
of a two-step reaction in which k,~k286 As expected, the curve for the formation of the product 
48 is sigmoidal in shape and has a point of inflexion at the time corresponding to (49jm,,86 The 
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delay in the appearance of the product 48 (which is respons ible for the sigmoidal curve) 
implies involvement of an intermediate in the reaction." 
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Figure 45. Graph of concentration against time for the reaction of phosphonate ester 35e with TMSBr, 
at 283 K, showing the three phosphorus-containing species:- starting material 35e as black diamonds; 
intermediate 49 as grey squares and product 48 as open circles. 
Analysis of the first step, involving consumption of the starting material 35e, indicated that it 
follows second-order rather than the simple first-order kinetics used in the treatment 
provided by Schmid and Sapunov." Consequently, the reaction was attempted under pseudo 
first-o rder conditions by using 32 equivalents of TMSBr. Under these conditions, however, the 
3lp signals broadened significantly and changes in the chemical shift values were noted. In 
order to avoid unnecessary complications (involving, perhaps, the formation of polysilylated 
products, such as compound 51),'7 the well-resolved, second-order data were used. 
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Frost and Schwemer," have integrated the differential rate equations for competitive 
consecutive second-order reactions based on very similar reactions, viz., the saponification of 
ethyl adipate and ethyl succinate, and their treatment was extended into a computer 
57 
programme by Burkhard." Unfortunately, these approaches only apply to the use of 
stoichiometrically equivalent amounts of the two reactants. However, the system we 
examined involves the reaction between the phosphonate ester 3Se and four equivalents of 
TMSBr and our ana lysis has been based on a consideration of two, separate, second-order 
reactions of the general form:-
A+B-tP 
The rate of such a reaction is given by equation 1 in which k is the second-order rate constant:-
-d[AJ = k[A][BJ 
dt 
Eqn.l 
When the sta rting concentrations [AJ o and [BJ o of the two reactants are different, the 
variable x is used such that [AJ. - x = [AJ and [BJ o - x = [BJ, and equation 1 becomes:-
dx 
--- -.,--- = kdt ([AJo -x)([BJo -x) 
After partial fraction expansion and integration, equation 2 becomes:-
I I =--[ A.;.eJ._-_x ~-~~n-:-[BJo -[AJo [BJo-x 
kt + C 
I [AJ 
where C = In--o when x = 0 and t = 0 [Bl. -[AJ. [BJ. 
In [BJ.[AJ kt([BJ. -[AJo) [AJo[BJ 
Eqn. 2 
Eqn.3 
Eqn.4 
As the reactant concentrations [A] and [B] can be measured using the NMR integral data, 
equation 4 (developed by Keusch);o was used to calculate the rate constants, k, and kz for the 
first and second steps respectively. For the first step, Ao = initial concentration of the substrate 
3Se, while Bo = initial concentration of TMSBr. In(BoA/AoB) was plotted against time and the 
gradient for the initial linear portion of the graph was divided by (Bo - Ao) to afford the rate 
constant k, for the first step (3Se -7 49) . The second-order component of the second step (49 
-7 48) occurs upon complete consumption of the substrate 3Se, at which stage the only 
reaction occurring involves conversion of the monosilylated intermediate 49 to the product 
48. At this point, Ao = [49] and Bo = [TMSBr] and equation 4 was again used to determine the 
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second-order rate constant for the second step, k2• The linearity of the second-order kinetic 
plots confirms that both steps are second-order - observations which are consistent with the 
mechanism proposed by McKenna (Scheme 5).82 
Reactions were conducted at various temperatures between 283 and 303 K and Arrhenius 
plots for the first (35e -7 49) and second steps (49 -7 48) permitted evaluation of the 
respective activation energies E. using equation 5 (Table 4). The Eyring equation (equation 6) 
provides an alternate treatment of the activation parameters," and Eyring plots (Figure 46) 
permitted direct evaluation of the activation parameters IIH' and liS' (Table 4) and, thence, 
using equation 7, IIG' at 298.15 K. Uncertainties were calculated from the respective standard 
error values of the slope and intercept for each graph. 
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Figure 46. Eyring plot of In(kIT) against lIT (K" ) for step 1 (shown in black squares) and step 2 (shown in 
grey circles) for the reaction between 35e and TMSBr. 
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Table 4. Kinetic parameters of the reaction between phosphonate ester 35e and TMSBr. 
Parameter 
E, 
IIH' 
liS' 
IIG' 
Calculated value (kcai.mor') 
Step 1 Step 2 
11.63 ± 0.80 10.7 ± 1.4 
10.29 ± 0.74 10.1 ± 1.4 
-38.9 ± 2.S' -41.8 ± 4.8' 
21.9 ± 1.S 22.S ± 1.6 
A computational method was then employed to refine the estimates of the activation 
parameters obtained using equation 4 and improve the fit with the experimental data. Using 
the values of k, and k, calculated by the above method as initial estimates, the concentrations 
of each of the species 35e, 49 and 48 were predicted at one second intervals from the second-
order rate equation (equation 1). Building on a method used in earlier work," k, and k, were 
varied independently within a range of ± 50% of their initial values. For each pair of k, and k" 
the resultant curve of the calculated concentrations was compared with the experimental 
values and an R' value was calculated. The va lues of k, and k, giving the minimum R' value 
were easily identified and were considered to correspond to the best fit with the experimental 
data. These calculations were carried out using a specially written computer programme 
(Supplementary Data)." For each experiment, graphs were plotted (Supplementary Data) 
comparing the experimental data with those calculated using:- a) the original k, and k, 
obtained from equation 4; and b) the optimised k, and k, calculated using the above method 
(Table 5). An example of the distinct improvement in the fit with the experimental data using 
the optimised k, and k, values is shown in Figure 47 for the experiment at 297 K. The linearity 
of the Arrhenius and Eyring (Figure 48) plots is also improved, thus giving activation 
parameters (Table 6) with smaller uncertainty values, particularly for the second step of the 
reaction. As expected for a bimolecular reaction, liS' is negative due to the decrease in 
entropy when 35e and TMSBr combine. 
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Table 5. Values of k, and k, obtained at different temperatures using the two methods. 
T (K) Equatian 4 Madel 
k, (L.marls·') k, (L.marls·' ) k, (L.marls·') k, (L.mal·'.s·' ) 
282.46 -2.290E-04 -8.747E-Os -1.s3sE-04 -6.73sE-Os 
282.46 -1.s20E-04 - a -1.231E-04 a -
284.61 -1.9s3E-04 -7.221E-Os -1.87sE-04 -8.232E-Os 
287.83 -3.091E-04 -1.l23E-04 -2.906E-04 -1.269E-04 
289.98 -3.742E-04 -2.896E-04 -3 .330E-04 -1.s06E-04 
293.20 -3.83sE-04 -1.433E-04 -3.682E-04 -1.s62E-04 
29S.3S -4. 164E-04 -1.l69E-04 -4.080E-04 -1.S90E-04 
297.49 -S.S4SE-04 -1.604E-04 -S.213E-04 -2.181E-04 
297.49 -s.178E-04 -8.373E-Os -4. SS6E-04 -1.2s6E-04 
300.71 -6.129E-04 -2.28sE-04 -S .884E-04 -2.s82E-04 
303.93 -8.601E-04 -3.s00E-04 -8.S1sE-04 -3.9ssE-04 
306.08 -9.348E-04 -3.16sE-04 -8.881E-04 -3.703E-04 
a The experiment at 282.46 K was interrupted by a power failure so only k, could be calculated. 
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Figure 47. Plots of concentration against time for the reaction of phosphonate ester 35e with TMSBr at 
297 K, showing the three phosphorus-containing species:- starting material 35e as open triangles; 
intermediate 49 as open squares and product 48 as open circles. The fit of the experimental data with 
the values of k, and k, obtained from equation 4 is shown by dashed lines. The significa ntly improved fit 
of the experimental data with the computationally optimised k, and k, values is shown by sol id lines. 
For clarity, only a limited number of points are plotted for each curve. 
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Table 6. Kinetic parameters of the reaction between phospho nate ester 3Se and TMSBr using optimised 
kl and k2 values. 
Parameter Calculated value (kcal.mor') 
Step 1 Step 2 
E, 13.07 ± 0.76 12.44 ± 0.81 
IIH' 11.67 ± 0.64 11.86 ± 0.81 
LIS' -34.4 ± 2.2' -35.4 ± 2.7' 
IIG' 21.9 ± 1.3 22.4 ± 1.6 
a caI,K'l,mol"l 
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Figure 48. Eyring plot of In(kIT) against 1/T (K-1) for step 1 (shown in black squares) and step 2 (shown in 
grey circles) for the reaction between 35e and TMSBr using optimised kl and k2 values. 
These results show that the second-order rate equation gives an accurate description of each 
step of the reaction, supporting the mechanism proposed by McKenna" (Scheme 5). The 
initial estimates of k, and k2' calculated using equation 4, fit well with the experimental data 
but only for the initial parts of the two reactions 3Se ~ 49 and 49 ~ 48 as only the initia l 
linear portions of the graphs were used to calculate k, and k2 • The optimised values of k, and 
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k, provided by the model, however, fit the experimental data much better for the entire 
course of the transformation:- 35e --7 49 --7 48. This kinetic study has thus illustrated the use of 
both an approximate and a more accurate method for the analysis of second-order kinetic 
data which does not require equimolar amounts of the starting materials or pseudo first-order 
conditions. These analyses have provided rate constants and activation parameters for each of 
the consecutive reactions. In addition, the study has highlighted the value of 3lp NMR 
spectroscopy for kinetic studies with the advantages of uncluttered spectra and short 
relaxation times enabling accurate determination of the concentrations of the species 
involved. The results of this kinetic study have been accepted for publication. 94 
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2.3. Enzyme-binding and inhibition studies 
2.3.1. Saturation transfer difference (STD) NMR experiments 
The saturation transfer difference (STD) experiment" is based on the nuclear Overhauser 
effect (NOE) and uses the difference between two spectra to determine whether a small 
molecule (ligand) binds to a protein. " Provided that their 'H NMR spectra are sufficiently 
different, a set of 5 to 7 ligands can be studied in one experiment and so the STD experiment 
can be used as a screening assay for potential drug molecules. " To obtain the STD spectrum, 
the protein is irradiated at a frequency at which the ligands do not absorb - usually the upfield 
region of the protein spectrum. In large molecules such as proteins, fast spin diffusion leads to 
rapid saturation of the whole protein due to an intramolecular NOE effect" If a ligand in the 
set binds to the protein, intermolecular spin diffusion results in the ligand resonances 
becoming saturated as well. The second, referen ce, spectrum is obtained by irradiating the 
protein-ligand mixture at a frequency at which none of the ligand or protein nuclei resonate 
(off-resonance irradiation) and therefore the signal intensities remain unchanged as all species 
are equally saturated." Subtraction of the two spectra yields a spectrum in which only the 
signals whose intensities have changed are present, thus enabling identification of the ligands 
which bind to the protein" Differences between the two spectra due to temperature 
differences or magnetic field homogeneity are greatly reduced by phase cycling between the 
on- and off-resonances" According to Mayer and Meyer, the STD NMR method can be 
applied to ligands which bind to a protein with dissociation constants Ko between 10'3 and 
10" ." The STD technique can also be extended to enable identification of the ligand moieties 
which interact with the protein as the degree of saturation of the ligand resonances is 
proportional to their distance from the protons in the protein ."·97 
In order to confirm that the STD pulse programme and parameters were set up correctly and 
to determine whether the assay could be carried out in H20 rather than D20, an STD 
experiment was carried out using bovine serum albumin (BSA) as the protein and glucose and 
L-tryptophan as the ligands. This standard STD assay is expected to show that L-tryptophan 
binds to the protein" whilst glucose does not'9 As shown in Figure 49, the results of this STD 
experiment carried out in H20 suggest that both glucose and L-tryptophan bind to BSA as 
signals for both ligands could be observed in the STD difference spectrum. 
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Figure 49. BSA STD difference spectrum (bottom) resulting from an STD experiment carried out in H20 
with ' H NMR spectra of ligands glucose (middle) and L-tryptophan (top). showing the presence of both 
glucose and L-tryptophan signals in the difference spectrum (dashed arrows) . 
These results indicate that H20 is not a suitable solvent in which to carry out the STD 
experiments. This could be due to saturation transfer between the protein and unbound 
ligand mediated by intervening solvent protons. This problem would be avoided if D20 was 
used as the solvent. The use of D,O, however, means that it is necessary to freeze-dry the 
protein solution and re-suspend it in D,O, a process wh ich may result in some denaturation of 
the protein . The experiment was therefore repeated using D,O as the solvent and the 
resultant difference spectrum is shown in Figure 50. 
The glucose signals in this second experiment are much lower than those observed in H,O. The 
fact that weak signals corresponding to the glucose resonances can still be seen may be due to 
the presence of a low concentration of HOD or H,O in the D,O, thus permitting the transfer of 
magnetisation to the ligand. Alternatively, there may be a weak interaction between glucose 
and BSA. 
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Figure 50. BSA STD difference spectrum (bottom) resulting from an STD experiment carried out in D,O 
with ' H NMR spectra of ligands glucose (middle) and L-tryptophan (top), showing the presence of L-
tryptophan signals in the difference spectrum (dashed arrows) and a very weak glucose signal (dotted 
arrow). 
The use of STO NMR has not been very widely reported, but the examples in the literature 
appear to be inconclusive as to which solvent should be used. Ji and co-workers carried out 
successful STO NMR studies in an aqueous sodium phosphate buffer, with 10% 0 ,0 added for 
the frequency lock, and used a WATERGATE (water suppression by gradient-tailo red 
excitation) pulse sequence to suppress the water signal. " Mayer and Meyer carried out their 
experiments in 0,0 buf claim that the STO experiment works just as well in H,O.9S A 
comparison between spectra obtained in H,O and 0,0 was carried out by Mayer and James for 
paromycin binding to RNA targets.'oo It was found that the STD signal was smaller for spectra 
recorded in H,O, as compared to 0,0 , and rapidly rea ched its maximum intensity of about 40% 
as the saturation transfer time was increased. In contrast, the signal intensity of spectra 
recorded in 0,0 increased steadily as t he saturation transfer time was increased. These 
observations have been attributed to the faster longitudinal relaxation rate of the receptor 
protein in H, O, due, in turn, to the abundant unsaturated wat er protons wh ich readily accept 
the magnetisation. Mayer and James have therefore concluded that, although the STD 
66 
experiment can be carried out in H20, the use of 0 20 is preferable, especially if the signal 
intensities are low. lOO 
The ligands to be tested for binding to EcOXR were divided into four sets (35a-e, 36b-e, 39a-e 
and 40b-e + 36a) and an STO experiment was carried out for each set. In each experiment, 
EcOXR in sodium phosphate buffer was freeze-dried and re-suspended in 0 20 and the set of 
ligands was dissolved in the protein solution to give a 1:40 protein to ligand molar ratio 
(except for the set 35a-e which was prepared with a 1:80 protein to ligand molar ratio). For 
the first group of ligands, the STO difference spectrum showed very weak signals and 
increasing the number of scans resulted in little improvement. Although the EcOXR 
concentration was relatively low for the first experiment (4.6 ~M), the STO experiment is one 
of the most sensitive ligand-detected screening methods and protein concentrations as low as 
100 nM" and even 1 nM95 have been reported. A possible reason for the lack of sensitivity, 
despite the large number of scans, could be the length of the protein pre-saturation time. In 
this experiment, only 4 Gaussian-shaped pulses were applied whilst the use of 40,95 and even 
58, has been reported." If the protein was not fully saturated by the on-resonance pulse, spin 
diffusion would lead to further reduction of the saturation, resulting in very little being 
transferred to the binding ligands. An alternative explanation for the weak signals could be 
competitive binding between the ligands in the set due to their similar chemical properties, 
thus resulting in decreased saturation transfer to all of the ligands. 
The parameters used in the STO experiment were therefore optimised in terms of the number 
of Gaussian pre-saturation pulses, the power used for saturation and the number of scans, and 
it was found that the sensitivity of the experiment improved significantly when 40 Gaussian-
shaped pre-saturation pulses were applied at an attenuation of power of only 40 dB. Once the 
experiment had been optimised, STO experiments were carried out on the four sets of ligands 
using EcOXR at a concentration of ca. 15 ~M. The resulting STO spectra and spectra of the 
individual ligands are shown as stacked plots in Figures 51-54. The underlying protein 
spectrum is visible in Figure 51 as, during the STO experiment on the first set, a spin-lock filter 
was not used. All other STO experiments included a spin-lock filter. 
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Figure 51. fcOXR STO difference spectrum for the first set of ligands (35a-e) showing correlations 
between characteristic ligand Signals and signals in the STD difference spectrum (coloured dashed lines) . 
Individual ligand spectra in 0, 0 are shown from top to bottom :- 35a, 35b, 35c, 35d and 35e. 
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Figure 52. EcDXR srD difference spectrum for the second set of ligands (36b-e) showing correlations 
between characteristic ligand signals and signals in the srD difference spectrum (coloured dashed lines) . 
Individual ligand spectra in 0 , 0 are shown from top to bottom:- 36b, 36c, 36d and 36e. 
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Figure 53. EcOXR STO difference spectrum for the third set of ligands (39a-e) showing correlations 
between characteristic ligand signals and signals in the STO difference spectrum (coloured dashed lines). 
Individual ligand spectra in 0,0 are shown from top to bottom:- 39a, 39b, 39c, 39d and 3ge. 
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Figure 54. EcOXR STO difference spectrum for the fourth set of ligands (36a and 40b-e) showing 
correlations between characterist ic ligand signals and signals in the STO difference spectrum (coloured 
dashed lines). Individual ligand spectra in 0 , 0 are shown from top to bottom:- 36a, 40b, 4Oc, 40d and 
40e. 
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Comparison of the individual ligand spectra with the STO difference spectra sh ows that all of 
the ligands appear to bind to EcOXR. This is surprising as the phosphonate esters 35e and 3ge 
are bulky and were not expected to fit into the restricted active-site cavity. 50 The phosphonate 
esters appear to bind as well as the phosphonate salts indicating that, perhaps, the more 
hydrophobic phosphonate esters favour the more hydrophobic enzyme environment over the 
polar solvent, despite their larger size. In Figure 52, the signal at 8.51, corresponding to the 5' 
aromatic proton in ligand 36b, does not appear in the STO difference spectrum whilst the 
signal corresponding to the 4' aromatic proton does. This may be due to a difference in the T, 
relaxation times of the two protons or it could mean that the 5' proton is not sufficiently close 
to the protein to experience saturation transfer. Interestingly, the corresponding signal for 
ligand 40b is also absent in Figure 54, but is observed for the esters 35b and 39b. 
Since the STO experiments were run for co. 12 hours, the stability of EcOXR was tested to 
ensure that the protein remains active during the course of the STO experiment. A sample of 
EcOXR in sodium phosphate buffer was left at room temperature for 24 hours and was found 
to have retained 88% of its activity after this period. The protein was therefore considered to 
be sufficiently active during the 12 hour STO experiments to provide accurate binding data. In 
addition to determining binding ligands from a mixture, the STO experiment, once it has been 
optimised for a particular ligand, can be used to explore competition effects and calculate 
binding affinities"''''o Such experiments, however, require successive titrations of ligand with 
the protein followed by a lengthy STO experiment after each titration, and were only 
considered to be warranted for ligands which exhibited really promising enzyme inhibition 
activity (see Section 2.3.2.). 
Although the STO results indicate binding for all the ligands examined, the enzyme inhibition 
assays show that the ligands have, at best, relatively low inhibitory activity. This highlights the 
fact that, although the STO data provide an indication of protein-ligand binding, the possibility 
of non-specific binding in regions other than the active site cannot be excluded." In fact, the 
presence of ligands in very high concentrations relative to the protein may promote non-
specific binding to regions other than the active site." In order to determine if the observed 
binding was specific or allosteric, the highly active inhibitor fosmidomycin was added to the 
assay mixtures of the last two groups of compounds after the STO experiment and the 
experiment was re-run under exactly the same conditions. The STO difference and reference 
spectra for the fourth set of ligands (36a and 40b-e) with and without fosmidomycin are 
shown in Figure 55. 
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Figure 55. EcDXR STD difference and reference spectra for the fourth set of ligands (36a and 40b-e) 
without (a, b) and with (c, d) fosmidomycin 19 present. Fosmidomycin signals are indicated by red 
circles. 
As a highly active inhibitor, fosmidomycin 19 is assumed to bind tightly in the active site and to 
displace any weakly bound ligands. The STD technique relies on saturation transfer followed 
by exchange of the ligands, and is therefore unable to identify ligands which bind so tightly to 
the protein that they undergo slow chemical exchange on the NMR timescale."· Hence, the 
presence of fosmidomycin signals in the difference spectrum (Figure 55) implies that, although 
fosmidomycin is a highly active inhibitor, its exchange in and out of the active site must be 
sufficient to permit its resonances to be observed. The appearance of the ligand signals in the 
difference spectrum when fosmidomycin is present indicates that the ligands are not 
completely displaced by fosmidomycin and therefore still bind to the protein to some degree. 
This binding could therefore be either weak binding in the active site or binding to some site 
other than the active site. These conclusions are consistent with the enzyme assay results 
discussed in Section 2.3.2. and suggest that the weak inhibition observed by most of the 
ligands is due either to weak active-site binding or to allosteric inhibition. 
73 
As the STD experiment is based on the detection of ligand signals, it is a valuable technique for 
proteins which cannot be labelled, have high molecular weights, are membrane-bound or can 
only be obtained in small quantities.99 The disadvantage is that the binding site in the protein 
cannot be determined easily by this method?' Although the sensitivity and applications of the 
STD technique have been illustrated by the above experiments, the possibility of apparently 
positive results caused by non-specific binding has been highlighted. In addition, the 
importance of optimising the experiment in terms of the solvent used and the pre-saturation 
frequency and number of pulses has been emphasised. The STD experiment provides a usefu l 
initial screen for ligand binding of several compounds simultaneously but a thorough 
understanding of the technique, as well as its limitations, is necessary before any firm 
conclusions about inhibition potential can be drawn from the results. 
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2.3.2. Enzyme inhibition assays 
Binding assays may provide a useful initial screen for binding of a ligand to the enzyme of 
interest, but the binding must result in inhibition if the ligand is to be of any potential 
medicinal benefit. Biological assays are therefore crucial for determining the potential of 
synthesised molecules as well as guiding the design of new ones. The standard assay for 
determining EcDXR inhibition has been described by Kuzuyama 'O' This assay has been widely 
used as an indication of PjDXR inhibition potential and was the assay which first established 
fosmidomycin as an inhibitor of DXR.41,S4,60 Although it only affords a measure of DXR 
inhibition ability and not necessarily anti-parasitic activity, the DXR inhibition assay gives a 
quick and inexpensive indication of the activity of the ligands tested. Once promising 
compounds have been identified, a parasite growth inhibition assay, such as the 8-
[' Hjhypoxanthine incorporation assay, can be carried out. 'o, EcDXR is used in the DXR 
inhibition assay as it can be easily expressed and purified in large quantities and is more stable 
than PjDXR6S and, for closely related compounds, there appears to be a good correlation 
between the 1(" values of the ligands in both EcDXR and PjDXR60 
The assay is based on the spectrophotometric measurement of the conversion of NADPH to 
NADP which occurs when DOXP is converted to MEP by DXR40 The ligands were tested on 
behalf of the author'o, at concentrations between 10 11M and 500 11M for compounds 35a-e 
and 36a-e and lOI1M and 1000 11M for 39a-e and 40a-e. In each assay, the slope of the initial 
linear portion of the absorbance-time graph was determined and taken to indicate the 
reaction rate. Rates of decrease in absorbance were compared with the respective control 
experiments and a percentage relative inhibition was determined in triplicate for each ligand 
by considering the enzyme activity in the absence of inhibitor to be 100% (i.e, 0% inhibition), 
Under these conditions, fosmidomycin 19 at 0.3 11M exhibited 99.3% inhibition, Plots of the 
absorbance-time graphs for the control, the mild inhibitor 35c and the highly active inhibitor 
fosmidomycin 19 are shown in Figure 56. 
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Figure 56. Absorbance-time graphs showing progress of the reaction catalysed by EcDXR in the presence 
of inhibitor 35c (250 IlM), shown as triangles, and fosmidomycin 19 (0.3 IlM), shown as circles. The 
control experiment is shown as diamonds. Absorbance values, which reflect the decreasing 
concentration of NADPH, have been scaled to account for differences in the initial absorbance readings. 
Fosmidomycin is a slow, tight-binding inhibitor of DXR55 and, consequently, the compounds to 
be tested were pre-incubated with the enzyme for 5 minutes before the reaction was started 
by addition of the enzyme-inhibitor mixture to the substrate, cofactor and buffer mixture. 
Other authors have accommodated a pre-incubation time by adding the substrate last to 
initiate the reaction.57•59 NADPH has been found to bind before either DOXP or fosmidomycin 
in the ordered reaction mechanismss and this should be taken into account when deciding on 
the order in which to add compounds to the assay mixture. As shown in Figure 56, the 
absorbance decreased immediately, suggesting that, either DOXP very quickly replaces any 
bound ligand, or that the ligand binds allosterically and therefore does not interfere with 
DOXP binding. In some reports, bovine serum albumin (BSA) was added to the assay mixture 
to stabilise the enzyme at low concentrations. 55 However, this was not deemed to be 
necessary in our assays as the enzyme concentration was higher than that used by other 
authors and no problems with stability were encountered. 
For each of the ligands, the percentage inhibition was plotted against the ligand concentration 
and, by extrapolation of the trend-line, ICso values were calculated. The percentage inhibition 
at 500 IlM and the ICso values determined for the synthetic ligands are summarised in Table 7. 
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Table 7. Results of EcDXR inhibition assays at 500 I'M and I(so values calculated for each of the ligands. 
Compound Inhibition' at 500 IJM (%) ICso (IJM) 
35a 58.5 472 
35b 11.7 1171 
35c 28.9 730 
35d 67.7 408 
35e 21.6 1286 
36a - b - b 
3Gb 12.2 >1500 
36c 7.4 >1500 
36d 30.0 1027 
36e 16.6 >1500 
39a -0.1 >1500 
39b 0.0 >1500 
39c 0.1 >1500 
39d 0.2 >1500 
3ge 0.3 >1500 
40a 0.0 >1500 
40b 0.2 >1500 
40c 0.2 >1500 
40d 0.3 >1500 
40e 0.0 >1500 
46 10.1 1006 
II Activity in the absence of inhibitor set at 100% 
b Anomalous result suggesting enzyme activation (negative % inhibition) 
While most of the percentage inhibition values are relatively low and the IC50 values relatively 
high, several of the ligands exhibit IC50 values in the micromolar range, the most active of 
these being the furan and pyridine derivatives 35d and 35a, respectively. Compared to the 
most active inhibitors reported in the literature,"·II" with IC50 values in the nanomolar range 
(30 to 459 nM), the inhibition observed for the tested compounds is rela tively low. 
Nevertheless, the fact that some measure of inhibition is shown by the ligands, which differ 
quite significantly from the fosmidomycin structure, provides a starting-point for the design of 
more effective DXR inhibitors. 
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Interestingly, the phosphonate esters 35a-e appear to exhibit significantly lower ICso values 
than the corresponding phosphonic acid salts 36a-e - due, perhaps, to their more hydrophobic 
character and, hence, their relative preference for the enzyme environment rather than the 
aqueous environment. Perruchon et a/57 explored the effect of extending the phosphonate 
ester groups and suggested that the negative effect of decreasing the charge on the 
phosphonate moiety may be partly counteracted by the occupation of a nearby hydrophobic 
pocket by the alkyl ester groups5' Occupation of such a pocket by the phosphonate ester 
groups in our ligands may we ll account for the higher inhibition levels exhibited by the 
phosphonate esters compared to the phosphonic acid salts. (See Section 2.4.2. for discussion 
on the topology ofthe receptor cavity.) 
The ligands with two methylene groups (39a-e and 40a-e) show significantly lower percentage 
inhibition and higher IC,o values than their analogues containing one methylene group (35a-e 
and 36a-e) . Thus, whilst compounds 35a-e and 36a-e show minimal to moderate inhibition, 
compounds 39a-e and 40a-e show almost no inhibition at all, illustrating the importance of the 
length of the carbon backbone in the ligands examined here. The restricted length of the DXR 
active site, wi th the phospho nate-binding region at one end and the metal cation and NADPH 
at the other, has been considered to limit the length of potential fosmidomycin analogues" 
The acyl residue, which distinguishes FR900098 20 from fosmidomycin 19, is thought to be the 
limit to which the length of the molecule can be extended if it is to occupy the same binding 
site " Interestingly, however, data from a cognate study using anilide derivatives has revealed 
that ligands containing two methylene groups between the polar termini are better DXR 
inhibitors than their analogues containing one.B' 
The STD experiments (Section 2.3.1.) have indicated that the compounds all show binding to 
EcDXR, but this binding may be weak or non-speci f ic as the ligands did not appear to be 
completely displaced by fosmidomycin in the STD experiment. The results displayed in Table 7 
seem to confirm this conclusion in that, despite positive STD binding results, little inhibition 
was observed for most of the ligands. 
Compounds 35a-e and 36a-e were also subjected to a set of qualitative assays to determine 
whether they had any biological activity against some common pathogens. The GIBEX (G lobal 
Insti tute for Bioexploration)'o, assays have been designed as field-based assays to screen 
crude plant extracts for antibacterial, antifungal, anti protozoan and antimycobacteria l activity. 
The assays were designed to be quick and involve minimal equipment but provide only 
qualitative results indicating either a positive or negative inhibition of growth. Extracts 
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exhibiting some inhibitory activity against one or more of the representative pathogens can 
then be studied further. The GIBEX antibacterial assay was modified for uselO' on the pure 
compounds 3Sa-e and 36a-e but no inhibition of bacterial growth was observed at a 
concentration of 1 mM. The DOXP/MEP pathway is found in many Gram-positive and Gram-
negative bacteria" and, not surprisingly, fosmidomycin 19 has been found to completely 
inhibit the growth of E. coli at a concentration of 3.13 Ilg/mL.40 
Although the ligands prepared in this study have not exhibited significant DXR inhibitory 
activity, the bioassays have provided some interesting structure-activity data for use in the 
design of future inhibitors as discussed in Section 2.4.2. 
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2.4. In silico studies 
2.4.1. Molecular modelling and simulated docking of synthetic ligands 
Simulated docking studies were carried out to:- i) predict the DXR binding affinity of the 
ligands 35a-e and 36a-e; ii) explore the topology of the DXR binding site; and iii) identify 
additional binding regions which could be exploited in the modification and design of potential 
inhibitors. An in vacuo global minimum was located for each of the ligands by means of a 
systematic conformational search using Cerius2 106 Solvent-corrected, energy-minimised 
structures (including frequency calculations) were then obtained at the density functional 
theory (DFT) level using Gaussian 03.'°7 AutoDock version 4.0'°8 was used for the docking 
studies, Discovery Studio Visualizer 2.0'°9 to visualise the docked conformations and UCSF 
Chimera"° to explore the active site. 
AutoDock uses a genetic algorithm to perform a search of the possible orientat ions, positions 
and conformations of a ligand in the active site of a protein.'08 A genetic algorithm is an 
efficient search method wh ich utilises the biological concepts of genetics and evolution, 
encoding the position, orientation and conformation of a ligand on a 'chromosome'. The 
information on the ligand's chromosome (its genotype) determines its atomic coordinates (its 
phenotype)108 An initial population is randomly generated and 'crossover' ofthe genes occurs 
during 'mating' of random pairs of individuals in which the 'progeny' inherit genes from both 
'parents,. '08 The 'fitness' of the progeny is determined by the total interaction energy between 
the ligand and the protein and therefore, on 'selection', only the individuals best suit ed to 
their environment survive to 'reproduce,.,08.11l A user-defined level of random mutation is also 
included to ensure adequate sampling of the docking possibilities. The Lamarkian genetic 
algorithm includes a further step (in which it deviates from Mendelian genetics), allowing the 
results of a local search (the individual's phenotype) to be mapped back onto the genotype for 
further optimisation.,08.111 
Preliminary in silica docking of the phosphonate esters 35a-e, the corresponding phosphonic 
acids and their dian ions 36a-e, was explored using the active site (from which fosmidomycin 
19 and the solvating water molecules had been removed) in the crystal structure 1QOL47 of 
EcDXR (which includes bound fosmidomycin 19 and NADPH). In order to simulate coordination 
to the divalent metal cation, Mn" was included in the model and positioned according to its 
location relative to fosmidomycin 19 and the coordinating ligands Asp150, Glu231 and Glu152 
in the EcDXR crystal structure 10NP." A charge of +2 was manually assigned to the 
manganese ion. The active-site residues Ser186, Asn227, Lys228 and Glu231 (residue 
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numbering from lQOL) were defined as flexible residues and simulated dockings were carried 
out with each of the ligands 35a-e and 36a-e (as both the free acids and deprotonated 
analogues) as well as with DOXP 9, MEP 10, fosmidomycin 19, FR900098 20 and the 
intermediate 2-C-methylerythrose-4-phosphate 15. Examination of the docked conformations 
of each of the ligands relative to the crystal structure conformation of fosmidomycin 19 (from 
lQOL) and the proximal amino acid residues in the active site of the EcDXR crysta l st ructure 
lQOL permitted potential hydrogen-bonding and Mn'+-coordination distances to be 
determined. The relative docked conformations of the phosphonate ester, phosphonic acid 
and corresponding dianionic form of each phosphonic acid were also compared. 
While the conformations of the majority of the docked ligands appeared to differ little from 
their minimum energy conformers, the solvent-corrected energies calculated for the docked 
ligands were all higher (by 32-84 kcal.mol·' ) than the corresponding energies for their 
undocked conformers. The energy differences between the solvent-corrected, energy-
minimised and docked conformers are shown in Table 8 and give an indication of the 
conformational cost of binding which must be compensated for by the protein-ligand 
interaction energy. 
Table 8. Conformational binding cost on docking of phosphonate esters 35a-e and their corresponding 
acids in DXR. 
Compound 
35a 
35b 
35c 
35d 
35e 
36a' 
36b' 
36c' 
36d' 
36e' 
, As the protonated phosphonic acid 
Conformational binding cost (kcal.mor' ) 
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31.92 
54.45 
67.10 
81.01 
66.08 
84.47 
45.02 
44.79 
47.06 
41.60 
In most cases, the ligands exhibited, unexpectedly, docking orientations opposite to that of 
fosmidomycin 19 (as illustrated in Figure 57). In all of the crystal structures which include 
bound fosmidomycin, the hydroxamate moiety coordinates to the metal ion, close to NADPH, 
while the phosphonate group occupies a well -defined phosphonate-binding pocket. In the 
case of the natural substrate DOXP 9, this orientation is crucial as coordination of the a-
hydroxy ketone to the metal anchors the substrate in a suitable position for catalysis, locating 
the aldehyde moiety ofthe intermediate 15 close to NADPH for the reduction step'O However, 
this does not preclude competitive 'reverse' binding of DOXP 9, nor would it necessarily 
prevent a 'reverse'-bound ligand from acting as an inhibitor. The most likely explanation for 
the observed 'reverse' binding is the electrostatic attraction between the negatively charged 
phosphonic acid moiety of the ligands and the divalent metal cation. Although the 'reverse'-
binding mode is chemically feasible, Cheng and Oldfield have pointed out that the resultant 4-
membered ring would be more strained than the 5-membered ring formed by 'normal' 
coordination of the hydroxamate moiety in fosmidomycin 19 to the metal cation (Figure 11, p. 
21).58 There may, of course, be several plausible orientations of fosmidomycin 19 in the active 
site and the orientation found in the crystal structure may merely be a static representation of 
a dynamic system. 
Figure 57. Docked conformation of phosphonic acid dianion 36b in the EcDXR active site (lQOL) with 
Mnh added, showing 'reverse' binding of the ligand relative to fosmidomycin 19. Protein active-site 
residues are shown in wireframe and coloured by atom type, NADPH as green sticks, Mn2-i" as a purple 
sphere, and the ligand as sticks coloured by atom type. The crystal structure conformation of 
fosmidomycin 19 is shown in yellow ball-and-stick format. Hydrogen atoms have been omitted for 
clarity and hydrogen-bonding distances (in A) are shown as yellow dashed lines. 
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The most active inhibitors against PfDXR reported so far are analogues of fosmidomycin 
contain ing an aromatic ring a to the phospho nate moiety.76,l04 No docking stud ies have yet 
been reported for these compounds but the results observed for ligands 35a-e and 36a-e 
(Figure 58) strongly suggest the existence of an additional binding pocket adjacent to the 
phosphonate-binding pocket and lined by the residues, His257, Thr184, Glu152, Trp212 and 
the backbone atoms of Ser254 and Gly185. 
Figure 58. Docked conformation of phosphonic acid dianion 36c in the EcDXR active site (lQOL) with 
Mn" added, showing the thiazole ring occupying a pocket adjacent to the phosphonate-binding site. 
Protein active-site residues are shown in wireframe and coloured by atom type, NADPH as green sticks, 
Mn" as a purple sphere, and the ligand as sticks coloured by atom type. The crystal structure 
conformation of fosmidomycin 19 is shown in ball-and-stick format and coloured by atom type. 
Hydrogen atoms have been omitted for clarity and hydrogen-bonding distances (in A) are shown as 
green dashed lines. 
The phosphonate esters 35a-e are intended to act as pro-drugs as it is anticipated that the 
ester moieties would be hydrolysed in vivo by cellular esterases6 2,76 Not surprisingly, the 
docking results suggest that the phospho nate esters are too large to fit the 'normal' binding 
site, and many of the phosphonate esters adopt the orientation shown in Figure 59 - an 
arrangement in which crucial interactions with the metal cation and phosphonate-binding 
residues would not be possible.54,76 Subsequent docking studies were therefore carried out 
only on the deprotonated phosphonic acid forms ofthe ligands. 
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Figure 59. Docked conformation of the phosphonate ester 35b in the EcDXR active site (lQOL) with Mn" 
added, showing alignment of the ethyl ester groups along the fosmidomycin backbone and projection of 
the isoxazole ring into a pocket adjacent to the phosphonate-binding site. Protein active-site residues 
are shown in wireframe and coloured by atom type, NADPH as green sticks, Mn" as a purple sphere, 
and the ligand as sticks coloured by atom type. The crystal structure conformation of fosmidomycin 19 
is shown in ball-and-stick format and coloured by atom type. Hydrogen atoms have been omitted for 
clarity and hydrogen-bonding distances (in A) are shown as green dashed lines. 
The close alignment with fosmidomycin observed for the phosphonic acid dianions 36b, 36d 
and 36e (Figure 60), despite the 'reverse' docking, would suggest that these ligands could 
show favourable chemical interactions with DXR and thus prove to be good inhibitors. The 
enzyme inhibition assay results, however, revealed that compounds 36a-e exhibit minimal 
inhibition, indicating that, although they may fit into the active site, there are insufficient 
chemical interactions with the protein for effective binding and inhibition to occur. In the 
docked conformations, the majority of the ligands appear to be anchored at either end by the 
metal-binding and phosphonate-binding receptor-site residues, with some degree of 
conformational flexibility in between. This agrees with the proposed mechanisms of the DOXP-
MEP reaction in wh ich the central region of the active site would need to accommodate the 
re-arrangement of the carbon backbone 'o Perruchon et 01. 57 found that a methyl extension to 
the phosphonate group increased activity and the ability of such elongated ligands to fit into 
the active site is supported by the observation that even some of the larger ligands such as 
36d and 36e appear to fit into the active site, even though they project beyond fosmidomycin 
19. 
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Figure 60. Docked conformation of phosphonic acid dian ion 36d in the EcDXR active site (lQOL) with 
Mn" added, illustrating the potential for variability in the conformation of the linking region between 
the phosphonate-binding and metal-coordinating ends. Protein active-site residues are shown in 
wireframe and coloured by atom type, NADPH as green sticks, Mn" as a purple sphere, and the ligand 
as sticks coloured by atom type. The crystal structure conformation of fosmidomycin 19 is shown in ball-
and-stick format and coloured by atom type. Hydrogen atoms have been omitted for clarity and 
potential hydrogen bonds are shown as green dashed lines. 
Little attention appears to have been given to placing the M" cation in the protein model and 
to assigning a realistic charge to the metal centre. Typically, in docking studies which actually 
include the metal cation, Mg" has been used and has either been assigned a full +2 charge or 
the docking programme has been allowed to calculate a charge.'o.S8 Although Silber et 01. 52 and 
Perruchon et 01. 57 state that Mg" is better parameterised than Mn" in AutoDock, a 
Gasteiger1l2 charge of 0.00 is automatically assigned to either metal in AutoDock 4.0. Neither a 
charge of +2 nor 0 is likely to model the metal co-factor realistically in the presence of the 
surrounding, negatively charged, coordinating ligands. The importance of substrate or 
inhibitor binding to the metal cation ,o,74 surely requires that attention be given to including a 
well-parameterised and accurately charged metal cation when carrying out docking studies on 
DXR. Consequently, in order to investigate the effect of the ligands on the +2 charge, the Mg" 
cation, its coordinating residues (Asp149, Glu151 and Glu230), a water molecule and 
fosmidomycin 19 were all removed, as a group, from the crystal structure 2EGH," and the 
group was energy-minimised, using a Hartree-Fock calculation (Figure 61) .'°7 This calculation 
afforded a charge of +1.058 on the Mg cation - a value consistent with significant dissipation 
of the formal +2 charge by the coordinating ligands. The calculated Mulliken charges on all of 
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the atoms in the energy-minimised group were transferred to the input files used by AutoDock 
and, when fosmidomycin 19 (with its Hartree-Fock calculated charges) was docked into the 
modified protein model, an increase in the number of correctly oriented dockings was 
observed . Replacement of the empirical charges with quantum-mechanical-calculated values 
in the force-field parameters of docking algorithms has also been shown by other researchers 
to increase the accuracy of the calculation of the electrostatic interactions.ll3 As the 
electrostatics term in the free-energy equation is independent of the other terms, 
replacement of the empirical charges with quantum-mechanical-calculated values does not 
affect the other terms'14 and the quantum-mechanics-refined parameters were then used in 
subsequent docking experiments. 
Figure 61. Magnesium cofactor (shown in green) with surrounding ligands, Asp149, Glu151, Glu230, H20 
and fosmidomycin 19 following Hartree-Fock energy minimisation, showing Mulliken charges assigned 
to each atom. All atoms are coloured by atom type. 
AutoDock 3.0108 appears to give very reproducible docking results and has been widely used 
for DXR docking studies"-59 The use of the more recent version, AutoDock 4.0, however, has 
not yet been reported for DXR docking studies and, therefore, a series of docking runs was 
performed to determine the effectiveness of AutoDock 4.0 for the reliable prediction of 
inhibition. The EcDXR crystal structure 2EGH S3 was prepared as the receptor and Mulliken 
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charges, obtained from the energy minimisation process described above, were substituted 
for Gasteiger charges on the atoms of the active-site residues Glu230, Asp149, Glu151, the 
coordinating water molecule, the Mg cation and fosmidomycin 19. The Ser221, Lys227, 
Ser185, His256, Met213, Asp149, Glu230 and Glu151 residues were defined as flex ible, having 
been identified by others as be ing involved in the binding of either fosmidomycin 19 or DOXP 
9 to the active site.,,·,o.51 
To validate the docking protocol and determine reproducibility, fosmidomycin 19 was 
removed from the model and then subjected to three docking experiments, each experiment 
using the same parameters and generating ten docking results. Analysis of the results was 
based on the clustering of the results and the closeness ofthe docked conformations to that of 
the crystal structure. The clustering of the docking results gives an indication of the similarity 
of the docked structures to each other, based on the root-mean-square-deviation (rmsd) 
between the atomic coord inates.1l5 The docking results are ranked according to energy and 
the lowest energy (best) docked structure is placed in the first cluster. Calculation of the rmsd 
between the lowest and second-lowest energy structures then determines whether the 
second structure is placed in the first cluster or becomes the reference for a second cluster, 
depending on the cut-off rmsd value (default 2.0 iI). This process is repeated until each of the 
docking results is placed in a c1uster. 1l5 The number and distribution of the clusters gives an 
indication of the reliability of the docking method and it is assumed that increasing the 
number of energy evaluations within each docking run will increase the likelihood that similar 
low-energy docks will be achieved in each of the docking runs and therefore the number and 
distribution of the clusters w ill decreasell' ln each of the three replicates of the fosmidomycin 
docking, eight or more clusters were generated, indicating that, within each experiment, the 
docked conformations were significantly different to each other. 
On visual inspection of the three docking experiments, the lowest energy docks appear to 
align most closely with the crystal structure conformation of fosmidomycin 19 whilst the 
higher energy docks appear to bind in the channel region. Although this confirms the correct 
positioning of the grid box for the docking, the variability in the docking results indicates that, 
either fosmidomycin 19 can adopt several binding orientations and conformations, or that the 
programme does not consistently converge to the minimum energy docked conformation. 
Figure 62 shows the ten docking results obtained in one of the docking experiments with 
fosmidomycin. 
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Figure 62. Docked conformations of fosmidomycin 19 in the EcDXR active site {2EGH} with Mulliken 
charges added, illustrating the variability in the docked conformations when several flexible residues are 
chosen. Protein active-site residues are shown in wireframe coloured by atom type, docked 
fosmidomycin conformations as sticks coloured by atom type and the crystal structure fosmidomycin in 
ball-and-stick format, coloured yellow. 
Increasing the number of docking runs or increasing the number of energy evaluations within 
each run did not appear to substantially improve the results or decrease the number and 
distribution of clusters. Energy minimisation and subsequent docking of DOXP 9 yielded similar 
results; with only one or two docks looking feasible. Replacment of the Gasteiger charges on 
DOXP 9 with Mulliken charges also appeared to make little difference. 
Unlike AutoDock 3.0, AutoDock 4.0 allows the selection of flexible residues in the receptor in 
order to better approximate the 'hand and glove' concept of a ligand binding to a protein. 
There is no limit to the number of flexible residues which can be selected but the maximum 
number of torsions in the ligand and flexible residues combined may not exceed 32. 115 In order 
to ascertain the effect that the choice and number of flexible residues has on the docking 
results, the input file was altered to include only Ser221 as a flexible residue. Ser221 was 
chosen as it is found at the edge of the active site and only has two torsion angles in the side 
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chain. This was the minimum which could be selected as a completely rigid dock is not possible 
in AutoDock 4.0. Docking of fosmidomycin 19 into this model produced surprisingly different 
results. For the default, medium length, run, only three clusters were generated with eight of 
the ten conformations in the lowest energy cluster. In addition, all of the eight lowest energy 
conformations aligned very closely with the crystal structure fosmidomycin as shown in Figure 
63. 
Figure 63. Docked conformations of fosmidomycin 19 in the EcDXR active site (2EGH) with Mulliken 
charges added, illustrating the reproducibility of the docked conformations when only one flexible 
residue (Ser221) is chosen. Protein active-site residues are shown in wireframe coloured by atom type, 
docked fosmidomycin conformations as sticks coloured by atom type and the crystal structure 
fosmidomycin in ball-and-stick format, coloured yellow. 
Increasing the length of the run increased the reproducibility of the results with nine out of 
ten docks showing close alignment and low energy. These experiments show that the choice 
and number of flexible residues significantly influences the docking results. Although the 
choice of fewer flexible residues leads to greater reproducibility, the simulation system then 
deviates considerably from the biological system in which the enzyme is flexible. 
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The experiments described above were used to validate the docking results obtained with 
AutoDock in terms of the parameterisation of the metal cation, the reliability of the docking 
and the influence of the number of flexible residues. The results obtained show the 
importance of gaining a good understanding of the parameters used and of how the docking 
programme works before attempting to interpret the docking results. It is also important to 
balance the reproducibility of 'good' in silica results with their correspondence to the real 
enzyme-ligand system. In subsequent docking experiments, the Mulliken charge was 
substituted for the automatically-assigned Gasteiger charge on the metal cofactor, the 
clustering of the docking results wa s analysed and the number offlexible residues was limited. 
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2.4.2. Exploration of the DXR active site and design of navel inhibitors 
Many analogues of fosmidomycin 19 and FR900098 20 have been synthesised and evaluated 
as DXR inhibitors but few have proved to be more active than these two lead compounds. 
Most analogues have been based on chemical modifications of the lead compounds and 
attempts to probe the DXR active site. Although this is a va lid and rational approach to drug 
discovery, little use appears to have been made of computational techniques to study the 
topology and properties of the active site for de novo inhibitor design; this, however, is an 
approach which we have begun to explore. 
Significant binding residues in DXR have been identified previously from the available crysta l 
structures and Giessman et 01. have summarised the essential features of fosmidomycin 19 
and DOXP 9 and their interactions with the protein in order to highlight opportunities for the 
variation of ligand structure.47.".54 The importance of a metal-coordinating moiety has been 
stressed by Deng et 01.74 and hard ligands, such as hydroxamate or catechol groups, have been 
suggested as suitable Lewis bases for coordination to the hard Mg'+ ion. 74 However, due to 
their possible degradation in vivo by several pathways, hydroxamate groups appear to confer 
poor pharamacokinetic propert ies on potential medicinal compounds. Consequently, there is a 
need to consider other metal-coordinating moieties." Variations on the length and properties 
of the 3-carbon spacer have been largely unsuccessful in increasing inhibition, supporting the 
assumption that closure of the loop region of the enzyme resu lts in a relatively narrow active 
Site,"'" while the significance of a double negative charge on the phosphonate group has 
been highlighted by Perruchon et 01.57 With these known structure-activity relationships in 
mind, we have explored both the EcDXR and PjDXR active sites to identify residues with 
binding potential or adjacent pockets which may be exploited in the design of novel inhibitors. 
Analysis of the ligand docking results revealed that some of the docked ligands occupied a 
pocket adjacent to the phosphonate-binding site. This prompted further investigation into the 
dimensions, shape and properties of this cavity in DXR. Visualisation was achieved with 
Chimera"o using the EcDXR crystal structure (2EGH)" as this model contains bound 
fosmidomycin 19, NADPH and Mg2+. Measurements of the pocket occupied by fosm idomycin 
19 revealed a narrow elongated pocket with the metal ion at one end, near to the channel 
through which the ligand enters, a narrow central region and a phospho nate-binding site as 
shown in Figure 64. The largely polar nature of the active site of DXR is also highlighted in 
Figure 64 with a highly polar region (shown in blue) at the back of the pocket and in the 
vicinity of the metal cation, and a more hydrophobic area (shown in orange) towards the top 
of the pocket and close to the channel due, mostly, to the presence of lIe217. 
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Figure 64. Active site of fcDXR (2EGH), showing some dimensions and the polarity of the cavity around 
fosm idomycin 19. The surface zone at 7.7 A from fosmidomycin is shown with 40% transparency and 
coloured by hydrophobicity [polar (blue), non-polar (white), hydrophobic (orange)). Protein residues are 
shown in wireframe, coloured by atom type, fosmidomycin as sticks, coloured by atom type, Mg'> as a 
green sphere and the crystal structure water molecules as red spheres. 
Analysis of the docking results revealed the existence of a pocket (I) adjacent to the 
phospho nate-binding region. Figure 65 shows the phosphonic acid dian ion 36c docked in 
EcDXR (lQOL) with the thiazole ring occupying the pocket (I) 'in front' of the phosphonate-
binding region. This pocket was regularly occupied by the heterocyclic moieties of the docked 
ligands and, of the ligands docked, the thiazole ring appears to fit best into pocket I although 
many of the other ligands, including fosmidomycin 19, were observed to bend 'forward' into 
this pocket. In Figure 64, three crystal structure water molecules can be seen occupying this 
pocket, highlighting its relatively hydrophilic nature. Fosmidomycin analogues containing an 
aryl group a to the phosphonate moiety have shown increased inhibition but, as yet, the cavity 
in which this moiety binds has not been identified. 76•104 The size and shape of pocket (I) 'in 
front' of the phospho nate-binding site suggest that this may, in fact, be the region in which 
these a-aryl compounds bind and also, possibly, the same region in which Perruchon et 01." 
reported binding of a propyl extension to the phosphonate group. Deng et 01. also suggest the 
presence of a hydrophobic pocket near the DOXP binding site which may be occupied by 
phenyl or benzyl groups.74 
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Figure 65. Docking of the phosphonic acid dianion 36c in fcDXR (1QOL) showing the pocket (I) 'in front' 
of phosphonate-binding site occupied by thiazo le ring. The surface zone at 4.1 A from fosmidomycin 19 
is shown with 50% transparency and coloured by atom type. Protein residues are shown in wireframe, 
coloured by atom type, the crystal structure fosmidomycin in ball-and-stick format coloured by atom 
type and ligand 36c and NADPH as sticks coloured by atom type. 
Further exploration of the cavities around the phosphonate-binding region revealed two 
add itional pockets (II and III; Figure 66) wh ich could be exploited in the design of new 
inhibitors. The first, a small, generally hydrophobic pocket (II) 'behind' the phospho nate group 
may well accommodate the methyl ester moiety in a ligand described by Perruchon et 01.,57 
and the small size of this pocket could explain why the methyl ester was found to be more 
active than the ethyl ester. A second, relatively large cavity (III) extends 'above' the 
phosphonate-binding region, as shown in Figure 66. A number of docking results suggest 
occupation of this pocket and Deng et 01. also mention a hydrophobic pocket which may be 
occupied by a phenyl ring.74 Figure 66 shows a 'front' view of the active site illustrating the 
positions of the three pockets (I , II and III) close to the phosphonate-binding region. In 
contrast, the space around the central region is relatively restricted and the metal-binding site 
is constrained by the metal cation, the bound NADPH and the channel. 
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Figure 66. Active site of EcDXR (2EGH), showing the three available pockets (I, II and III) close to the 
phosphonate-binding site. The surface zone at 7.7 A from fosmidomycin 19 is coloured by 
hydrophobicity [polar (blue), non-polar (white), hydrophobic (orange)] and clipped in front. Protein 
residues are shown in wireframe, coloured by atom type, fosmidomycin in ball·and-stick format 
coloured by atom type, NADPH as sticks coloured by atom type, Mg" as a green sphere and the crystal 
structure water molecules as red spheres. 
Although several crystal structures of EcDXR are available, none has yet been elucidated for 
PjDXR and, therefore, the homology model developed by Goble et al. was used to compare 
the properties of the active sites of EcDXR and PjDXR.51 It is widely accepted that, in enzyme 
assays, the inhibition of EcDXR is a reasonable indicator of PjDXR inhibition potential; 
however, small differences between the two enzymes may provide useful gUides for the 
design of better PjDXR inhibitors" As the model developed by Goble et al. does not include 
fosmidomycin 19 or Mg", these structures were extracted from the 2EGHS3 crystal structure 
and superimposed on the PjDXR model by overlaying corresponding residues. The active-site 
residues of the two models superimposed very closely, enabling the inhibitor and metal 
cofactor to be positioned with confidence. Table 9 shows the dimensions of the active sites of 
the EcDXR crystal structure (2EGH)S3 and the PjDXR model51 with distances measured between 
corresponding residues in the two structures. The active site of PjDXR appears to be slightly 
shorter and deeper than the EcDXR counterpart but, as the active-site residues are highly 
conserved, the receptor cavities in PjDXR and EcDXR are very similar in shape.so,51 Significantly, 
however, in PjDXR, a cysteine residue (Cys267) replaces the smaller Ser253 in EcDXR (2EGH)S3 
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resulting in the presence of two cysteine residues (Cys197 and Cys267) in pocket I 'in front' of 
the phosphonate-binding site as shown in Figure 67. The larger size of the cysteine residue in 
PjDXR slightly decreases the size of pocket I, and this difference, as well as the differences in 
polarity and chemical properties between serine and cysteine could be exploited in the design 
of new PjDXR-specific inhibitors. 
Table 9. Comparison of the dimensions of the EcDXR (2EGH) and PjDXR (homology model) active sites. 
Dimension Dista nce (A) Corresponding amino acid residues 
EcDXR PjDXR EcDXR PjDXR 
Length 12.2 10.3 5er185 OG - Asp149 aD 5er199 OG - Asp160 aD 
Width 8.9 9.9 Trp211 CD - Glu230 OE Trp225 CD - Glu244 OE 
Height 9.6 10.2 lIe217 C(O) - Glu151 OE lIe231 C(O) - Glu162 OE 
Figure 67. Active site of PjDXR with Mg'·, NADPH and fosmidomycin 19 from 2EGH, showing some 
dimensions of the cavity, the pockets (I, II and III) and highlighting differences between EcDXR and 
PjDXR. The surface zone at 7.3 A from fosmidomycin is coloured by atom type and clipped in front. 
Protein residues are shown in wireframe, coloured by atom type, NADPH as sticks coloured by atom 
type, fosmidomycin in ball-and-stick format, coloured by atom type, Mg'· as a green sphere and water 
molecules as red spheres. 
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In PjDXR, as in EcDXR, there are three pockets close to the phosphonate-binding site (Figure 
67). Compared with the corresponding pockets in EcDXR, pocket I in PjDXR is smaller and less 
flattened, pocket II is slightly larger and pocket III is wider. The distances measured from the 
phosphate atom in fosmidomycin 19 to the end of each of the three pockets (I, II and III) are 
shown in Figure 68, as is the height of pocket I. Binding of the active ligand 26 '04 (Figure 14, p. 
24) may well involve occupation of either pocket I or pocket III by the 3,4-dichlorophenyl ring. 
Distances such as those shown in Figure 68 can, however, only be taken as approximations 
since the dynamic nature of the enzyme structure allows a degree of conformational flexibil ity. 
Figure 68. Active site of PfDXR with Mg", NADPH and fosmidomycin 19 from 2EGH, viewing along the 
axis of fosmidomycin 19 towards the phosphonate group and showing the dimensions of the nearby 
pockets (I, II and III). The surface zone at 8.0 A from fosm idomycin is coloured by atom type and clipped 
in front. Protein residues are shown in wireframe, coloured by atom type, and residues less than 8.0 A 
away from fosmidomycin are labelled. Fosmidomycin is shown in ball-and-stick format, coloured by 
atom type and water molecules are shown as red spheres. 
Figure 69 highlights the polarity of the cavity in PjDXR and shows some of the surrounding 
residues, while the narrowness of the central portion of the binding site is illustrated in Figure 
70. The latter figure shows a view down the length of the cavity from the phospho nate end, 
with the central region clearly bordered by the planar p-indole ring of Trp225 in the front and 
by Ser235 at the back. 
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Figure 69. Active site of PjDXR, showing the three available pockets (I, II and III) close to the 
phosphonate-bind ing site. The surface zone at 8.0 A from fosmidomycin 19 is shown with 30% 
transparency, coloured by hydrophobicity [polar (blue), non-polar (white), hydrophobic (orange)] and 
clipped in front. Protein residues are shown as sticks, coloured by atom type and residues less than 8.0 
A away from fosmidomycin are labelled. Fosmidomycin is shown in ball-and-stick format, coloured by 
atom type, NADPH as sticks coloured by atom type, Mg" as a green sphere and the coordinating water 
molecule as a red sphere. 
The information obtained from this study of the topology of the EcDXR and PfDXR active sites, 
structure-activity relationship data reported in the literature and the pharmaco-kinetic 
observations detailed below were used to design a set of potential inhibitors. It is widely 
accepted that the cause of the limited plasma half-life of fosmidomycin 19 is its high 
hydrophilicity which leads to low membrane permeability. " A possible solution to this 
problem is the synthesis of phosphonate ester pro-drugs which can be hydrolysed in vivo to 
yield the active phosphonic acids. The rate of hydrolysis of the phosphonate ester linkages can 
be decreased by increasing the bulkiness of the ester group,'9 and diaryl, acyloxyalkyl and 
pivaloyloxymethyl ester analogues of fosmidomycin have been synthesised and have shown 
increased plasma levels after oral administration :,,7S,76 The phosphonate moiety has been 
widely used because it is more stable than the phosphate moiety found in DOXP 9. Additional 
disadvantages of phosphates as potential drug molecules are their lower membrane solubility 
and greater susceptibility to hydrolysis compared to phosphonates.79,116 The importance of a 
metal-coordinating group, on one hand, and a dianionic phosphonate group, on the other, has 
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been highlighted, and the studies of the active site described above suggest that the distance 
between these two functionalities needs to correspond to a 3 carbon atom chain for the 
groups to reach their respective binding sites.57,74 The decrease in activity in the enzyme 
inhibition assays observed on increasing the number of methylene groups (Section 2.3.2.) 
supports this assumption. Attempts to place substituents at positions j3 and y to the 
phosphonate on the carbon chain have led to a decrease in inhibition - an observation 
attributed to the narrowness and highly polar nature of the central region of the cavity.,o,76 
Only a-substituted fosmidomycin analogues such as 26'04 have shown higher inhibition 
properties than fosmidomycin 19 and this is probably due to occupation of one of the pockets 
(lor III) described above, by the a-substituent. 
Figure 70. Active site of PfDXR with Mg'·, NADPH and fosmidomycin 19 from 2EGH, viewing along the 
axis of fosmidomycin towards NADPH and showing the dimensions of the pocket at the widest (12.7 A) 
and narrowest (8.1 A) points. The surface zone at 8.0 A from fosmidomycin is shown with 30% 
transparency, coloured by hydrophobicity [polar (blue), non-polar (white), hydrophobic (orange)] and 
clipped in front. Protein residues less than 10 A away from fosmidomycin are shown in wireframe, 
coloured by atom type, and residues less than 8.0 A away from fosmidomycin are labelled. 
Fosmidomycin is shown in ball-and-stick format, coloured by atom type, NADPH as sticks coloured by 
atom type and the crystal structure water molecules as red spheres, 
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Consideration of the above requirements led to the design of compounds 52a-e (Figure 71). as 
potential PfDXR inhibitors. Whilst maintaining the phosphonate and hydroxamate moieties of 
fosmidomycin 19, the a-carbon has been replaced by a nitrogen atom to:- i) provide a point of 
attachment for a-substituents; ii) provide a hydrogen-bonding atom in the a-position similar 
to the DOXP phosphate group; and iii) avoid introducing a chiral centre at the a-position, thus 
facilitating synthesis. Instead of the aromatic a-substituents employed by Kurz et 01. and 
Haemers et 01.:°.76 less bulky ethyl substituents were proposed for compounds 52b-d with 
terminal atoms designed to permit interaction with serine or cysteine residues close to the 
phosphonate-binding site. Such interactions could involve the formation of covalent disulphide 
or thioether links between the inhibitor and the enzyme receptor site. 
R 
a H 
/"-.-Sr o OH II I HO-----!'N~Ny 
HO I 0 
b 
c 
R 
52a-e d 
e 
Figure 71. Structures of the proposed novel ligands 520-e. 
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2.5. Preliminary studies towards the synthesis of novel, 
customised ligands 
As indicated in the previous section, analysis of the molecular topology of the DXR active site 
led to the design of compounds 52a-e and, although time was limited, it was decided to, at 
least, commence an approach to their synthesis. The synthetic strategy outlined in Scheme 6 
was adapted from established syntheses of fosmidomycin 19 and its analogues,59,68,75,80,117 a 
variation being the introduction of a nitrogen atom a to the phosphonate group to facilitate 
attachment of a-substituents to occupy pocket I and enhance activity'O' In addition, 
attachment of such subsituents to the nitrogen avoids the introduction of chirality which 
would have to be considered if the attachment was to an sp' hybridised carbon atom, 
53 
; 
-
54 
o 
II 
/""'--./p ........... ~o 
/0 \ NH ( 
55 
, 
o OH b II I 
Ho----i ....... N~Ny 
HO I 0 
R 
, 
52a-e d 
• 
Scheme 6, Proposed synthesis of novel ligands 52a-e, 
R 
H 
../'--., 
../'--CI 
../'--SH 
../'--Ph 
Proposed reagents:- (i) NaH, bromoacetaldehyde diethylacetal; (ii) 2M-HCI; (iii) O-benzylhydroxylamine; 
NaCNBH,; (iv) acetyl chloride, Et,N; (v) NaH, RCI; (vi) H" Pd/C or acetyl chloride, EtOH. 
Zwierzak has reported that monoalkylation of diethyl phosphoramidate 53 gave poor results-
due mainly to formation of a mixture of the mono- and dialkylated products - but found that 
this problem could be avoided by protecting the primary amide"' Following Zwierzak's 
method,117 diethyl phosphoramidate 53 was reacted with hexamethyldisilazane in refluxing 
benzene (Scheme 7)117 to afford the protected amide 59 as an oil which, on cooling, 
crysta llised as off-white, highly hygroscopic crystals. The reaction was high-yielding (95-97%) 
and the product 59 was very clean as shown in the 'H NMR spectrum (Figure 75), 
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53 59 60 54 
Scheme 7. Monoalkylation of diethyl phosphoramidate 53.117 
Reagents and conditions:- (i) Hexamethyldisilazane (20 % mol excess), C, H" 3 h, reflux (80 'C); Iii) NaH 
(l.2 eq.), C,H" r.t.; bromoacetaldehyde diethylacetal, tetrabutylammonium bromide (10 mol%), C,H" 4 
h, reflux (80 'C); (iii) EtOH, 1 h, 80 ' c. 
Alkylation of the protected phosphorus amide 59 was achieved by deprotonation of the amide 
using sodium hydride followed by reaction with bromoacetaldehyde diethyl acetal in the 
presence of 10 mol% tetrabutylammonium bromide to afford compound 60 {Scheme 7)'17 The 
role of tetrabutylammonium bromide is not clear but it has been suggested that the catalyst 
may facilitate formation of a reactive ionised species.ll7 Deprotection of the amide 60 was 
carried out in situ by the addition of ethanol, and, after work-up, compound 54 was isolated in 
90% yield. Comparison of the 'H NMR spectra of the protected substrate 59 and the 
deprotected product 54 (Figure 72) reveals the presence of the signals due to the trimethylsilyl 
protons at 0.18 ppm in the protected substrate 59 and their subsequent disappearance in the 
de protected product 54. Integration of the signals in the 'H NMR spectrum of the product 54 
indicates that the protection method successfully prevented dialkylation of the diethyl 
phosphoramidate. The methylene signals of the diethyl acetal moiety appear as a doublet of 
quartets due to coupling to the methyl protons and to each other, as confirmed by the COSY 
NMR spectrum. This is due to the chemical non-equivalence of these two protons and 
therefore their magnetic non-equivalence and consequent geminal coupling. 
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Figure 72. 'H NMR spectra of (i) protected phosphorus amide 59, and {iii alkylated phosphoramidate 54 
(CDCI" 600 MHz). 
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The next step in the synthesis involves cleavage of the diethyl acetal 54 (Scheme 8). This is a 
well-established procedure but application of the methods used by Ortmann et 01. and 
Perruchon et al. 57,7S failed to yield the desired product 55. The reaction was repeated several 
times and the reaction time was varied as shown in Scheme 8. Analysis of the crude products 
by 'H NMR spectroscopy suggested that very little of the desired aldehyde 55 was formed and 
that cleavage may also have occurred elsewhere. As time was limited, this reaction could not 
be investigated further but exploration of different methods for the cleavage of the diethyl 
acetal 54 is being continued in our group and the synthesis of compounds 52a-e will be 
pursued, 
o 
i-iv .. II ....::;0 /'-O/P\,NH~ 
( 
54 55 
Scheme 8, Attempted cleavage of diethyl acetal 54 to the aldehyde 55, 
Reagents and canditians:- 2M-HCI; (i) r.t., overnight; (ii) r.t., 3.5 days; (iii) r.t ., 3 h; (iv) 40 ' c, 4h. 
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2.6 Conclusions 
The phosphonate esters 3Sa-e and the corresponding phosphonic acid salts 36a-e have been 
successfully synthesised as fosmidomycin 19 analogues. Reaction of a series of heterocyclic 
amines with chloroacetyl chloride, followed by phosphonation with triethyl phosphite led to 
the esters 3Sa-e, hydrolysis of which afforded the disodium salts 36a-e. A second series of 
phosphonate esters 39a-e and their corresponding phosphonic acid salts 40a-e with a 
bimethylene spacer have also been synthesised, using 3-chloropropionyl chloride in place of 
chloroacetyl ch loride, to investigate the effect of lengthening the carbon backbone of 
fosmidomycin 19 analogues. Further investigation into some of the reactions employed led to 
the purification and characterisation of various side products formed during the synthesis of 
the 2-aminopyridine derivative 41a. All of the above compounds, with the exception of the sa lt 
36a, are new and have been fully characterised using elemental (HRMS or combustion 
analysis) and spectroscopic (1- and 2-D NMR and IR) techniques. A kinetic study of the 
transesterification reaction between the phospho nate esters and bromotrimethylsilane 
employed for hydrolysis of the phosphonate esters was undertaken and illustrated the use of 
3lp NMR for following the rea ction progress. Rate constants for the two, consecutive, second-
order reactions involved and activation parameters for the reactions were calculated following 
variable temperature studies and a computational method was developed for the optimisation 
of the rate constants. 
The phosphonate esters 3Sa-e and 39a-e and the corresponding phosphonic acid salts 36a-e 
and 40b-e were subjected to prelim inary screening for their ability to bind to DXR using the 
STD NMR technique, following optimisation of the solvent and the pulse sequence 
parameters. Comparison of the STD difference spectra with the ligand spectra indicated that 
all of the synthesised ligands exhibited binding to EcDXR, although the STD experiment, used 
alone, does not distinguish between specific and non-specific binding of the ligand to the 
protein. A second, competitive binding experiment involving the inclusion of the highly active 
inhibitor fosmidomycin 19 in the ligand mixture was therefore carried out. The results of this 
experiment suggested that, either the ligands bind non-competitively at a site other than the 
active site and, perhaps, cause allosteric inhibition, or that their binding in the active site is 
much more transient than that of fosmidomycin 19. Enzyme inhibition assays on the 
synthesised ligands supported these conclusions as most of the inhibitors were found to 
exhibit relatively low inhibitory activity compared to fosmidomycin 19. Several structure-
activity relationships were, however, suggested by the enzyme inhibition results. Thus, 
increasing the length of the carbon spacer in the ligands from one to two methylene groups 
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decreased the ICso values, the more hydrophobic phosphonate esters generally showed 
greater inhibition than the corresponding phosphonic acid salts, and the furfuryl-derived ester 
3Sd and acid salt 36d showed the greatest inhibition of the ligands tested. 
Simulated docking studies using AutoDock revealed the ability of the ligands to fit into the 
active site of DXR and to form hydrogen-bonding interactions with active-site residues. 
Repeated observation of a 'reverse' binding orientation for many of the ligands led to an 
investigation of the effect of the charge assigned to the divalent metal cofactor included in 
DXR. Substitution of the automatically-assigned charges with quantum-mechanical calculated 
charges resulted in a decrease in the number of 'reverse' docks. Validation of the docking 
parameters revealed that decreasing the number of flexible residues selected improved the 
reproducibility of the docking. However, increasing the rigidity of the model may compromise 
its approximation to the biological system. Exploration of the DXR active-site topology 
revealed the presence of three pockets of different sizes in close proximity to the 
phosphonate-binding site. Occupation of these pockets, and possible chemical interaction with 
their constituent amino acid residues, was proposed to increase the inhibitory activity of a 
new generation of DXR inhibitors. Consideration of these results, as well as the structure-
activity relationships described above, directed the design of a series of novel, customised 
inhibitors for PjDXR, compounds S2a-e, the synthesis of which has been commenced and will 
be continued within our group. 
Overall, the project has involved a combination of various complementary approaches to 
novel drug discovery. Thus, synthetic, physical organic, computer modelling and biochemical 
evaluation techniques have all been used and have led to the identification of structure-
activity relationships for two series of potential inhibitors and the rational design of a third 
series of novel DXR inhibitors S2a-e. 
The study of the active-site topology of DXR and the design of compounds S2a-e has provided 
a platform for future work on DXR inhibitors, especially those customised for PjDXR, and 
opportunities for future research include:-
i) the design of ligands capable of occupying several of the available pockets; 
ii) further development of the PjDXR model to include the metal cofactor; 
iii) extension of the STD NMR technique to permit calculation of binding 
constants or binding epitopes of the ligands; and 
iv) following the enzyme inhibition assays with cell-based assays to test the 
bioavailability and toxicity of the inhibitors. 
105 
3. EXPERIMENTAL 
3.1. Synthesis of potential DXR inhibitors 
General 
Synthesis and Purification 
Starting materials were obtained from Sigma-Aldrich or Fluka and used without further 
purification. THF and benzene were distilled from sodium/benzophenone under nitrogen. 
DCM was stored over CaCl, overn ight and then distilled from CaH, under nitrogen. Normal-
phase thin layer chromatography was performed on Merck TLC silica gel 60 F254 plates, and 
reverse-phase on Fluka TLC silica gel RP-18 F2S4 plates. Plates were viewed under UV light (2S4 
nm) or developed with iodine vapour. Flash chromatography"' was performed using silica gel 
60 (70-230 mesh) for normal-phase and Sep-Pak Vac 3Scc C18 cartridges for reverse-phase. 
Normal-phase semi-preparative HPLC was performed on a Whatman Partisil 10 column and 
reverse-phase on a Phenomenex C-18 LUNA column, using a Spectra-Physics Spectra Series 
PlOD isocratic pump and a Waters 401 Differential Refractometer with a Perkin-Elmer S61 
Recorder. 
Analysis and Characterisation 
NMR spectra were recorded on a Bruker Biospin 600 MHz Avance spectrometer at 298 K 
(except where described otherwise for kinetics experiments) and calibrated on the residual 
protonated solvent signals (for CDCI,: IiH = 7.26 ppm; lie = 77.00 ppm; for 0,0: Ii" = 4.79 ppm). 
Multiplicities described for "c spectra were obtained from the DEPT or multiplicity-edited 
HSQC spectra and refer to "C_'H coupling except in the case of "C_31P coupling where the i e_p 
values are recorded and the multipliCity refers to this coupling. IR spectra were recorded on a 
Perkin-Elmer Spectrum 100 FT-IR spectrometer with neat compounds on a diamond window. 
Melting points were determined using a Reichert hot-stage apparatus and are uncorrected. 
Low-resolution mass spectrometry was performed on a Finnigan MAT GCQ mass 
spectrometer, using the electron ionisation mode. High-resolution mass spectra were 
recorded on Micromass 70-70E (Northwest University, Potchesfstroom, South Africa) and 
Waters API Q-TOF Ultima spectrometers (University of Stellenbosh, Stellenbosh, South Africa). 
The names of new compounds are italicised and literature references are cited for known 
compounds; § denotes that no melting point data were given. 
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Procedure 1. Synthesis of 2-chloro-N-arylacetamides 38a-e." 
A solution of the relevant primary amine (37a-e) in dry THF was stirred under N, . NaH (60% 
dispersion in mineral oil; 1 eq.) was added slowly to allow controlled evolution of H, . 
Chloroacetyl chloride (1 eq.) was then added through a septum and the mixture was stirred for 
ea. 6 h. The solvent was removed in vacuo and the residue dissolved in EtOAc (2 x 50 mL). The 
resulting solution was washed sequentially with saturated aqueous NaHCO, (2 x 100 mL), 
water (2 x 100 mL) and brine (2 x 100 mL). The combined aqueous layers were then re-
extracted with EtOAc (100 mL). The organic layers were combined, dried with anhydrous 
Na,SO, or Mg50, and evaporated in vacuo to afford the 2-chloro-N-arylacetamide product. 
2-Chloro-N-(pyridine-2-yl)acetamide 38a 
The general procedure 1 was followed, using 2-aminopyridine 37a (2.64 g, 28 mmol), THF (30 
mL), NaH (1.20 g, 30 mmol) and chloroacetyl chloride (2.2 mL (3.12 g), 28 mmolJ. The crude 
product (2.65 g, 55%) was isolated as a red-brown oil which partly crystallised on standing. 
Purification by column chromatography [on silica; elution with hexane-EtOAc (1:3)J afforded 2-
chloro-N-(pyridine-2-yl)acetamide 38a as pale purple crystals (0.50 g, 21%), mp 82-86 °c 
(1it. ,"·l1' 110-115 and 123-125 0C); v/cm" 1676 (C=O); IiH (600 MHz; CDCI , ) 4.19 (2H, s, CH,CI), 
7.10 (lH, dd,J=7.2 and 4.8 Hz, 5'-H), 7.73 (lH, dd, J=8.5 and 7.2 Hz, 4'-H), 8.19 (lH, d, J=8.5 Hz, 
3'-H), 8.32 (lH, d, J=4.8 Hz, 6'-H) and 8.86 (lH, s, NH); lie (150 MHz; CDCI, ) 42.7 (t, CH,CI), 
113.9 (d, C-3'), 120.6 (d, C-5'), 138.5 (d, C-4'), 148.1 (d, C-6'), 150.3 (s, C-2') and 164.4 (s, C=O); 
mlz 171 (MH+, 100%). 
2-Chloro-N-(isoxazole-3-yl)acetamide 38b 
The general procedure 1 was followed, using 3-aminoisoxazole 37b [1.4 mL (1.59 g), 19 mmol], 
THF (30 mL), NaH (1.20 g, 50 mmol) and chloroacetyl chloride [2.2 mL (3.12 g), 28 mmolJ. 2-
Chloro-N-(isoxazole-3-yl)acetamide 38b was isolated as a dark brown solid (3.89 g, 100%), mp 
109-113 °c (lit., '2O §); v/cm" 1715 (C=O); Ii H (600 MHz; CDCI, ) 4.22 (2H, s, CH,CI), 7.07 (lH, d, 
J=l.4 Hz, 4'-H), 8.34 (lH, d, J=l.4 Hz, 5'-H) and 9.10 (lH, s, NH); lie (150 MHz; CDCI, ) 42.5 (t, 
CH,CI), 99.1 (d, C-4'), 156.7 (s, C-3' ), 159.3 (d, C-5') and 164.4 (s, C=O); mlz 161 (MH+, 100%). 
2-Chloro-N-(1,3-thiazole-2-yl)acetamide 38c 
The general procedure 1 was followed, using 2-aminothiazole 37c (1.90 g, 19 mmol), THF (30 
mL), NaH (1.20 g, 30 mmol) and chloroacetyl chloride [2.2 mL (3.12 g), 28 mmolJ. 2-Chloro-N-
(1,3-thiazole-2-yl)acetamide 38c was isolated as a yellow-brown solid (2 .34 g, 70%), mp 111-
113 °c (Iit.,121 162-164 °C); v/cm"1701 (C=O); IiH (600 MHz; CDCI, ) 4.28 (2H, s, CH,CI), 7.05 (lH, 
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d, 1=3.5 Hz, 5'-H) and 7.50 (lH, d, 1=3.5 Hz, 4'-H); DC (150 MHz; CDCI,) 42.1 (t, CH,CI), 114.6 (d, 
C-5'), 137.8 (d, C-4'), 157.4 (s, C-2') and 164.0 (s, C=O); mlz 177 (MH', 100%). 
2-Chloro-N-(furan-2-ylmethyl)acetamide 38d 
The general procedure 1 was followed, using furfurylamine 37d (2.5 mL (2.66 g), 28 mmol), 
THF (30 mL), NaH (1.20 g, 30 mmol) and ch loroacetyl ch loride (2.2 mL (3.12 g), 28 mmol]. 2-
Chloro-N-(furan-2-ylmethyl)acetamide 38d was isolated as a brown solid (3 .97 g, 84%), mp 58-
60°C (lit.,,,,·m §); v/cm" 1645 (C=O); 0" (600 MHz; CDCI,) 4.07 (2H, s, CH,CI), 4.48 (2H, d, 1=5.4 
Hz, CH, N), 6.26 (lH, d, 1=3.2 Hz, 3'-H), 6.33 (lH, dd, 1=3.2 and 1.9 Hz, 4'-H), 6.89 (lH, s, NH) 
and 7.37 (lH, d, 1=1.9 Hz, 5'-H); DC (150 MHz; CDCI, ) 36.8 (t, CH,NH), 42.5 (t, CH,CI), 107.9 (d, 
C-3'), 110.5 (d, C-4'), 142.6 (d , C-5'), 143.0 (s, C-2') and 150.3 (s, C=O); mlz 173 (M', 22%) and 
343 (100) . 
N-(S-Acetyl-4-methyl-l,3-thiazol-2-yl)-2-chloroacetamide 38e 
The general procedure 1 was followed, using 5-acetyl-2-amino-4-methylthiazole 37e (2.20 g, 
14 mmol), THF (15 mL), NaH (0.67 g, 28 mmol) and chloroacetyl chloride [1.1 mL (1.56 g), 14 
mmol]. N-(5-Acetyl-4-methyl-l,3-thiazol-2-yl)-2-chloroacetamide 38e was isolated as a dark 
brown solid (2.42 g, 74%), mp 148-151 °c (lit.,''' §); "/cm" 1713 (C=O); 0" (600 MHz; CDCI, ) 
2.52 (3H, s, 4'-CH, ), 2.66 (3H, s, CO.CH,) and 4.30 (2H, s, CH,CI); Dc (150 MHz; CDCI,) 18.0 (q, 
CO.CH, ), 30.4 (q, CH,-4'), 41.9 (t, CH,CI), 126.5 (d, C-5'), 156.3 (d, C-4' ), 157.5 (s, C-2'), 164.2 (s, 
NHC=O) and 190.5 (s, CH,C=O); mlz 233 (MH', 100%). 
Procedure 2. Synthesis of 2-chloro-N-arylacetamides 38a and 38d in 1,2-dichloroethane 
(non-microwave).77 
The relevant amine (37a or 37d) was dissolved in 1,2-dichloroethane and stirred for 10 min 
under N, in an ice bath. Chloroacetyl chloride (1 eq.) was added dropwise and, after stirring for 
1 h at room temperature, the pH of the solution was adjusted to pH 9 with aqueous NaOH. 
After separation, the aqueous layer was extracted twice with 1,2-dichloroethane (25 mL) and 
the organic layers were combined and dried over anhydrous Na,SO, followed by removal of 
the solvent in vacua. 
Attempted synthesis of 2-chloro-N-(pyridine-2-yl)acetamide 38a 
The general procedure 2 was followed, using 2-aminopyridine 37a (2.80 g, 30 mmol), 1,2-
dichloroethane (25 mL) and chloroacetyl chloride [2.6 mL (3.69 g), 33 mmol] . Evaporation of 
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the solvent afforded a red-brown solid (2.03 g), NMR analysis of which showed the presence 
of the starting material alone. 
2-Chloro-N-(furan-2-ylmethyl)acetamide 38d 
The general procedure 2 was followed, using furfurylamine 37d [2.7 mL (2.84 g), 30 mmol], 
1,2-dichloroethane (25 mL) and chloroacetyl chloride [2.6 mL (3.69 g), 33 mmol] . 2-Chloro-N-
(furan-2-ylmethyl)acetamide 38d was isolated as a brown solid (4.70 g, 91%), mp SO-55 °C 
(Iit. ,m.l2' §); v/cm·' 1648 (C;O); Ii H (600 MHz; CDCI, ) 4.07 (2H, s, CH,CI), 4.49 (2H, d, J;5.4 Hz, 
CH,N), 6.27 (IH, d, J;3.3 Hz, 3'-H), 6.33 (IH, dd, J;3.3 and 1.8 Hz 4'-H), 6.88 (IH, s, NH) and 
7.37 (IH, d, J=I.8 Hz, 5'-H); lie (150 MHz; CDCI , ) 36.7 (t, CH, NH), 42.5 (t, CH, CI), 107.9 (d, C-3'), 
110.5 (d, C-4'), 142.5 (d, C-5'), 150.2 (s, C-2') and 165.6 (s, C;O) . 
Procedure 3. Attempted synthesis of 2-chloro-N-(pyridine-2-yl)acetamide 38a in 1,2-
dichloroethane (microwave method).77 
A solution of 2-aminopyridine 37a (0.56 g, 6.0 mmol) in 1,2-dichloroethane (5 mL) was made 
up in a 10 mL glass microwave tube. Chloroacetyl chloride [0.52 mL (0.74 g), 6.5 mmol] was 
added dropwise and the tube was sealed with a septum and irradiated at 80 °C for 5 min at 
300 W in standard mode, with stirring and 5 min cooling time. The pH of the solution was then 
adjusted to pH 9 with aqueous NaOH. After separation, the aqueous layer was extracted twice 
with 1,2-dichloroethane (2 x 5 mL). The organic layers were combined and dried over 
anhydrous Na,50, and then the solvent was removed in vacuo to give a red-brown solid (0.23 
g), NMR analysis of which showed the presence of only the starting material and impurities. 
Procedure 4. Synthesis of phosphonate esters 3Sa-e.72 
The relevant a-chloroamide (38a-e) was placed in a dry, round-bottomed flask under N, and 
triethyl phosphite [P(DEt),; 5 eq.] was added through a septum. The mixture was boiled under 
reflux (oil bath at 110 °C) for co. 9 h. After cooling, hexane (20 mL) was added and the mixture 
stirred for co. 20 min. The hexane was then decanted and stirring and decanting was repeated 
with three further aliquots (20 mL each) of hexane. Evaporation of residual hexane and P(OEt), 
in vacuo afforded the desired ester 35a-e. 
Diethyl {2-oxo-2-(pyridin-2-ylaminoJethy/]phosphonate 35a 
General procedure 4 was followed, using 38a (0.43 g, 2.5 mmol) and P(OEt), [2.0 mL (1.94 g), 
12 mmol] to yield diethyl {2-oxo -2-(pyridin-2-ylaminoJethyl]phosphonate 35a as a da rk brown 
oil (0.078 g, 12%) (Found : M+, 272.091731. CllH17N,O,P requires M, 272.092596); v/cm·' 1691 
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(C=O) and 1018 (P-OR); IiH (600 MHz; COCl, ) 1.35 (6H, t, 1=6.6 Hz, 2xCH , ), 3.04 (2H, d, 1=21.0 
Hz, CH ,P), 4.20 (4H, q, 1=6.6 Hz, 2xOCH , ), 7.04 (lH, t, 1=6.0 Hz, 5'-H), 7.69 (lH, t , 1=7 .8 Hz, 4'-
H), 8.13 (lH , d, 1=8.4 Hz, 3'-H), 8.28 (lH, d, 1=4.8 Hz, 6'-H) and 8.96 (lH , s, NH); lie (150 MHz; 
CDCI, ) 16.4 (q, 2xCH, ), 36.9 (d, 1e.p=129.0 Hz, CH , P), 63.0 (t, 2xOCH, ), 114.0 (d, C-3'), 120.0 (d, 
C-5'), 138.3 (d, C-4' ), 148.0 (d, C-6'), 151.0 (s, C-2) and 162.7 (s, C=O); mi l 272 (M ' , 48%) and 
94 (100). 
Diethyl [2-(isoxazol-3-ylaminoJ-2-oxoethyIJphosphonate 35b 
Ge neral procedure 4 was followed, using 38b (1.02 g, 6 mmol) and P(OEt), [5.2 mL (5 .04 g), 30 
mmol] to yield diethyf {2-{isoxalof-3-yfaminoJ-2-oxoethyfJphosphonate 35b as a dark brown oil 
which crystallised on standing (0.800 g, 48%), mp 60-66 °c (Found: M' , 262.071312. 
C, H15N,OsP requires M, 262 .071860); v/cm·' 1693 (C=O) and 1010 (P-OR); IiH (600 MHz; COCI,) 
1.35 (6H, t, 1=7.2 Hz, 2xCH, ), 3.10 (2H, d, 1=21.0 Hz, CH , P), 4.20 (4H , q, 1=7.3 Hz, 2xOCH, ), 6.98 
(lH, d, 1=1.8 Hz, 4'-H), 8.25 (lH , d, 1=1.8 Hz, 5'-H) and 9.95 (lH, s, NH); lie (150 MHz; CDCI, ) 
16.3 (q, 2xCH, ), 36.2 (d, 1(.p=130.5 Hz, CH , P), 63.2 (t, 2xOCH, ), 99.3 (d, C-4'), 157.1 (s, C-3'), 
158.7 (d, C-5') and 162.5 (5, C=O); mi l 262 (M', 67%) and 179 (100) . 
Diethyf {2-oxo-2-{1,3-thiazof-2-yfaminoJethyf]phosphonote 35c 
General procedure 4 was followed, using 38c (1.13 g, 6 mmol) and P(OEt), [5.2 mL (5.04 g), 30 
mmol] to yield diethyf {2-oxo-2-{1,3-thialof-2-yfaminoJethyfJph osphonate 35c as a brown oil 
(1.04 g, 59%) (Found: M' , 278.047217. C, H15N,O, PS requires M, 278.049017) ; v/cm" 1684 
(C=O) and 1015 (P-OR); IiH (600 MHz; COCl, ) 1.32 (6H, t, 1=7.1 Hz, 2xCH, ), 3.17 (2H, d, 1=21.6 
Hz, CH ,P), 4.18 (4H, q, 1=7.1 Hz, 2xOCH, ), 6.96 (lH, d, 1=3.0 Hz, 5'-H) and 7.47 (lH, d, 1=3.0 Hz, 
4'-H); lie (150 MHz; COCl , ) 16.2 (q, 2xCH , ), 35.6 [d , lc.p=131.3 Hz, CH , P), 63.1 (t, 2xOCH, ), 113.6 
(d, C-5'), 137.2 (d, C-4'), 158.5 (s, C-2' ) and 162.4 (s, C=O); mil 278 (M', 50%) and 179 (100) . 
Diethyf {2-[(/uran-2-yfmethyIJaminoJ-2-oxoethyfJphosphonate 35d 
General procedure 4 was followed, using 38d (1.11 g, 6 mmol) and P(OEt), [5 .2 mL (5.04 g), 30 
mmol] to yield diethyf {2-{{Juran -2-yfmethyfJaminaJ-2-oxoethyf)phosphonate 35d as a red-
brown oil (1.09 g, 62%) (Found: M' , 275.090706. CUH,. NOsP requires M, 275.092261); v/cm·' 
1662 (C=O) and 1015 (P-OR); IiH (600 MH z; COCl, ) 1.29 (6H, t , 1=7.3 Hz, 2xCH, ) 2.85 (2H, d, 
1=20.7 Hz, CH , P), 4.90 (4H , q, 1=7.3 Hz, 2xOCH, ), 4.42 (2H, d, 1=5.7 Hz, CH , N), 6.22 (lH, d, 1=3.0 
Hz, 3'-H), 6.28 (lH, dd, 1=3.0 and 1.7 Hz, 4'-H), 7.17 (lH, s, NH) and 7.31 (lH , d, 1=1.7 Hz, 5'-H); 
lie (150 MHz; CDCI, ) 16.2 (q, 2xCH ,), 35.0 (d, 1(.p=129.0 Hz, CH , P), 36.7 (t, CH , NH), 62.7 (t, 
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2xOCH,), 107.3 (d, C-3'). 110.3 (d, C-4'), 142.1 (d, C-5'), 151.0 (s, C-2') and 163.8 (s, C=O); m/z 
275 (M+, 22%) and 96 (100). 
Diethyl {2-{{5-acetyl-4-methyl-l,3-thiazol-2-yl)aminoJ-2-oxoethyl}phosphonate 35e 
The general procedure 4 was followed, using 38e (1.49 g, 6 mmol) and P(OEtj, [5.2 mL (5.04 g), 
30 mmol] to yield diethyl {2-[(5-acetyl-4-methyl-l,3-thiazol-2-yl)aminoJ-2-oxoethyIj-
phosphonate 35e as a yellow-brown solid (1.44 g, 67%). mp 151-154 DC [Found: (M-1l', 
333.0667. C12H19N,O, PS requires M-l, 333.0674]; v/cm" 1682 (C=O) and 1011 (P-OR); OH (600 
MHz; CDCI , ) 1.38 (6H, t, J=7.2 Hz, 2xCH,). 2.42 (3H, s, 4'-CH, ). 2.49 (3H, s, CO.CH, ). 3.19 (2H, d, 
J=22.2 Hz, CH, P) and 4.27 (4H, q, J=7.2 Hz, 2xOCH,); oe (150 MHz; CDCI, ) 16.3 (q, 2xCH, ). 18.2 
(q, CO.CH, ). 30.2 (q, CH,.4') 35.7 (d, J(.p=129.0 Hz, CH,P), 63.6 (2xOCH,), 125.5 (s, C-5'), 155.4 
(s, C-4'). 158.4 (s, C-2'), 162.6 (s, NHC=O) and 190.6 (s, CH,C=O); m/z 333 [(M-Hl', 100%]. 
Procedure 5. Hydrolysis of phosphonate esters 35b-d in acetonitrile.81 
The phosphonate ester starting material (35b-d) was placed in a 10 mL microwave tube and 
dissolved in acetonitrile (3 mL). The tube was sealed with a septum and trimethylsilyl bromide 
(TMSBr; 2 eq.) was added. The mixture was irradiated in a microwave at 100 Wand 60 DC for 
10 min in standard mode with stirring and 2 min allowed for cooling. The reaction was then 
quenched with 10 mL of a 95:5 methanol-water mixture and stirred for 30 min followed by 
removal of the solvent in vacuo. 
Attempted synthesis of {2-{isoxazol-3-ylaminoj-2-oxoethyIJphosphonic acid 36b 
The general procedure 5 was followed, using 35b (0.524 g, 2 mmol) and TMSBr [0.53 mL (0.61 
g). 4 mmol]. Removal of the solvent gave a dark brown solid, 0.481 g, NMR analysis of which 
showed very broad signals which could not be assigned to either the desired product or to 
starting material; op (243 MHz; D,O) -0.43. 
{2-0xo-2-{1,3-thiazol-2-ylamino)ethyIJphosphonic acid 36c 
The general procedure 5 was followed, using 35c (0.557 g, 2 mmol) and TMSBr [0.53 mL (0.61 
g), 4 mmol] . Removal of the solvent afforded [2-oxo-2-(l.3-thiazol-2-ylomino)ethyljphosphonic 
acid 36c as brown solid (0.613 g); OH (600 MHz; D,O) 3.16 (2H, d, J=21.6 Hz, CH, P). 6.95 (lH, d. 
J=3.6 Hz, 5'-H) and 7.40 (lH, d, J=3.6 Hz, 4'-H) ; op (243 MHz; D, O) -1.38. Compound 36c was 
fully characterised following its synthesis using procedure 7. 
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Attempted synthesis of {2-[(furan-2-ylmethyl)aminoJ-2-oxoethyl}phosphonic acid 36d 
The general procedure 5 was followed, using 35d (0.550 g, 2 mmol) and TMSBr [0.53 ml (0.61 
g), 4 mmol]. Removal of the solvent gave a brown solid, 0.547 g, NMR analysis of which 
showed very broad signals which could not be assigned to either the desired product or to 
starting material; 0,(243 MHz; D,O) -0.39. 
Procedure 6. Attempted synthesis of {2-[(5-acetyl-4-methyl-l,3-thiazo/-2-yl)aminoJ-2-
oxoethyl}phosphonic acid 36e.54 
The phosphonate ester 35e (0.60 g, 2 mmol) was dissolved in dry CH,Ci, (3 ml) under N,. 
TMSBr [0.95 ml (1.10 g), 7 mmol] was dissolved in dry CH,CI, (3 ml) and added dropwise. The 
mixture was stirred under nitrogen for 2 h at room temperature. After removal of the volatile 
compounds in vacuo, the residue was dissolved in 0.25M-NaOH. The aqueous layer was 
washed twice with 20 ml EtOAc and then acidified by adding 2M-HCI dropwise. NaCi was 
added to the acidic aqueous layer and this was extracted three times with EtOAc. The organic 
laye rs were dried with anhydrous MgS04 and evaporated to afford a dark brown oil (0.025 g), 
NMR analysis of wh ich showed only the presence of starting material. 
Procedure 7. Synthesis of the disodium phosphonates 36a-e. 
The relevant phosphonate ester (35a-e) was dissolved in dry CH,CI, (3.5 ml) under N, and 
TMSBr (4 eq.) was added dropwise. The mixture was stirred overnight at room temperature. 
After removal of the volatile compounds in vacuo, the residue was dissolved in water (2 ml) 
and then titrated with OAM-NaOH to a pH of ca. 8. After titration, the aqueous solution was 
added to methanol (ca. 200 ml) and evaporated to dryness in vacuo. Purification of the 
products was carried out using reverse-phase column chromatography on C" cellulose, eluti ng 
with 1% NH40H in MeOH. 
Oisodium [2-oxo-2-(pyridin-2-ylamino)ethyl]phosphate 36a 
The general procedure 7 was followed, using 35a (0.143 g, 0.52 mmol) and TMSBr [0.28 ml 
(0.32 g), 2.1 mmol]. Disodium [2-oxo-2-(pyridin-2-ylamino)ethyl]phosphate 36a was isolated as 
a red-brown solid which was further purified by reverse-phase HPlC (lUNA lOu C,. column, 
250 x 10.00 mm; elution with H,O) (3 mg, 2.3% from HPlC), decomposes above 300 °C (Iit.,125 
§); [Found: (MH-Na,t, 215.0221. C, H.N,04P requires M, 215.0222]; v/cm·' 3242 (NH), 1668 
(C=O) and 1058 (P-O); 0" (600 MHz; 0,0) 2.79 (2H, d, J=18.6 Hz, CH, P), 7.23 (lH, t , J=6.0 Hz, 5'-
H), 7.87 (2H, overlapping m, 3'-H and 4'-H) and 8.31 (lH, d, J=4.8 Hz, 6'-H); Oc (150 MHz; D,O) 
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40.1 (d, 1(.p=109.5 Hz, (H , P). 115.8 (d, (-3'). 120.8 (d, (-5'). 139.6 (d, (-4'), 147.7 (d, (-6'). 
150.4 (s, ( -2') and 171.9 (s, (=0); mil 215 [(MH-Na,f, 25%] and 218 (100). 
Disodium {2-(isoxazol-3-ylaminoJ-2-oxoethyIJphosphonate 36b 
The general procedure 7 was followed, using 3Sb (0.300 g, 1.1 mmol) and TMSBr [0.60 mL 
(0.52 g), 4.6 mmol]. Oisodium {2-(isoxalol-3-ylaminoJ-2-oxoethyIJphosphonote 36b was 
isolated as a dark brown oil (0.438 g, 100%), mp 283-285 o( [Found: (M+1)', 250.9806. 
( sHsN,OsPNa, requires M+l, 250.9810]; v/cm·' 3038 (NH). 1682 ((=0) and 1067 (P-O); OH (600 
MHz; 0,0) 2.79 (2H, d, 1=18.6 Hz, (H,P). 6.80 (lH, d, 1=1.8 Hz, 4'-H) and 8.51 (lH, d, 1=1.8 Hz, 
5'-H); oe (150 MHz; 0 ,0) 39.5 (d, lc.p=111.0 Hz, (H , P). 99.1 (d, C-4'), 157.2 (s, ( -3'), 160.0 (d, (-
5' ) and 170.8 (s, (=0); mil 251 [(M+l)', 87%] and 217 (100) . 
Disodium {2-oxo-2-(1,3-thiazol-2-ylaminoJethy/]phosphonate 36c 
The general procedure 7 was followed, using 3Sc (0.243 g, 0.87 mmol) and TMSBr [0.46 mL 
(0.53 g), 3.5 mmol]. Oisodium {2-oxo-2-(1,3-thialol-2-ylaminoJethy/]phosphonate 36c was 
isolated as a light brown solid which was further purified by HPL( (LUNA lOu (,. column, 250 x 
10.00 mm; elution with H,O) (0.385 g, 100%), decomposes above 290°C [Found: (M+l) ' , 
266.9582. ( sHsN,O,SPNa, requires M+l, 266.9581]; v/cm·' 3090 (NH), 1687 ((=0 ) and 1070 (P-
O); OH (600 MHz; 0, 0) 2.80 (2H, d, 1=18.6 Hz, (H,P), 7.14 (lH, d, 1=3.6 Hz, 5'-H) and 7.43 (lH, d, 
1=3.6 Hz, 4'- H); oe (150 MHz; 0 ,0) 39.1 (d, l e.p=108.0 Hz, (H,P). 114.0 (d, (-5'), 136.8 (d, C-4'), 
159.0 (s, C-2') and 170.4 (s, ( =0); mil 267 [(M+1)', 22%] and 223 (100). 
Disodium {2-{(furan-2-ylmethyIJaminoJ-2-oxoethyl}phosphonate 36d 
The general procedure 7 was followed, using 35d (0.300 g, 1.1 mmol) and TMSBr [0.57 mL 
(0.66 g). 4.4 mmol]. Oisodium {2-{{furon-2-ylmethyl)aminoJ-2-oxoethyl}phosphonate 36d was 
. isolated as a brown solid (0.567 g, 100%). decomposes above 250 o( [Found: (M+l)" 
264.0010. ( , H. NOsPNa, requires M+l, 264.0014]; v/cm·' 2971 (NH), 1643 ((=0) and 1075 (P-
O); OH (600 MHz; 0,0) 2.63 (2H, d, 1=19.2 Hz, (H ,P). 4.40 (2H, d, (H , N), 6.36 (lH, d, 1=3.6 Hz, 
3'-H). 6.44 (lH, dd, 1=3.6 and 1.8 Hz, 4'-H) and 7.48 (lH, d, 1=1.8 Hz, 5'-H); oe (150 MHz; D,O) 
36.4 (t, (H, NH). 38.2 (d, 1(.p=114.0 Hz, (H , P). 107.1 (d, C-3'). 110.5 (d, ( -4'). 142.5 (d, (-5'). 
151.3 (s, (-2') and 172.1 (s, ( =0); mlz 264 [(M+l)', 3%] and 394 (100). 
Disadium {2-[(5-acetyl-4-methyl-l,3-thiazol-2-yIJaminoJ-2-oxoethyl}phosphonate 36e 
The general procedure 7 was followed, usi ng 35e (0.180 g, 0.54 mmol) and TMSBr [0.28 mL 
(0.32 g). 2 mmol]. Oisodium {2-{{5-acetyl-4-methyl-l ,3-thiazol-2-yIJaminoJ-2-oxoethyI}-
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phosphonate 36e was isolated as a light brown solid (0.197 g, 100%), decomposes above 
290 °C [Found: (M+l)', 322.9856. C, H,N,O,Na,PS requires M+l, 322.9843]; v/cm" 3146 (NH), 
1652 (C=O) and 1103 (P-O); OH (600 MHz; D,O) 2.59 (3H, s, CH 3), 2.61 (3H, S, CO.CH3) and 2.90 
(2H, d, 1=18.6 Hz, CH,P); Oe (150 MHz; D,O) 17.4 (q, CH3) 29.3 (q, CO.CH3), 38.9 (d, 1e.,,=109.5 
Hz, CH,P), 125.7 (s, C-4'), 156.3 (s, C-5' ), 161.1 (s, C-2' ), 170.5 (s, NHC=O) and 195.7 (s, 
CH3C=0); mil 323 [(M+l) ' , 100%]. 
Procedure 8. Synthesis of bis(trimethylsilyl) intermediates 48 and 50. 
As the bis(trimethylsilyl) phosphonates hydrolyse on contact with air, compounds 48 and 50 
were synthesised in an NMR tube and characterised in the reaction mixture, in the presence of 
the by-product ethyl bromide, excess TMSBr and the NMR standard trimethoxybenzene 
(TMB). A solution of the diethyl phosphonate 35e or 3Sb and TMB (0.33 eq.) in dry CDCl3 (0.6 
mL) under N, was transferred to an NMR tube which was flushed with N, and sealed with a 
septum. TMSBr (4 eq.) was added through the septum and the reaction progress was 
monitored by ' H and 31 p NMR spectroscopy until the reaction was complete. 
Bis(trimethylsilyl) (2-{{S-acetyl-4-methyl-l,3-thiazol-2-yl)ominoJ-2-oxoethyl}phosphonote 48 
The general procedure 8 was followed, using 35e (0.060 g, 0.18 mmol), TMB (0.010 g, 0.060 
mmol) and TMSBr [0.095 mL (0.11 g), 0.72 mmol]. After completion of the reaction, the highly 
reactive bis( trimethylsilyl) {2 -f( S·acetyl-4-meth yl-l,3-th ialol-2 -yl)a mine J-2-oxoethyl}-
phosphonate 48 was characterised without further purification; OH (600 MHz; CDCl3) -0.03 
(18H, s, 6xCH3Si), 2.48 (3H, s, CO.CH3), 2.66 (3H, s, CH 3) and 3.45 (2H, d, 1=22.8 Hz, CH, P); oe 
(150 MHz; CDCI3) 1.7 (q, 6xCH 3Si), 15.4 (q, CH 3"4'), 29.9 (q, CO.CH3), 38.4 (d, lc.,,=136.5 Hz, 
CH, P), 125.4 (s, C-5'), 144.8 (s, C-4'), 160.4 (s, C-2'), 164.4 (s, NHC=O) and 189.0 (s, CH 3C=0); 0, 
(243 MHz; CDCI3) -0.69. 
Bis(trimethylsilyl) {2-(isoxazol-3-ylamino)-2-oxoethyIJphosphonate 50 
The general procedure 8 was followed, using 35b (0.024 g, 0.090 mmol) and TMSBr [0.045 mL 
(0.052 g), 0.36 mmol] . After completion of the reaction, the highly reactive bis(trimethylsily/) 
{2-(isoxalol-3-ylamino)-2-oxoethyl]phosphonate 50 was characterised without further 
purification; OH (600 MHz; CDCI3) -0.04 (18H, s, 6xCH3Si), 3.72 (2H, d, 1=21.6 Hz, CH, P), 7.00 
(lH, d, 1=1.8 Hz, 4'-H), 8.40 (1H, d, 1=1.8 Hz, 5'-H) and 11.65 (lH, s, NH); oe (150 MHz; CDCl3) 
1.8 (q, 6xCH3Si), 37.4 (d, 1e.p=141.0 Hz, CH, P), 100.0 (d, C·4'), 154.8 (s, C-3'), 159.3 (d, C-5') and 
162.2 (s, C=O); 0, (243 MHz; CDCl3) 0.00. 
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Procedure 9. Synthesis of diethyl (3-oxo-3-phenylpropyl)phosphonate 4S. 
The starting material, 3-chloropropiophenone 47 (1.00 g, 5.93 mmol). was placed in a dry, 
round-bottomed flask under N, and P(OEtj, [5.1 mL (4.94 g). 30 mmolJ was added through a 
septum. The mixture was boiled under reflux (oil bath at 110°C) for ca. 9 h. After cooling, 
hexane (20 mL) was added and the mixture stirred for ca. 20 min. The hexane layer did not 
separate from the product so the solvent and some of the excess P(OEtj, were evaporated in 
vacuo to yield diethyl (3-oxo-3-phenylpropyl)phosphonate 4S as a pale yellow oil, which was 
purified by column chromatography [on silica; elution with hexane-EtOAc (5:1)]. (0.784 g, 49%) 
[Found: (M+lt, 271.1098. C1lH"O,P requires M+l, 271.1099J; v/cm-' 1687 (C=O) and 1018 (P-
OR); OH (600 MHz; CDCI ,) 1.35 (6H, t, J=7.3 Hz, 2xCH,), 2.19 (2H, m, CH,P), 3.29 (2H, m, 
CO.CH, ). 4.11 (4H, q, J=7.3 Hz, 2xOCH,), 7.46 (2H, t, J=7.4 Hz, 3'- and 5'-H). 7.57 (lH, d, J=7.4 
Hz, 4'-H) and 7.97 (2H, d, J=7.4 Hz, 2'- and 6'-H); Oc (150 MHz; CDC I, ) 16.3 (q, 2xCH,). 19_8 (d, 
Jc_,.=144.0 Hz, CH,P). 31.7 (t, CO.CH,), 61.7 (t, 2xOCH,), 128.0 (d, C-2' and -6'). 128.7 (d, C-3' 
and -5'). 133.3 (d, C-4'), 136.3 (s, C-l') and 197.5 (s, C=O); op (243 MHz; CDCI, ) 32.76; mlz 271 
(MH', 18%) and 563 (100). 
Procedure 10. Synthesis of disodium (3-oxo-3-phenylpropyl)phosphonate 46. 
The phosphonate ester 4S (0.60 g, 2_2 mmol) was dissolved in dry CH ,CI, (5 mL) under N, and 
TM5Br [1.2 mL (1.39 g), 8.8 mmolJ was added dropwise. The mixture was stirred overnight at 
room temperature . After removal of the volatile compounds in VDCUO, the residue was 
dissolved in water (2 mL) and then titrated with O.4M-NaOH to a pH of CD_ 8. After titration, 
the aqueous solution was added to methanol (ca. 200 mL) and evaporated to dryness in VDCUO. 
Purification was carried out using reve rse-phase column chromatography on C" ce llulose, 
eluting with 1:1 MeOH/H,O to yield disodium (3-oxo-3-phenylpropyl)phosphonate 46 as a 
cream solid (0.165 g, 29%), decomposes above 300 °C (lit.,126,127 115-117 and 123-124 0C); 
[Found: (M-l) ', 213.0312, C,H,O,P requires M-l, 213.0317J; v/cm" 3196 (NH). 1645 (C=O) and 
1119 (P-O); OH (600 MHz; CDCI, ) 2.00 (2H, dt, J=17.4 and 7.8 Hz, CH,P). 3.38 (2H, t, J=7.8 Hz, 
CO.CH, ), 7.60 (2H, t, J=7.4 Hz, 3'- and 5'-H), 7.73 (lH, d, J=7.4 Hz, 4'-H) and 8.06 (2H, d, J=7.4, 
2'- and 6'-H); Oc (150 MHz; CDC!,) 23.0 (d, Jc_,.=130.5 Hz, CH,p)' 33.4 (t, CO.CH,), 128.4 (d, C-2' 
and -6'). 129.0 (d, C-3' and -5'), 134.2 (d, C-4'), 136.5 (s, C-1') and 214.8 (s, C=O); mlz 271 [(M-
H)', 77%J and 421 (100). 
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Procedure 11. Synthesis of 3-chloro-N-arylpropanamides 41a-e. (Adapted from a literature 
method.") 
A solution of the relevant primary amine (37a-e) in dry THF was stirred under N,. NaH (60% 
dispersion in mineral oil; 1 eq.) was added slowly to allow controlled evolution of H,. 
Chloropropionyl chloride (1 eq.) was then added slowly through a dropping funnel and the 
mixture was stirred overnight at room temperature. The solvent was removed in vacuo and 
the residue dissolved in EtOAc (2 x 50 mL). The resulting solution was washed seq uentially 
with saturated aqueous NaHCO, (2 x 100 mL), water (2 x 100 mL) and brine (2 x 100 mL). The 
combined aqueous layers were then re-extracted with EtOAc (100 mL). The organic layers 
were combined, dried with anhydrous Na,SO. or MgSO. and evaporated in vacuo to afford the 
3-chloro-N-arylpropanamide product 41a-e. 
3-Chloro-N-(pyridin-2-yl)propanamide 41a and side-products 42-44 
The general procedure 11 was followed, using 2-aminopyridine 37a (2.64 g, 28 mmol), THF (30 
mL), NaH (1.20 g, 30 mmol) and chloropropionyl chloride (2.7 mL (3.56 g), 28 mmol) . The 
crude product (1.87 g, 36%) was isolated as a yellow solid. The mixture of products from the 
crude reaction mixture was separated using reverse-phase HPLC [on C18; elution with 
MeOH:H,O (1:1)] to afford 4 products. 
i) 3-Chloro-N-(pyridin-2-yl)propanamide 41a as an off-white solid (0.046 g, 39%), mp 190-196 
°c (lit.,'" §); (Found: C, 47.1; H, 4.9; N, 13.5. C. H, ON,Ci requires C, 52.0; H, 4.9; N, 15.2%); 
v/cm" 1685 (C=O); OH (600 MHz; 0,0) 3.05 (2H, t, 1=7.2 Hz, CO.CH,), 4.79 (2H, t, 1=7.2 Hz, 
CH,CI), 7.39 (lH, d, 1=8.7 Hz, 3'-H), 7.49 (1H, t, 1=6.6 Hz, 5'-H), 8.28 (lH, t, 1=8.7 Hz, 4'-H) and 
8.34 (lH, d, 1=6.6 Hz, 6'-H); DC (150 MHz; 0,0) 28.4 (t, CO.CH , ), 50.7 (t, CH,CI), 115.8 (d, C-3'), 
120.4 (d, C-5'), 141.5 (d, C-6'), 146.5 (d, C-4' ), 147.8 (s, C-2') and 169.2 (s, C=O). 
ii) N-(3-ChloropropanoyIJ-N-(pyridin-2-yIJprop-2-enamide 42 as a cream solid (0.008 g, 7%), 
mp 98-103 °C;' v/cm" 1679 and 1648 (C=O); OH (600 MHz; 0,0) 2.68 (2H, t , 1=6.6 Hz, CO.CH,), 
4.33 (2H, t, 1=6.6 Hz, CH,Ci), 5.59 (lH, d, J=1O.2 Hz, 3-H), 5.96 (lH, d, 1=17.4 Hz, 3-H), 6.06 (lH, 
dd,1=17.4and 10.2 Hz, 2-H), 6.83 (lH, t ,1=6.6 Hz, 5"-H), 7.00 (1H, d,1=8.7 Hz, 3"-H), 7.76 (1H, 
t, 1=8.7 Hz, 4"-H) and 7.78 (lH, d, 1=6.6 Hz, 6"-H); lie (150 MHz; 0,0) 34.8 (t, CO.CH, ), 51.0 (t, 
CH,CI), 113.6 (d, C-5"), 116.3 (d, C-3"), 126.6 (dd, CH,-3), 133.6 (d, C-2), 139.5 (d, C-6"), 142.5 
(d, C-4"), 153.7 (s, C-2"), 175.3 (s, C=O-l) and 177.90 (s, ( =0-1'). 
, It was not possible to obtain mass spectrometry or elemental data for this compound due to its highly 
hygroscopic nature. 
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iii) 3-Chloro-N-(pyridin-2-yl}-N-{3-(pyridin-2-ylomino}proponoylJproponomide 43 as a cream 
solid (0.006 g, 5%), mp 88-91 DC;' v/cm-1 1684 and 1645 (C=O); OH (600 MHz; 0 , 0) 2.72 (2H, t, 
J=6.5 Hz, 2-CO.CH,), 2.93 (2H, t, J=6.5 Hz, 2"-CO.CH,), 3.89 (2H, t, J=6.5 Hz, 3"-CH, N), 4.42 (2H, 
t, J=6.5 Hz, 3-CH,CI), 6.94 (lH, t, J=6.8 Hz, 5'-H), 7.23 (lH, d, J=9.0 Hz, 3'-H), 7.26 (lH , t, J=5.8 
Hz, 5'''-H), 7.75 (lH, d, J=7 .8 Hz, 3'''-H), 7.88 (lH, t, J=7.8 Hz, 4'''- H), 7.90 (lH, d, J=6.8 Hz, 6'-
H), 7.94 (lH, t , J=9.0 Hz, 4'-H) and 8.31 (lH, d, J=5 .8 Hz, 6"'-H); Oc (150 MHz; 0 ,0) 35_1 (t, 
CO.CH , -2), 35.9 (t, CO.CH,-2"), 39.0 (t, CH , N-3"), 51.5 (t, CH ,CI-3), 111.4 (d, C-3'), 113.4 (d, C-
5') 116.3 (d, C-3"'), 121.4 (d, C-5'''), 139.7 (d, C-4'''), 141.1 (d, C-6'), 143.4 (d, C-4'), 147.9 (d, C-
6''') ,149.8 (s, C-2'''), 152.5 (s, C-2'), 172.4 (s, C=O-l) and 177.9 (s, C=O-l"). 
iv) N-(Pyridin-2-yl)prop-2-enamide 44 as a white solid (0.002 g, 2%), mp 76-78 'c (lit.,129 §);' 
v/cm·' 1648 (C=O); OH (600 MHz; 0 ,0) 5.88 (lH, d, J=1O.3 Hz, 3-H), 6.36 (lH, d, J=17.1 Hz, 3-H), 
6.45 (lH, dd, J=17.1 and 10.3 Hz, 2-H), 7.21 (lH , t, J=6.1 Hz, 5'-H), 7.83 (2H, m, 3'-H and 4'-H) 
and 8.28 (lH, d, J=4.6 Hz, 6'-H); Oc (150 MHz; 0 ,0) 116.3 (d, C-3' ), 121.3 (d, C-5'), 129.5 (dd, 
CH,-3), 130.2 (d, C-2), 139.6 (d, C-4'), 147.9 (d, C-6'), 150.0 (s, C-2') and 167.0 (s, C=O). 
3-Chloro-N-(1,2-oxazol-3-yl}propanamide 41b 
The general procedure 11 was followed , using 3-a minoisoxazole 37b [2.1 mL (2.35 g), 28 
mmol], THF (30 mL), NaH (1.20 g, 30 mmol) and chloropropionyl ch loride [2.7 mL (3.56 g), 28 
mmol]. The product was washed 3 times with hexane and dried to yield 3-chloro-N-(1,2-
oxazol-3-yl)propanamide 41b as a pale yellow solid (6.34 g, 100%), mp 110-114 DC; [Found: 
(M+l)', 175.0256. C, H, N,O,CI requires M+l, 175.0274]; v/cm-1 1667 (C=O); OH (600 MHz; 
CDCI, ) 2.94 (2H, t, J=6_6 Hz, CO .CH, ), 3.89 (2H, t, J=6.6 CH, CI), 7.13 (IH, d, J=1.2 Hz, 4'-H), 8.31 
(IH, d, J=1.2 Hz, 5'-H) and 9.70 (IH, s, NH); Oc (150 MHz; COCI, ) 39.0 (t, CH, CI), 39.7 (t, CO.CH, ), 
99.5 (d, C-4'), 157.4 (s, C-3'), 159.1 (d, C-5') and 167.9 (s, C=O); mlz 175 (MH' , 100%). 
3-Chloro-N-(1,3-thiazol-2-yl)propanainide 41c 
The general procedure 11 was followed, using 2-aminothiazole 37c (2.80 g, 28 mmol), THF (30 
mL), NaH (1.20 g, 30 mmol) and chloropropionyl chloride [2.7 mL (3.56 g), 28 mmol] . The 
product was washed 3 times with hexane and dried to yield 3-chloro-N-(1,3-thiazol-2-
yl)propanamide 41c as a yellow-brown solid (3.30 g, 62%), mp 129-132 'c (1it. ,130 169 DC); 
[Found: (M+1)" 191.0020. C6H,N,OSCI requires M+l, 191.0046]; v/cm-1 1688 (C=O); OH (600 
MHz; COCl,) 3.01 (2H, t, J=6.6 Hz, CO.CH , ), 3.92 (2H, t, J=6.6 Hz, CH , CI), 7.04 (lH, d, J=3.6 Hz, 
• It was not possible to obtain mass spectrometry or elemental data for this compound due to its highly 
hygroscopic nature. 
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5'-H) and 7.49 (lH, d, 1=3.6 Hz, 4'-H); Oc (150 MHz; CDCI, ) 39.0 (t, CH,CI). 39.2 (t, CO.CH, ). 
114.0 (d, C-5' ). 136.5 (d, C-4'). 159.2 (s, C-2') and 167.5 (s, C=O); mil 191 (MH' , 62%) and 155 
(100). 
3-Chloro-N-(furan-2-ylmethyl)propanamide 41d 
The general procedure 11 was followed, using furfurylamine 37d (2.6 mL (2.72 g). 28 mmolJ. 
THF (30 mL), NaH (1.20 g, 30 mmol) and chloropropionyl chloride [2.7 mL (3.56). 28 mmol]. 
The product was washed 3 times with hexane and dried to yield the crude product as a brown 
solid (3.34 g, 63%). A portion of the crude product (0.10 g) was purified by column 
chromatography [on silica; elution with hexane-EtOAc (1:1)] to afford 3-chloro-N-(furan-2-
ylmethyl)propanamide 41d as a pale brown solid, mp 70-72 °c (lit.,131 §); (Found: M', 
187.0398. C,HlONO,CI requires M, 187.0400); v/cm'l 1633 (C=O); OH (600 MHz; CDCI, ) 2.65 (2H, 
t,l= 6.7 Hz, CO.CH, ). 3.81 (2H, t, 1= 6.7 Hz, CH,CI), 4.46 (2H, d, 1=5.3 Hz, CH,N), 6.06 (1H, s, NH), 
6.24 (1H, d, 1= 3.3 Hz, 3'-H), 6.32 (1H, dd, 1=3.3 and 1.9 Hz, 4'-H) and 7.35 (lH, d, 1=1.9 Hz, 5' -
H); Oc (150 MHz; CDCI,) 36.5 (t, CH,N). 39.3 (t, CO.CH,), 39.9 (t, CH,CI). 107.5 (d, C-3'). 110.4 (d, 
C-4'). 142.2 (d, C-5'). 150.9 (s, C-2') and 169.4 (s, C=O); mil 187 (M', 82%) and 97 (100). 
N-(5-Acetyl-4-methyl-1,3-thiazol-2-yl)-3-chloropropanamide 41e 
The general procedure 11 was followed, using 5-acetyl-2-amino-4-methylthiazole 37e (1.56 g, 
10 mmol). THF (10 mL). NaH (0.43 g, 11 mmol) and chloropropionyl chloride [0.9 mL (1.27 g). 
10 mmol]. The crude product was isolated as a yellow solid (2.07 g, 84%). A portion of the 
product was purified by column chromatography [on silica; elution with CHCI,-EtOAc (1:1)] to 
afford N-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-chloropropanamide 41e as a pale yellow solid, 
mp 167-169 °c (Iit.,'" §); [Found: (M+1j', 247.0297. C, Hn N,O,SCI requires M+l, 247.0308]; 
v/cm'l 1635 (C=O); OH (600 MHz; CDCI, ) 2.52 (3H, s, 4'-CH,). 2.64 (3H, 5, CO.CH, ), 2.95 (2H, t, 
1=6.0 Hz, CO.CH,) and 3.89 (2H, t, 1=6.0 Hz, CH,CI); Oc (150 MHz; CDCI,) 18.0 (q, C-4'). 30.4 (q, 
CO.CH3), 38.6 (t, CH,CI), 39.3 (t, CO.CH,), 125.6 (5, C-5' ). 154.8 (5, C-4' ), 158.5 (5, C-2' ), 167.7 (5, 
NHC=O) and 190.6 (5, CO.CH, ); mil 247 (MH', 7%) and 295 (100). 
Procedure 12. Synthesis of phosphonate esters 39a-e." 
The 3-chloropropanamide starting material (41a-e) was placed in a dry, round-bottomed flask 
under N, and P(OEt), (5 eq.) was added through a septum. The mixture was boiled under 
reflux (oil bath at 110 °C) for ca. 9 h. After cooling, hexane (20 mL) was added and the mixture 
stirred for ca. 20 min. The hexane was then decanted and stirring and decanting was repeated 
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with three further aliquots (20 mL each) of hexane. Evaporation of residual hexane and P(OEt), 
in vacuo afforded the desired ester 39a-e. 
Diethyl [3-oxo-3-(pyridin-Z-ylamino)propyIJphosphonate 39a 
The general procedure 12 was followed, using 41a (0.69 g, 3.7 mmol) and P(OEt), [3 .2 mL (3.11 
g), 19 mmol) to yield diethyl [3-oxo-3-(pyridin-2-ylamino)propyJ]phosphonate 41a as an orange 
oil (0.36 g, 33%) [Found: (M+l) ', 287.1161. C12H'9N,O,P requires M+l, 287.1161); v/cm·' 1690 
(C=O) and 1020 (P-OR); OH (600 MH,; COCl, ) 1.31 (6H, t, J=7.0 H" 2xCH, ), 2.18 (2H, dt, J=18.0 
and 7.9 Hz, CH , P), 2.70 (2H, dt, J=13.4 and 7.9 Hz CO.CH, ), 4.12 (4H, q, J=7.0 Hz, 2xOCH, ), 7.03 
(lH, dd, J=7.3 and 5.0 Hz, 5'-H), 7.69 (lH, dd, J=8 .8 and 7.3 Hz, 4'-H), 8.17 (lH, d, J=8.8 Hz, 3'-
H), 8.27 (lH, d, J=5 .0 Hz, 6'-H) and 8.52 (lH, 5, NH); Oe (150 MHz; CDCI ,) 16.4 (q, 2xCH , ), 20.9 
(d, Je.p=142.5 Hz, CH,P), 30.5 (t, CO.CH, ), 61.92 (t, 2xOCH, ), 114.0 (d, C-3'), 119.8 (d, C-5'), 
138.4 (d, C-4' ), 147.9 (d, C-6'), 151.3 (5, C-2' ) and 169.8 (5, C=O); mlz 287 (MH', 100%). 
Diethyl [3-(1,Z-oxazol-3-ylamino)-3-oxopropyJ]phosphonate 39b 
The general procedure 12 was followed, using 41b (1.11 g, 6 mmol) and P(OEt), [5.2 mL (5.04 
g), 30 mmol) to yield diethyl [3-(1,2·oxozol-3-yfomino)-3-oxopropyfJphosphonate 39b as an 
orange oil (1.29 g, 74%) [Found: (M+l)', 277.0962. ClOH17N,O, P requires M+l, 277 .0953J; 
v/ cm·' 1701 (C=O) and 1021 (P-OR); OH (600 MHz; CDCI, ) 1.29 (6H, t, J=7.2 Hz, 2xCH , ), 2.16 (2H, 
dt, J=18.0 and 8.4 Hz, CH , P), 2.79 (2H, dt, J=15.6 and 8.4 Hz, CO.CH , ), 4.11 (4H, m, 2xOCH , ), 
7.02 (lH, d, J=1.2 Hz, 4'-H), 8.24 (lH, d, J=1.2 Hz, 5'-H) and 10.51 (lH, 5, NH); Oe (150 MHz; 
CDCI, ) 16.3 (q, 2xCH, ), 20.6 (d, Jc.p=144.0 Hz, CH , P), 29 .4 (t, CO.CH, ), 62.1 (t, 2xOCH, ), 99.3 (d, 
C-4'), 157.6 (5, C-3'), 158.6 (d, C-5') and 170.0 (5, C=O); ml z 277 (MH' , 35%) and 299 (100) . 
Diethyl [3-oxo-3-(1,3-thiazol-2-yfamino)propyIJphosphonate 39c 
The general procedure 12 was followed, using 41c (1.22 g, 6 mmol) and P(OEt), [5.2 mL (5.04 
g), 30 mmolJ . The product diethyf {3-oxo-3-(1,3-thiozof-2-yfamino)propyJ]phosphonate 39c 
crystallised out of hexane as pale yellow crystals (1.29 g, 69%), mp 50-52 °C; [Found: (M+l)', 
293.0723. ClOH17N,O, P5 requires M+l, 293 .0725J; v/cm·' 1686 (C=O) and 1028 (P-OR); OH (600 
MH z; COCl, ) 1.32 (6H, t , J=7.2 Hz, 2xCH, ), 2.22 (2H, dt, J=6.6 and 1.2 Hz, CH , P), 2.86 (2H, dt, 
J=6.6 and 1.2 Hz, CO.CH, ), 4.13 (4H, qd, J=7.2 and 1.2 Hz, 2xOCH , ), 6.99 (lH, d, J=3.4 Hz, 5'-H) 
and 7.53 (lH, d, J=3.4 Hz, 4'-H); Oe (150 MHz; CDCI , ) 16.4 (q, 2xCH, ), 20.8 (d, lc.e=144 .0 Hz, 
CH , P), 29.3 (t, CO.CH , ), 62. 0 (t, 2xOCH , ), 113.6 (d, C-5' ), 136.9 (d, C-4' ), 159. 3 (5, C-2') and 
169.2 (5, C=O); ml z 293 (MH ' , 100%). 
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Diethyl {3-[(furan-2-ylmethyl)aminoJ-3-oxopropyl)phosphonote 39d 
The general procedure 12 was followed, using 41d (1.20 g, 6 mmol) and P(OEtj, [5.2 ml (5.04 
g), 30 mmolJ to yield diethyl {3-{{furan-2-ylmethyl)aminoJ-3-oxopropyl)phosphonate 39d as a 
brown oil (1.48 g, 80%) [Found: (M+lt, 290.1169. CllH20NOsP requires M+l, 290.11s7J; v/cm·' 
1654 (C=O) and 1020 (P-OR); IiH (600 MHz; CDCI, ) 1.29 (6H, t, 1=7.2 Hz, 2xCH, ) 2.08 (2H, dt, 
1=17.8 and 8.0 Hz, CH,P), 2.49 (2H, dt, 1=14.7 and 8.0 Hz, CO.CH,), 4.04 (4H, qd, 1=7.2 and 2.9 
Hz, 2xOCH,), 4.41 (2H, d, 1=5.5 Hz, CH,N), 6.21 (lH, dd, 1=3.2 and 0.6 Hz, 3'-H), 6.29 (lH, dd, 
1=3.2 and 1.9 Hz, 4'-H), 6.67 (lH, 5, NH) and 7.33 (lH, dd, 1=1.9 and 0.6 Hz, s'-H); liells0 MHz; 
CDCI, ) 16.4 (q, 2xCH,), 21.0 (d, lc.p=142.s Hz, CH,P), 29.0 (t, CO.CH,), 36.6 (t, CH, N), 61.8 (t, 
2xOCH,), 107.4 (d, C-3'), 110.4 (d, C-4'), 142.1 (d, C-5'), 151.3 (5, C-2') and 170.8 (5, C=O); mlz 
290 (MH', 14%) and 312 (100). 
Diethyl {3-[(5-acetyl-4-methyl-l,3-thiozol-2-yl)ominoJ-3-oxopropyl}phosphonate 3ge 
The general procedure 12 was followed, using 41e (0.050 g, 0.2 mmol) and P(OEtj, [0.2 ml 
(0.17 g), 1 mmolJ to yield diethyl {3-{{5-acetyl-4-methyl-l,3-thiazol-2-yl)aminoJ-3-oxopropyl}-
phasphonate 3ge, which crystallised out of acetone as a white solid (0.028 g, 40%), mp 195-
198 °C; [Found: (M+1t, 349.1003. C13H21N,OsPS requires M+l, 349.0987]; v/cm·' 1668 (C=O) 
and 1017 (P-OR); IiH (600 MHz; CDCI,) 1.33 (6H, t, 1=7.3 Hz, 2xCH,), 2.21 (2H, dt, 1=17.9 and 7.7 
Hz, CH,P), 2.49 (3H, 5, CO.CH,), 2.59 (3H, 5, 4'-CH, ), 2.87 (2H, dt, 1=15.4 and 7.7 Hz, CO.CH,), 
4.18 (4H, qd, 1=7.3 and 3.6 Hz, 2xOCH,) and 11.51 (lH, 5, NH); lie (150 MHz; CDCI,) 16.4 (q, 
2xCH, ), 18.2 (q, CH,-4'), 20.5 (d, lc_.=144.0 Hz, CH, P), 29.0 (t, CO.CH,), 30.4 (q, CO.CH, ), 62.5 (t, 
2xOCH, ), 125.1 (5, C-5'), 155.7 (5, C-4'), 158.9 (5, C-2' ), 169.9 (5, NHC=O) and 190.7 (5, CO.CH, ); 
mlz 349 (MH' , 17%) and 719 (100). 
Procedure 13. Hydrolysis of phosphonate esters 39a-e in OeM. 
The relevant phosphonate ester (39a-e) was dissolved in dry CH,CI, (3.5 ml) under N, and 
TMSBr was added dropwise. The mixture was stirred overnight at room temperature. After 
removal of the volatile compounds in vacuo, the residue was dissolved in water (2 ml) and 
then titrated with O.4M-NaOH to a pH of ca. 8. After titration, the aqueous solution was added 
to methanol (ca. 200 ml) and evaporated to dryness in vacuo. Purification of the products was 
carried out using reverse-phase column chromatography on C18 cellulose, eluting with 1:1 
H,O:MeOH. Compounds 40b, 40c, 40d and 40e were further purified by reverse-phase HPlC 
(lUNA lOu C'8 column, 250 x 10.00 mm; elution with H,O). 
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Disodium [3-oxo-3-(pyridin-2-ylamino}propyIJphasphonate 40a 
The general procedure 13 was followed, using 39a (0.20 g, 0.69 mmol) and TMSBr (0.37 mL 
(0.43 g), 2.8 mmol]. Oisodium {3-oxo-3-(pyridin-2-ylamino}propyIJphosphonate 40a was 
isolated as a light brown solid (0.052 g, 100%),' IiH (600 MHz; 0,0) 1.77 (2H, t, J=8.4 Hz, CH , P), 
2.67 (2H, t, J=8.4 Hz, CO.CH,), 7.26 (lH, t, J=6.0 Hz, 5'-H), 7.77 (lH, d, J=7.9 Hz, 3'-H), 7.90 (lH, 
t, J=7.9 Hz, 4'-H) and 8.33 (lH, d, J=6.0 Hz, 6'-H); lie (lS0 MHz; 0 ,0) 25.3 (d, Je_,,= 129.0 Hz, 
CH,P), 32.6 (t, CO.CH,), 116.3 (d, C-3'), 121.1 (d, C-5' ), 139.S (d, C-4'), 147.8 (d, C-6' ), 150.3 (s, 
C-2') and 176.6 (s, C=O). 
Disodium [3-(1,2-oxazol-3-ylaminoJ-3-axopropylJphasphanate 40b 
The general procedure 13 was followed, using 39b (0.50 g, 1.8 mmol) and TMSBr [0.96 mL 
(1.11 g), 7.2 mmol]. Oisodium {3-(1,2-oXOlol-3-ylamino}-3-oxopropyIJphosphonote 40b was 
isolated as a brown solid (0.038 g, 27% from HPLC), decomposes 184-187 °C; [Found: (M+l-
Na,(, 219.0191. CsH, N,OsP requires M+1-46, 219.0191]; v/cm" 3184 (NH), 1683 (C=O) and 
1047 (P-O); IiH (600 MHz; 0 ,0) 1.79 (2H, dt, J=16.8 and 8.4 Hz, CH,P), 2.68 (2H, dt, J=16.8 and 
8.4 Hz, CO.CH,), 6.78 (lH, d, J=0.6 Hz, 4'-H) and 8.54 (lH, d, J=0.6 Hz, 5'-H); lie (150 MHz; 0 ,0) 
25.3 (d, lc_p=129.0 Hz, CH, P), 32.6 (t, CO.CH, ), 99.8 (d, C-4'), 158.0 (s, C-3'), 160.8 (d, C-5') and 
176.3 (s, C=O); mil 219 [(MH -Na, l', 5%] and 371 (100). 
Disodium [3-oxo -3-(1,3-thiazol-2-ylaminoJpropyIJphasphonate 40c 
The general procedure 13 was followed, using 39c (0.80 g, 2.7 mmol) and TMSBr [1.4 mL (1.62 
g), 11 mmol]. Oisodium [3-oxo -3-(1,3-thiolol-2-ylaminoJpropyIJphosphonate 40c was isolated 
as a brown solid (0.009 g, 13.9 % from HPLC), decomposes above 266 °C; [Found : (M-l)', 
234.9943. C6H,N,O,SP requires M-l, 234.9942]; v/cm-1 3356 (NH), 1658 (C=O) and 1068 (P-O); 
IiH (600 MHz; 0 ,0) 1.73 (2H, dt, J=16.8 and 8.4 Hz, CH , P), 2.66 (2H dt, J=8.9 and 8.4 Hz, 
CO.CH,), 7.11 (lH, d, J=3.6 Hz, 5'-H) and 7.39 (lH, d, J=3.4 Hz, 4'-H); lie (1S0 MHz; 0 ,0) 24.3 (d, 
Jc.,,=130.5 Hz, CH,P), 31.0 (t, CO.CH, ), 114.1 (d, C-5'), 136.8 (d, C-4'), 158.9 (s, C-2') and 174.S 
(s, C=O); op (243 MHz; 0,0) 20.9; mil 235 [(M-H)', 91%] and 217 (100). 
Disodium {3-[(furan-2-ylmethyl}aminoJ-3-oxopropyIJphosphonate 40d 
The general procedure 13 was followed, using 39d (0.30 g, 1.0 mmol) and TMSBr [0.55 mL 
(0.64 g), 4.2 mmol] . Oisodium {3-[(Juran-2-ylmethyl)aminoJ-3-oxopropyIJphosphonate 40d was 
'It was not possible to obtain mass spectrometry or melting point data for this compound due to its 
highly hygroscopic nature. 
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isolated as a red-brown solid (0.23 g, 81%), decomposes above 273°C; [Found: (M-lt, 
232.0384. C,H lONOsP requires M-l , 232.0375]; v/cm" 3252 (NH), 1633 (C=O) and 1048 (P-O); 
IiH (600 MHz; D,O) 1.62 (2H, dt, )=17.1 and 4.4 Hz, CH, P), 2.38 (2H, dt, )=8.3 and 4.4 Hz, 
CO.CH, ), 4.30 (2H, 5, CH, N), 6.25 (lH, d, )=3.0 Hz, 3'-H), 6.35 (lH, dd, )=3.0 and 1.9 Hz, 4'-H) 
and 7.40 (lH, d, )=1.9 Hz, 5'-H); lie (150 MHz; D,O) 25.2 (d, Jc.p=130.5 Hz, CH,P), 31.8 (t, 
CO.CH, ), 36.4 (t, CH, N), 107.4 (d, C-3'), 110.7 (d, C-4'), 142.8 (d, C-5'), 151.3 (5, C-2') and 177.7 
(5, C=O); lip (243 MHz; D,O) 21.29; mil 232 [(M-Ht, 37%J and 421 (100) . 
Disodium {3-{{5-ocetyl-4-methyl-l,3-thiazol-2-yl)aminoJ-3-oxopropyl}phosphonate 40e 
The general procedure 13 was followed, using 3ge (0.233 g, 0.67 mmol) and TMSBr [0.35 mL 
(0.41 g), 2.7 mmolJ. Disodium (3·[(S-acetyl-4-methyl-l,3- th iazol-2-yl)aminoJ-3-oxopropy1)-
phosphonate 40e was isolated as a yellow solid (0.138 g, 61%), decomposes above 260 °C; ' 
v/cm" 3122 (NH), 1704 (C=O) and 1041 (P-O); IiH (600 MHz; D,O) 1.70 (2H, dt, )=16.8 and 8.4 
Hz, CH, P), 2.51 (3H, s, 4'-CH,), 2.53 (3H, s, CO.CH,) and 2.68 (2H, dt, )=16.8 and 8.4 Hz, 
CO.CH, ); Iid150 MHz; D,O) 17.5 (q, CH,-4'), 24.4 (d, Jc.p=129.0 Hz, CH,P), 29.4 (q, CO.CH,), 31.6 
(t, CO.CH, ), 125.8 (s, C-5'), 156.5 (s, C-4'), 161.5 (5, C-2' ), 175.7 (s, NHC=O) and 195.6 (s, 
CO.CH,). 
Procedure 14. Synthesis of diethyl N-(trimethylsilyl)phosphoramidate 59.117 
A solution of diethyl phosphoramidate 53 (5.0 g, 33 mmol) in benzene (10 mL) was made up 
under Ar. Hexamethyldisilazane [4.1 mL (3.2 g), 20 mmol (20% mol excess)] was added 
through a septum, with stirring. The mixture was then boiled under reflux in an oil bath (80 °C) 
under Ar for 3 h. The solvent and excess hexamethyldisilazane were removed in vacuo at 50-
60 °C for 1 h to afford diethyl N-(trimethylsilyl)phosphoramidate 59 as a pale brown oil which 
crystallised on cooling to form off-white crystals which were highly hygroscopic (7.16 g, 97%),' 
IiH (600 MHz; CDCI, ) 0.18 (9H, s, 3xSiCH , ), 1.30 (6H, t, )=7.2 Hz, 2xCH ,), 2.39 (lH, s, NH) and 
4.04 (4H, q, )=7.2 Hz, 2xOCH,); lic (150 MHz; COCl,) 0.6 (q, 3xSiCH, ), 16.2 (q, 2xCH,) and 61.9 (t, 
2xOCH,); lip (243 MHz; COCl, ) 10.14. 
Procedure 15. Synthesis of diethyl N-(2,2-diethoxyethyl)phosphoramidate 54.117 
A suspension of NaH [60% dispersion in mineral oil; 1.44 g, 36 mmol (1.2 eq.)] was stirred in 
hexane (30 mL) under N, and then allowed to settle. The hexane was removed with a syringe 
, It was not possible to obtain mass spectrometry data for this compound due to its highly hygroscopic 
natu re. 
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and the washing was repeated with 3 more aliquots (30 ml each) of hexane to remove the 
mineral oil. Dry benzene (20 ml) was added to the flask, followed by a solution of the 
protected phosphoramidate 59 (6.76 g, 30 mmol) in dry benzene (30 ml; added dropwise over 
30 min to allow for evolution of H,). Bromoacetaldehyde diethyl acetal [4.5 ml (5.9 g), 30 
mmol] and tetrabutylammonium bromide (0.97 g, 3 mmol) were then added and the mixture 
was boiled under reflux in an oil bath (80°C) under N, for 4 h. EtOH (25 ml) was then added 
slowly and the mixture was stirred for 1 h at 80°C. After cooli ng, EtOAc (100 ml) was added 
and the mixture was washed three times with water (3 x 10 ml). The combined aqueous layers 
were then washed with EtOAc (3 x 10 ml) and the organic layers were combined and dried 
with MgS04 • Evaporation of the solvent at 30-40 °c for 1 h afforded diethyl N-(2,2-
diethoxyethyl)phosphoramidate 54 as a brown oil (7.29 g, 90%), (lit.,'" §); IiH (600 MHz; CDCI,) 
1.19 (6H, q, 1=7.2 Hz, 2xCH,), 1.28 (6H, q, 1=7.2 Hz, 2xPOCH ,CH,), 3.10 (lH, s, NH), 3.32 (2H, d, 
1=5.4 Hz, NCH, ), 3.59 (4H, dq, 1=70.8 and 7.2 Hz, 2xOCH,), 4.04 (4H, q, 1=7.2 Hz, 2xPOCH,) and 
4.62 (IH, t, 1=5.4 Hz, CHI; lie (150 MHz; CDCI, ) 15.1 (q, 2xCH,), 16.1 (q, 2xPOCH, CH,), 31.7 (t, 
NCH,), 62.3 (t, 4xOCH,) and 101.3 (d, CHI; lip (243 MHz; CDCI,) 10.24. 
Procedure 16. Attempted synthesis of diethyl {2-oxoethyl)amidophosphate 55.75 
The alkylated phosphoramidate 54 (0.50 g, 1.9 mmol) was placed in a round-bottomed flask 
and 2M-HCI (5 ml) was added. The mixture was sti rred at room temperature overnight and 
then extracted with EtOAc (3 x 50 ml) . The organic layers were combined and dried with 
MgS04 • Removal of the solvent in vacuo afforded a brown oil (0.31 g, 86%), NMR analysis of 
which showed very little of the desired aldehyde 55 and suggested cleavage of the 
phosphoramidate substrate. The reaction was repeated at room temperature for reaction 
times of 3.5 days and 3 h and at 40 'c for 4 h with similar results. 
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3.2. Kinetic study of the reaction of phosphonate esters with 
bromotrimethylsila ne 
The study was conducted using a Bruker Biospin 600 MHz NMR spectrometer. Temperature 
calibration of the spectrometer was carried out between 283 K and 333 K using a standard 
solution of 4% MeOH in MeOD for 'nominal' temperatures between 283 K and 298 K, and a 
standard solution of 80% ethylene glycol in DMSO-d6 for 'nominal' temperatures between 297 
K and 333 K. The differences (ll ppm) between the -CH, and -OH signals for methanol and the -
CH, and -OH signals for ethylene glycol were measured at each 'nominal' temperature and 
used to calculate the actual temperature using the equations: T = (4.109 - 1I)/0.008708 for 
methanol and T = (4.218 - 1I)/0.009132 for ethylene glycol.'34.135 The reported temperatures 
for each ofthe kinetic runs are the corrected values. 
Measurement of the 31 p T, relaxation times 
Diethyl phosphonate 35e (0.060 g, 0.18 mmol). and 1,3,5-trimethoxybenzene (TMB; 0.012 g, 
0.068 mmol) were dissolved in dry CDCI, (0.6 mL; stored over molecular sieves and basic 
alumina) under N, . The solution was transferred to an NMR tube which was then flushed with 
N, and sealed with a septum. The 'H and 31 p NMR spectra [calibrated using 1M-phosphoric acid 
in 0,0 as an external standard (0.00 ppm)] of the substrate 35e and TMB were recorded and 
TMSBr [1 eq.; 0.024 mL (0.028 g). 0.18 mmolJ was then added through the septum. The 
reaction mixture was shaken and left to stand overnight at room temperature. The T, 
relaxation times of the phosphorus nuclei (in compounds 35e, 49 and 48) were measured by 
recording the inversion recovery 31p spectra in a series of 12 experiments involving different 
recovery times ranging from 100 ms to 20 s. The 31p signals were integrated and the intensity 
plotted against the delay time to give the T, relaxation times using curve fitting in Topspin. 
Kinetics of the reaction of phosphonate ester 35e with TMSBr 
For each kinetic run, weighed quantities of the substrate 35e and TMB were dissolved in dry 
CDCI, (0.6 mL; stored over molecular sieves and basic alumina) under N,. The solution was 
transferred to a graduated NMR tube, flushed w ith N, and sealed with a septum. The NMR 
spectrum of a 31 p standard (1 mL of 1M-phosphoric acid in 0,0) was obtained and the signa l 
was calibrated to 0.00 ppm. The 'H and 31 p spectra of the substrate solution were recorded 
and TMSBr (4 eq.) was then added. The total volume of the reaction mixture was recorded and 
the tube was immediately replaced in the probe. The NMR experiments were set to record 
both the 'H and 31 p spectra, followed by a delay of 90 s between acquisitions. The experiments 
were repeated at different temperatures ranging from 283 K to 305 K. 
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3.3. Enzyme-binding and inhibition studies 
Expression and purification of EcDXR69•101 
EcDXR was expressed and purified by Taryn Bodill in the Rhodes Centre for Chemico- and 
Biomedicinal Research, according to standard procedures. 69•101 In brief, XL-1 Blue competent 
cells were transformed with EcDXR plasmid DNA. Isopropylthiogalactoside (IPTG) was used to 
induce expression of the recombinant EcDXR gene. EcDXR was then purified by a combination 
of Ni" affinity- and size exclusion-chromatography. The protein was stored at -20 o( in a 
sodium phosphate buffer of pH 7. 
Saturation transfer difference (STD) NMR experiments" 
Standardisation of the SrD experiment. 136 
An STD assay using bovine serum albumin (BSA) as the protein with L-tryptophan and glucose 
as ligands was carried out to validate and optimise the STD parameters. Solutions of BSA (84 x 
10"' M), L-tryptophan (7.75 x 10-3 M) and glucose (a/~) (53.25 x 10-3 M) were made up in 50 
mM Tris/HCI buffer (pH 7.3). A sample containing BSA (240 >lL), Tris/HCI buffer (120 >ILL L-
tryptophan (130 >lL), glucose (19 >lL) and D,O (25 >lL) was made up in an NMR tube to give a 
final assay solution containing 40 >1M B5A, 2 mM L-tryptophan and 2 mM glucose in 50 mM 
Tris/HCI buffer (pH 7.3). An STD NMR experiment was run on a Bruker Biospin 600 MH, NMR 
spectrometer using water suppression at 4.7 ppm with the on-resonance pulse train set to 0.5 
ppm and the off-resonance pulse train set to 20 ppm with phase cycling. The pre-saturation 
Gaussian pulse was applied 4 times and 2048 scans were run. A second identical experiment 
was then carried out on a BSA sample (240 >lL) which had been freeze-dried and resuspended 
in an equal volume (240 >lL) of D,O. 
srD experiment using compounds 35a-e, 36a-e, 39a-e and 40b-e_ 
EcDXR was extracted and purified as described above. The ligands to be tested were divided 
into four groups (35a-e; 36b-e; 39a-e and 40b-e + 36a) and an STD experiment was run on 
each group. EcDXR in 50 mM Na, PO, buffer (pH 7.0) was freeze dried and re-suspended in D,O 
to make a final concentration of 15.0 >1M. Each group of ligands was dissolved in this solution 
to give a final ligand concentration of 600 11M and thus a protein:ligand ratio of 1:40. The STD 
assay was optimised in terms of the number of pre-saturation Gaussian pulses and the power 
level of the saturation pulse. Saturation of the protein was achieved using a train of 40 
Gaussian bell-shaped pulses separated by a 1 ms delay at an attenuation power level of 40 dB. 
The frequency of the saturating on-resonance pulse was at 0.73 ppm and the off-resonance 
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pulse at 20 ppm. Phase cycling between the on- and off-resonances was used to minimise the 
effects of slight changes in temperature or magnetic field homogeneity. No spin-lock filter was 
used. A 3-9-19 water suppression pulse was applied at 4.7 ppm and 6000 scans were acq uired. 
The on- and off-resonance spectra were subtracted from each other and processed using 
Topspin software from Bruker. For the last two groups of compounds, after running the STD 
experiment, fosm idomycin 19 was added (to a concentration of 600 "M) and the experiment 
was re-run under the same conditions to test for non-specific binding. 
DXR inhibition assay"·57." 
Assays were conducted in a reaction mixture containing 100 mM Tris-HCI (pH 7.5), 1 mM 
MgCI" 0.3 mM NADPH and 0.3 mM DOXP 9 in a total volume of 100 "l. Equal volumes of 
EcDXR and ligand were incubated at 37 'c for 5 min; 100 "L of this enzyme-ligand mixture was 
then added to the rest of the assay components to make a total of 200 "L with a final EcDXR 
concentration of 5 "g.mL" . The decrease in absorbance at 340 nm due to the decreasing 
concentration of NADPH (ENAD'H = 6.3 X 10' L.mor1cm") was followed for 10 min at 37 ' c, 
relative to a blank lacking the DOXP substrate. For each ligand, enzyme activity in the absence 
of inhibitor w as deemed to be 100% (i.e. 0% inhibition) and the % relative inhibition was 
determined in triplicate. 
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3.4. In silica studies 
Molecular modelling and simulated docking of synthetic ligands 
Geometry optimisation and energy minimisation of ligands 
The structures of ligands 35a-e and 36a-e were drawn in Discovery Studio Visualizer 2.0109 (in 
their phosphonate ester, protonated and deprotonated phosphonic acid forms) and an in 
vacuo global minimum was located for each of the ligands by means of a systematic 
conformational search using Cerius2 ,06 For the esters 35a-e, the torsion angles were rotated 
in increments of 60° whilst, for the acids 36a-e, the torsion angles were rotated in increments 
of 30° because the acids have fewer rotatable torsions. The energy maximum was set to 10.00 
kcal.mor' and a maximum of 10 000 conformers was generated for each compound. The 
lowest energy conformers were then subjected to geometry optimisation and energy 
minimisation with frequency analysis at the OFT (B3LVP) level with the 6-31G(d) basis set, 
using (IEFPCM) solvent correction (water) as implemented in Gaussian 03. '°7 
Preparation of the protein model for docking 
The X-ray crystal structure of f.cali DXR 1QOL47 was obtained from the Protein Data Bank (PDB; 
E.C. 1.1.1.267)48 As the divalent cation, M" was not present in the 1QOL crystal structure, this 
structure was compared with the crystal structure 10NP," which includes Mn'+. The distances 
from Mn" to the carbonyl and hydroxamate moieties of fosmidomycin (2.302 A and 2.131 A 
respectively) were measured in 10NP and used to position a Mn ' + ion in the 1QOL model 
relative to fosmidomycin. The Mn'+-coordinating water molecule was also added at a distance 
of 2.232 A from the metal ion and in a position consistent with an octahedral coordination 
sphere around the metal ion. Fosmidomycin 19 and the structural water molecules were 
removed from the active site in the modified 1QOL model, but the NADPH cofactor was 
retained . 
Flexible docking 
The geometry optimised and energy minimised ligands were imported into AutoDock 4.0, 
Gasteigerll2 charges were added and non-polar hydrogens were merged using AutoDock 
4.0.'°8 All possible torsions in the ligands were allowed. The protein was prepared using 
AutoDock 4.0, Gasteiger charges were calculated, non-polar hydrogens were merged and a +2 
charge was assigned manually to the Mn' + ion"' The active-s ite residues 5er186, 5er222, 
Asn227, Lys228 and Glu231 were selected as flexible residues, and atom maps were created 
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for possible interactions between the active-site residues and the ligand. The active site was 
represented by a grid box of dimensions 60 x 60 x 60 units with grid-point spacing of 0.375 A 
and offset from centre by 0.806,7.056 and 1.806 A along the x, y and z directions respectively. 
The dockings were simulated using a Lamarckian genetic algorithm in AutoDock 4.0 and 10 
docking runs were carried out for each ligand. lOS The parameters for the genetic algorithm 
were: population size = 150; mutation rate = 0.02; crossover rate = 0.8, allowing for a 
maximum of 27 000 generations and 2 500 000 energy evaluations. After the docking, the 
lowest energy conformers for each of the 10 docking runs were visualised using the Discovery 
Studio Visualizer 2.0109 A single-point DFT energy calculation was then carried out on each of 
the lowest energy conformers at the B3LYP 6-31G(d) level as implemented in Gaussian 03.107 
Refinement of the charge on the metal cofactor 
The Mg cofactor and its coordinating ligands (fosmidomycin 19, Glu151, Asp149, Glu230 and 
the crystal structure water HOH3153) were removed as a group from the EcDXR crystal 
structure 2EGH." The amino acid residues were capped with hydrogen atoms where they had 
been removed from the polypeptide chain and the group was assigned an overall charge of -3. 
A single point energy calculation was carried out on the group at the Hartree-Fock level using 
the 6-3 1G(d) basis set as implemented in Gaussian 03. '07 
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